Kamada (KMDA) 20-F 6 Mar 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information Line Items
Entity Registrant Name	Kamada Ltd.
Trading Symbol	KMDA
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	57,479,528
Amendment Flag	false
Entity Central Index Key	0001567529
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-35948
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	2 Holzman St
Entity Address, Address Line Two	Science Park P.O Box 4081
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670402
Entity Address, Country	IL
Title of 12(b) Security	Ordinary Shares, par value NIS 1.00 each
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1281
Auditor Name	KOST FORER GABBAY & KASIERER
Auditor Location	Tel-Aviv, Israel
Business Contact
Document Information Line Items
Entity Address, Address Line One	2 Holzman St
Entity Address, Address Line Two	Science Park
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670402
Entity Address, Country	IL
Contact Personnel Name	Amir London
City Area Code	972
Local Phone Number	8 9406472

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 55,641	$ 34,258
Trade receivables, net	19,877	27,252
Other accounts receivables	5,965	8,710
Inventories	88,479	68,785
Total Current Assets	169,962	139,005
Non-Current Assets
Property, plant and equipment, net	28,224	26,157
Right-of-use assets	7,761	2,568
Intangible assets, Goodwill and other long-term assets	140,465	147,072
Contract asset	8,495	7,577
Total Non-Current Assets	184,945	183,374
Total Assets	354,907	322,379
Current Liabilities
Current maturities of bank loans		4,444
Current maturities of lease liabilities	1,384	1,016
Current maturities of other long term liabilities	14,996	29,708
Trade payables	24,804	32,917
Other accounts payables	8,261	7,585
Deferred revenues	148	35
Total Current Liabilities	49,593	75,705
Non-Current Liabilities
Bank loans		12,963
Lease liabilities	7,438	2,177
Contingent consideration	18,855	17,534
Other long-term liabilities	34,379	37,308
Employee benefit liabilities, net	621	672
Total Non-Current Liabilities	61,293	70,654
Shareholder’s Equity
Ordinary shares	15,021	11,734
Additional paid in capital net	265,848	210,495
Capital reserve due to translation to presentation currency	(3,490)	(3,490)
Capital reserve from hedges	140	(88)
Capital reserve from share-based payments	6,427	5,505
Capital reserve from employee benefits	275	348
Accumulated deficit	(40,200)	(48,484)
Total Shareholder’s Equity	244,021	176,020
Total Liabilities and Shareholder’s Equity	$ 354,907	$ 322,379

Consolidated Statements of Prof

Consolidated Statements of Profit or Loss and Other Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statements [Line Items]
Total revenues	$ 142,519	$ 129,339	$ 103,642
Total cost of revenues	87,029	82,636	73,314
Gross profit	55,490	46,703	30,328
Research and development expenses	13,933	13,172	11,357
Selling and marketing expenses	16,193	15,284	6,278
General and administrative expenses	14,381	12,803	12,636
Other expense	919	912	753
Operating income	10,064	4,532	(696)
Financial income	588	91	295
Income (expenses) in respect of currency exchange differences and derivatives instruments, net	55	298	(207)
Revaluation of long-term liabilities	(980)	(6,266)	(994)
Financial expense	(1,298)	(914)	(283)
Income before tax on income	8,429	(2,259)	(1,885)
Taxes on income	145	62	345
Net Income (Loss)	8,284	(2,321)	(2,230)
Other Comprehensive Income:
Gain (loss) on cash flow hedges	(186)	(776)
Net amounts transferred to the statement of profit or loss for cash flow hedges	414	634	(303)
Remeasurement gain (loss) from defined benefit plan	(73)	497	171
Total comprehensive income (loss)	$ 8,439	$ (1,966)	$ (2,362)
Earnings per share attributable to equity holders of the Company:
Basic net earnings (loss) per share (in Dollars per share)	$ 0.17	$ (0.05)	$ (0.05)
Diluted net earnings per (loss) share (in Dollars per share)	$ 0.15	$ (0.05)	$ (0.05)
Revenues from proprietary products
Statements [Line Items]
Total revenues	$ 115,458	$ 102,598	$ 75,521
Revenues from distribution
Statements [Line Items]
Total revenues	27,061	26,741	28,121
Cost of revenues from proprietary products
Statements [Line Items]
Total cost of revenues	63,342	58,229	48,194
Cost of revenues from distribution
Statements [Line Items]
Total cost of revenues	$ 23,687	$ 24,407	$ 25,120

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share capital	Additional paid in capital	Capital reserve due to translation to presentation currency	Capital reserve from hedges	Capital reserve from share based payments	Capital reserve from employee benefits	Accumulated deficit	Total
Balance at Dec. 31, 2020	$ 11,706	$ 209,760	$ (3,490)	$ 357	$ 4,558	$ (320)	$ (43,933)	$ 178,638
Net income (loss)							(2,230)	(2,230)
Other comprehensive income (loss)				(303)		171		(132)
Total comprehensive income (loss)				(303)		171	(2,230)	(2,362)
Exercise and forfeiture of share-based payment into shares	19	444			(444)			19
Cost of share-based payment					529			529
Balance at Dec. 31, 2021	11,725	210,204	(3,490)	54	4,643	(149)	(46,163)	176,824
Net income (loss)							(2,321)	(2,321)
Other comprehensive income (loss)				(142)		497		355
Total comprehensive income (loss)				(142)		497	(2,321)	(1,966)
Exercise and forfeiture of share-based payment into shares	9	291			(291)			9
Cost of share-based payment					1,153			1,153
Balance at Dec. 31, 2022	11,734	210,495	(3,490)	(88)	5,505	348	(48,484)	176,020
Net income (loss)							8,284	8,284
Other comprehensive income (loss)				228		(73)		155
Total comprehensive income (loss)				228		(73)	8,284	8,439
Issuance of shares	3,283	54,948						58,231
Exercise and forfeiture of share-based payment into shares	4	405			(405)			4
Cost of share-based payment					1,327			1,327
Balance at Dec. 31, 2023	$ 15,021	$ 265,848	$ (3,490)	$ 140	$ 6,427	$ 275	$ (40,200)	$ 244,021

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities
Net (loss) income	$ 8,284	$ (2,321)	$ (2,230)
Adjustments to the profit or loss items:
Depreciation and amortization	12,714	12,155	5,609
Financial expense (income), net	1,635	6,791	1,189
Cost of share-based payment	1,314	1,153	529
Taxes on income	145	62	345
Gain from sale of property and equipment	(5)
Change in employee benefit liabilities, net	(125)	(111)	45
Adjustments to the profit or loss items	15,678	20,050	7,717
Changes in asset and liability items:
Decrease (increase) in trade receivables, net	7,835	7,603	(12,861)
Increase in other accounts receivables	(1,150)	(578)	(1,634)
Increase in inventories	(19,694)	(1,361)	(2,373)
Decrease (increase) in deferred expenses	2,814	(1,340)	(6,883)
Increase (decrease) in trade payables	(8,885)	7,055	7,917
Increase (decrease) in other accounts payables	765	290	(392)
Increase (decrease) in deferred revenues	113	(20)	1,815
Total Changes in asset and liability	(18,202)	11,649	(14,411)
Cash paid during the year for:
Interest paid	(1,228)	(853)	(228)
Interest received		97	375
Taxes paid	(217)	(36)	(42)
Cash received (paid) during the year	(1,445)	(792)	105
Net cash (used in) provided by operating activities	4,315	28,586	(8,819)
Cash Flows from Investing Activities
Investment in short term investments, net			39,083
Purchase of property and equipment and intangible assets	(5,850)	(3,784)	(3,730)
Business combination			(96,403)
Proceeds from sale of property and equipment	7
Net cash used in investing activities	(5,843)	(3,784)	(61,050)
Cash Flows from Financing Activities
Proceeds from exercise of share base payments	4	9	19
Receipt of long-term loans			20,000
Proceeds from issuance of ordinary shares, net	58,231
Repayment of lease liabilities	(850)	(1,098)	(1,221)
Repayment of long-term loans	(17,407)	(2,628)	(205)
Repayment of other long-term liabilities	(17,300)	(5,626)
Net cash provided by (used in) financing activities	22,678	(9,343)	18,593
Exchange differences on balances of cash and cash equivalent	233	212	(334)
Increase (decrease) in cash and cash equivalents	21,383	15,671	(51,610)
Cash and cash equivalents at the beginning of the year	34,258	18,587	70,197
Cash and cash equivalents at the end of the year	55,641	34,258	18,587
Significant non-cash transactions
Right-of-use asset recognized with corresponding lease liability	6,546	551	845
Purchase of property and equipment	$ 646	$ 618	$ 1,001

General

General	12 Months Ended
	Dec. 31, 2023
General [Abstract]
GENERAL	Note 1: - General a. General description of the Company and its activity Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products KEDRAB®, CYTOGAM®, VARIZIG®, WINRHO SDF®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers and in addition have eleven biosimilar products in its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and Israeli Ministry of Health (“IL MOH”) approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. In November 2021, the Company entered into an Assets Purchase Agreement with Saol Therapeutics Ltd. (“Saol” and the “Saol APA”) for the acquisition of CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B (collectively the “Four FDA-Approved Plasma Derived Hyperimmune Commercial Products”). The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers. Refer to Note 5 for further details on this acquisition. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited (“Takeda”). Through 2021, the Company generated revenues on sales of GLASSIA, manufactured by the Company, to Takeda for further distribution in the United States. In accordance with the agreement with Takeda, the Company ceased the production and sale of GLASSIA to Takeda during 2021, and during the first quarter of 2022, Takeda began to pay the Company royalties on sales of GLASSIA manufactured by Takeda, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each year from 2022 to 2040. Refer to Note 18 for further details on the engagement with Takeda. The Company’s activity is divided into two operating segments: Proprietary Products Development, manufacturing, sales and distribution of plasma-derived protein therapeutics. Distribution Distribute imported drug products in Israel, which are manufactured by third parties. The Company’s ordinary shares are listed for trading on the Tel Aviv Stock Exchange and the NASDAQ Global Select Market. FIMI Opportunity Funds (“FIMI”), the leading private equity firm in Israel beneficially owns approximately 38% of the Company’s outstanding ordinary shares and is a controlling shareholder of the Company; within the meaning of the Israeli Companies Law, 1999. Refer to Note 20 for further details and Item 7 within the Company annual reports on Form 20-F. The Company has four wholly-owned subsidiaries – Kamada Inc., Kamada Plasma LLC (wholly owned by Kamada Inc.), KI Biopharma LLC and Kamada Ireland Limited. In addition, the Company owns 74% of Kamada Assets Ltd. (“Kamada Assets”). b. Definitions In these Financial Statements – The Company - Kamada Ltd. The Group - The Company and its subsidiaries. Subsidiary - A company which the Company has a control over (as defined in IFRS 10) and whose financial statements are consolidated with the Company’s Financial Statements. Related parties - As defined in International Accounting Standard (“IAS”) 24. USD/$ - U.S. dollar. NIS - New Israeli Shekel EUR - Euro

Material Accounting Policies

Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Material Accounting Policies [Abstract]
MATERIAL ACCOUNTING POLICIES	Note 2: - Material Accounting Policies a. Basis of presentation of financial statements 1. These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board. 2. Measurement basis: The Company’s consolidated financial statements are prepared on a cost basis, except for financial assets and liabilities (including derivatives and contingent consideration) which are measured at fair value through profit or loss (See Note 16). The Company has elected to present profit or loss items using the “function of expense” method. b. The Company’s operating cycle is one year. c. Functional currency, presentation currency and foreign currency 1. Functional currency and presentation currency The consolidated financial statements are presented in U.S. dollars, which is the Company’s functional and presentation currency. 2. Transactions, assets and liabilities in foreign currency Transactions denominated in foreign currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in a foreign currency are translated at the exchange rate at the date of the transaction. d. Business combinations and goodwill: In November 2021, the Company acquired the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products from Saol, see Note 1(a). The acquisition was accounted for as a business combination, for which a key element of the consideration was contingent. The contingent consideration was recognized at fair value on the acquisition date and classified as a financial liability in accordance with IFRS 9. Contingent consideration is measured at fair value. The fair value is determined using valuation techniques and method, using future cash flows discounted. Subsequent changes in the fair value of the contingent consideration are recognized in profit or loss as finance income or finance expense. As part of the acquisition, the Company also assumed certain of Saol’s liabilities for the future payment of royalties (some of which are perpetual) and milestone payments to third party subject to the achievement of corresponding CYTOGAM related net sales. Such assumed liabilities were accounted for as a financial liability on the acquisition date. Subsequently, the financial liability is measured at amortized cost, per IFRS 9. Remeasurement of the financial liability is recognized as finance income or expense in the statement of operations. Refer to Note 5 and Note 16 for further information. Goodwill is initially measured at cost which represents the excess of the acquisition consideration over the net identifiable assets acquired and liabilities assumed. At each reporting date, the Company reviews the carrying amount of the goodwill to determine whether there is any indication of impairment. e. Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises of the costs of purchase of raw and other materials and costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. Cost of inventories is determined as follows: Raw materials At cost using the first-in, first-out method. Work in process Costs of raw materials, direct and indirect costs including labor, other materials and other indirect manufacturing costs allocated to the in process manufactured batches through the end of the reporting period. The allocation of indirect costs is accounted for on a quarterly basis by dividing the total quarterly indirect manufacturing cost to the batches manufactured during that quarter based on predetermined allocation factors. The Company determines a standard manufacturing capacity for each quarter. To the extent the actual manufacturing capacity in a given quarter is lower than the predetermined standard, than a portion of the indirect costs which is equal to the product of the overall quarterly indirect costs multiplied by the quarterly manufacturing shortfall rate is recognized as costs of revenues Finished products Costs of raw materials, direct and indirect costs including labor, other materials and other indirect manufacturing costs allocated to the manufactured finished products through completion of manufacturing process. Purchased products At cost using the first-in, first-out method. The Company periodically evaluates the condition and age of inventories and accounts for impairment of inventories with a lower market value or which are slow moving. f. Financial instruments 1 Financial assets The Company’s portfolio of financial assets consists mainly of trade receivables and bank deposits. The objective of the business model for managing the Company’s financial instruments is to collect the amounts due from them, and for bank deposits to earn contractual interest income on the amounts collected. All of the Company’s financial assets’ contractual cash flows represent solely payments of principal and interest (SPPI). Thus, the Company accounts for its financial assets under the amortized cost model. For those financial assets, the Company analyzes each material customer’s balance individually to evaluate and measure the expected credit losses (“ECLs”) of its trade receivables. Loss rates are based on actual credit loss experience, adjusted for current conditions and the Company’s view of the economic conditions over the expected lives of the trade receivables 2. Financial liabilities Financial liabilities within the scope of IFRS 9 are initially measured at fair value less transaction costs that are directly attributable to the issuance of the financial liability. After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows: a) Financial liabilities measured at amortized cost Loans and assumed liabilities are measured based on their terms at amortized cost using the effective interest method taking into account directly attributable transaction costs. b) Financial liabilities measured at fair value Derivatives are classified as fair value through profit and loss unless they are designated as effective hedging instruments (see below). Transaction costs are recognized in profit or loss. After initial recognition, changes in fair value are recognized either in income (expenses) in respect of currency exchange differences and derivatives instruments line item for non-hedge accounting derivatives or in other comprehensive income for hedge accounting derivatives. For accounting for contingent consideration, see Note 2(d). g. Derivative financial instruments designated as hedges The Company enters into contracts for derivative financial instruments such as forward currency contracts and cylinder strategy in respect of foreign currency to hedge risks associated with foreign exchange rates fluctuations and cash flows risk. Such derivative financial instruments are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. At the inception of a hedge relationship, the Company formally designates and documents the hedge relationship to which the Company wishes to apply hedge accounting and the risk management objective and strategy for undertaking the hedge. The hedge effectiveness is assessed at the end of each reporting period. Any gains or losses arising from changes in the fair value of derivatives that do not qualify for hedge accounting are recorded in profit or loss. Cash flow hedges The effective portion of the gain or loss on the hedging instrument is recognized as other comprehensive income (loss), while any ineffective portion is recognized immediately in profit or loss. Amounts recognized as other comprehensive income (loss) are reclassified to profit or loss when the hedged transaction affects profit or loss, such as when the hedged income or expense is recognized or when a forecast payment occurs. h. Property, plant and equipment Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and any related investment grants and excluding day-to-day servicing expenses. Cost includes spare parts and auxiliary equipment that can be used only in connection with the plant and equipment. The cost of assets includes the cost of materials, direct labor costs, as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to operate in the manner intended by management. The Company’s assets include computer systems comprising hardware and software. Software forming an integral part of the hardware to the extent that the hardware cannot function without the software installed on it is classified as property, plant and equipment. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly % Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10 (*) Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement. i. Leases The Company enters into leases of office including facility dedicated for the plasma collection centers and storage spaces, vehicles, office equipment and lands as a lessee (see Note 15). For leases in which the Company is the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Company has elected to apply the practical expedient and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.). On the commencement date, the lease liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Company’s incremental borrowing rate. The Company determines the incremental borrowing rate based on its credit risk, the lease term and other economic variables deriving from the lease contract’s conditions and restrictions. In certain situations, the Company is assisted by an external valuation expert in determining the incremental borrowing rate. After the commencement date, the Company measures the lease liability using the effective interest rate method. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life or the lease term, as follows: % Mainly % Land and Buildings 5-10 10 Vehicles 20-33 33 office equipment (i.e. printing and photocopying machines) 20 20 Lease modification: Most of the Company’s lease modifications are for the extension of existing lease contracts. Thus, they do not reduce the scope of the lease or result in a separate lease. Under those modifications, the Company re-measures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset. j. Intangible assets Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Intangible assets with a finite useful life are amortized on a straight-line basis over their useful life, as follows: Estimated life Amortization method Intellectual property 15-20 Straight-line Customer Relations 20 Straight-line Production agreement 6 Straight-line Distribution right 10-15 Straight-line over the contract period Goodwill Indefinite Not amortized For additional information regarding intangible assets, see Note 11. k. Impairment of non-financial assets At each reporting date, the Company reviews the carrying amount of non-financial assets (other than inventories, contract assets and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the assets’ recoverable amount is estimated. Goodwill is tested annually for impairment on December 31 or more frequently if events or changes in circumstances indicate that there is an impairment. The Company’s goodwill is attributed to the Proprietary Products segment, which represents the lowest level within the Company at which goodwill is monitored for internal management purposes (see Note 11). Goodwill is tested for impairment by assessing the recoverable amount of the CGU (or group of CGUs) to which the goodwill has been allocated. An impairment loss is recognized if the recoverable amount of the CGU (or group of CGU to which goodwill has been allocated is less than the carrying amount of the CGU (or group of CGUs). Any impairment loss is allocated first to goodwill. Impairment losses recognized for goodwill cannot be reversed in subsequent periods. In the years ended December 31, 2023, and 2022, the Company did not recognize impairment losses. l. Employee benefit liabilities The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation, and social security contributions are recognized as expenses as the services are rendered. A liability in respect of a cash bonus is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits The post-employment benefits plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. With respect to its employees in Israel, the Company has defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law, 1963 (the “Israeli Severance Pay Law”), under which the Company pays fixed contributions to certain employees under Section 14 and will have no legal or constructive obligation to pay further contributions. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee’s services. In addition, with respect to certain other employees who were hired by the Company prior to the establishment of the defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law, the Company operates a defined benefit plan in respect of severance pay pursuant to the Israeli Severance Pay Law. According to the Israeli Severance Pay Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The actuarial assumptions include expected salary increases and rates of employee’s turnover based on the estimated timing of payment. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with a term that is consistent with the estimated term of the severance pay obligation. In respect of its defined benefit plan obligation, the Company makes current deposits in pension funds and insurance companies (“plan assets”). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Company’s own creditors and cannot be returned directly to the Company. The liability for employee benefits shown in the statement of financial position reflects the present value of the defined benefit obligation less the fair value of the plan assets. U.S. employees defined contribution plan: Since August 2022, the Company’s U.S. subsidiary has a 401(k) defined contribution plan covering certain employees in the U.S. All eligible employees may elect to contribute up to 100% of their annual compensation to the plan through salary deferrals, subject to Internal Revenue Service limits. For the year ended December 31, 2023, the contribution limit was $22,500 per year (for certain employees over 50 years of age the maximum contribution was $30,000 per year). The U.S. subsidiary matches 3% of employee contributions to the plan with no limitation. m. Revenue recognition The Company’s main source of revenue is from the sale of products to strategic partners and distributors. Starting from 2022, the Company also generates revenue in the form of royalties received under license agreement that grant the use of the Company’s knowledge and patents. Under the royalty exception, revenue is recognized when the underlying sales have occurred. On the contract’s inception date the Company assesses the goods or services promised in the contract with the customer and identifies the performance obligations in it. In order to identify distinct performance obligations in a contract with a customer, the Company examines whether it is providing a significant service of integrating the goods or services in the contract into one integrated outcome. The Company identifies the performance obligations when the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the Company promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. The Company recognizes revenue from contracts with customers when the control over the goods or services is transferred to the customer. Revenue recognition occurs at a point in time when control of the Company’s product is transferred to the customer, generally on delivery of the goods according to the shipment terms. The Company determines the transaction price separately for each contract with a customer taking into consideration variable prices, discounts, chargeback, rebates, adjustments to the net market price etc. The Company includes the estimated variable consideration in the transaction price only to the extent it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty is resolved. Following the acquisition of the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products during November 2021, the Company, through its wholly-owned subsidiary Kamada Inc., sells these products in the U.S. market to wholesalers/distributors that redistribute/sell these products to other parties such as hospitals and pharmacies. Revenue recognition occurs at a point in time when control of the product is transferred to the wholesalers/distributors, generally on delivery of the goods. The Company’s gross sales are subject to various deductions, which are primarily composed of rebates and discounts to group purchasing organizations, government agencies, wholesalers, health insurance companies and managed healthcare organizations. These deductions represent estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions on gross sales for a reporting period. These adjustments are deducted from gross sales to arrive at net sales. The Company monitors the obligation for these deductions on at least a quarterly basis and records adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in the obligation is appropriate. The following summarizes the nature of the most significant adjustments to revenues generated from the sales of these products in the U.S. market: ● Wholesaler chargebacks: The Company has arrangements with certain indirect customers whereby the customer is able to buy products from wholesalers at reduced prices. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer’s contractual discounted price. Provisions for estimating chargebacks are calculated based on historical experience and product demand. The provision for chargebacks are recorded as a deduction from trade receivables on the consolidated statements of financial position. ● Fees for service: Consists of wholesaler/distributor fees. The wholesalers/distributors charge the Company fees for the redistribution of the products to hospitals and pharmacies. These fees are outlined in each wholesaler/distributor contract. The fees are invoiced to the Company monthly or quarterly by the wholesaler/distributor. The provisions for fees for service are recorded in the same period that the corresponding revenues are recognized. Costs to fulfill a contract: Costs to fulfill a contract, which primarily consist of costs arising from technology transfers in preparation of supply contracts or anticipated contracts, are recognized as an asset when the costs generate or enhance the Company’s resources that will be used in satisfying or continuing to satisfy the performance obligations in the future and are expected to be recovered. Costs to fulfill a contract consist of direct identifiable costs and indirect costs that can be attributed to a contract based on a reasonable allocation method. These costs include mainly salaries and other employee benefits costs. Costs to fulfill a contract are amortized on a systematic basis that is consistent with the provision of the goods and services under the contracts. As of December 31, 2023, and 2022, the Company recognized an asset related to the costs to fulfill a contract in the net amounts of $8,495 thousand and $7,577 thousand, respectively. The Company amortizes the contract asset over an 18-year period straight line basis, representing the expected duration of the relationship with the customer. In 2023, the Company recognized $51 thousand in amortization costs, which were included in the cost of goods sold. No impairment losses were recognized. Refer to Note 18e for further information. n. Research and development costs Research and development expenditures are recognized in profit or loss when incurred and include preclinical and clinical costs (as well as cost of materials associated with the development of new products or existing products for new therapeutic indications). In addition, these costs include additional product development activities with respect to approved and distributed products as well as post marketing commitment research and development activities. Since the Company’s development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and therefore, development expenditures are recognized in profit or loss when incurred. o. Taxes on income Current and Deferred taxes Taxes on income in profit or loss comprise of current taxes, deferred taxes and taxes in respect of prior years, which are mainly recognized in profit or loss. Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at the end of each reporting period and a respective deferred tax asset is recognized to the extent that their utilization is probable. The Company operates in multiple tax jurisdictions. Deferred taxes are offset in the statement of financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. As of December 31, 2023, the Company did not record deferred tax asset for the remaining carry forward losses due to estimation that their utilization in the foreseeable future is not probable. Uncertain tax positions The Company evaluates potential uncertain tax positions, including additional tax and interest expenses, and recognizes a provision when it is more probable than not that the Company will have to use its economic resources to pay the such obligation. As of December 31, 2023 and 2022, the application of IFRIC 23 did not have a material effect on the financial statements. p. Provisions A provision in accordance with IAS 37 is recognized when the Company has a present (legal or constructive) obligation as a result of a past event, it is expected to require the use of economic resources to clear the obligation and a reliable estimate can be made of it. q. Share-based payment transactions The Company’s employees and members of its Board of Directors are entitled to remuneration in the form of equity-settled share-based payment transactions, primarily in the form of options and restricted shares units. The cost of equity-settled transactions (options and restricted share units) with employees and members of the Board of Directors is measured at the fair value of the equity instruments granted at grant date. The fair value of options is determined using a standard option pricing model, the binomial option valuation model. The fair value of restricted share is determined using the share price at the grant date. The cost of equity-settled share-based payments transactions is recognized in profit or loss together with a corresponding increase in shareholder’s equity during the period which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees or directors become entitled to the award (“the vesting period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest.

Significant Accounting Judgment

Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements	12 Months Ended
	Dec. 31, 2023
Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS	Note 3: - Significant Accounting Judgments, Estimates And Assumptions Used In The Preparation Of The Financial Statements a. Judgments In the process of applying the significant accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in the financial statements: - Determining the fair value of share-based payment transactions The fair value of equity settled share-based payment transactions is determined upon initial recognition by an acceptable option pricing model. The inputs to the model include share price, exercise price (if applicable) and assumptions regarding expected volatility, expected life of the equity instrument and expected dividend yield. - Revenue Identification of performance obligations in contracts with customers: In order to identify distinct performance obligations in a contract with a customer, the Company uses judgment when it examines whether it is providing a significant service of integrating the goods or services in the contract into one integrated outcome. Measurement of variable consideration In order to determine the transaction price, the Company estimates the amount of the variable consideration and recognizes revenue in an amount where there is a high probability that its inclusion will not result in a significant revenue reversal in the future after the uncertainty has been resolved. Costs to fulfill a contract: Costs fulfill contracts or anticipated contracts with customers are recognized as an asset when the costs generate or enhance the Company’s resources that will be used in satisfying or continuing to satisfy the performance obligations in the future and are expected to be recovered. Costs to fulfill a contract consist of direct identifiable costs and other costs that can be directly attributed to a contract based on a reasonable allocation method. Costs to fulfill a contract are amortized on a systematic basis that is consistent with the provision of the services under the specific contract. - Inventory Work in process and finished goods includes direct and indirect costs. The allocation of indirect costs is accounted for on a quarterly basis by dividing the total quarterly indirect manufacturing cost to the batches manufactured during that quarter based on predetermined allocation factors. The criteria for allocation of indirect manufacturing expense to manufactured batches which eventually effect the Company's inventory value is subject to Company judgment. - Impairment of inventories with realizable value lower than cost or which are slow moving Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises costs of purchase of raw and other materials and costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business, net of selling expenses. The estimation of realizable value can affect the inventory value at the period end. In addition, and as part of the quarterly inventory valuation process, the Company assesses the potential effect on inventory in cases of deviations from quality standards in the manufacturing process to identify potential required inventory write offs. Such assessment is subject to Company’s judgment. - Inventory designated for R&D activities The Company recognizes inventory produced for commercial sale, including costs incurred prior to regulatory approval but subsequent to the filing of a regulatory request when the Company has determined that the inventory has probable future economic benefit. Inventory is not recognized prior to completion of a phase III clinical trial. For products with an approved indication, raw materials and purchased drug product associated with development programs are included in inventory and charged to research and development expense when it is designated. For products without an approved indication, drug product is charged to research and development expenses. - Lease extension and/or termination options In evaluating whether it is reasonably certain that the Company will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset to the Company’s operation and whether it is a specialized asset, the Company’s past experience with similar leases, etc. After the commencement date, the Company reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether the Company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying asset for a period that exceeds the end of the previously determined lease period, etc. - Recognition of deferred tax asset in respect of carry forward tax losses Deferred tax assets are recognized for unused carryforward tax losses and deductible temporary differences to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the timing and level of future taxable profits, its source and the tax planning strategy. For information regarding deferred taxes recognition, please refer to Note 22. - Determining cash-generating units Impairment testing for assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “CGU”). For the purpose of goodwill impairment testing, the Company aggregates CGUs so that the level at which impairment testing is performed reflects the lowest level at which goodwill is monitored for internal reporting purposes. When goodwill is not monitored for internal reporting purposes, it is allocated to operating segments and not to a CGU (or group of CGUs) lower in level than an operating segment. Goodwill acquired in a business combination is allocated to groups of CGUS, including CGUs existing prior to the business combination, that are expected to benefit from the synergies of the combination. Also refer to Note 11. - Impairment of Company’s non-financial assets The carrying amounts of the Company’s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. b. Estimates and assumptions The preparation of the financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate. The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. - Pensions and other post-employment benefits The liability in respect of post-employment defined benefit plans is determined using actuarial valuations. The actuarial valuation involves making assumptions about, among other things, discount rates, expected rates of return on assets, future salary increases and mortality rates. Due to the long-term nature of these plans, such estimates are subject to significant uncertainty. - Legal claims In estimating the likelihood of outcome of legal claims filed against the Company, the Company relies on the opinion of its legal counsel. These estimates are based on the legal counsel’s best professional judgment, taking into account the stage of proceedings and historical legal precedents in respect of the different issues. Since the outcome of the claims will be determined in courts, the results could differ from these estimates. - Discount rate for a lease liability When the Company is unable to readily determine the discount rate implicit in a lease in order to measure the lease liability, the Company uses an incremental borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no financing transactions that can serve as a basis, the Company determines the incremental borrowing rate based on its credit risk, the lease term and other economic variables deriving from the lease contract’s conditions and restrictions. In certain situations, the Company is assisted by an external valuation expert in determining the incremental borrowing rate. - Impairment of goodwill The Company reviews goodwill for impairment at least once a year. This requires management to make an estimate of the projected future cash flows from the continuing use of the CGU (or a group of CGUs) to which the goodwill is allocated and to choose a suitable discount rate for those cash flows. - Determination of Useful Life Intangible assets and property, plant and equipment are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. In determining the useful life and the depreciation or amortization method, the Company assesses the period over which an asset is expected to be available for use by the Company and the pattern in which the asset’s future economic benefits are expected to be consumed by the Company. - Purchase price allocation The Company allocates the purchase price based on the identifiable assets acquired and liabilities assumed at the acquisition date. The assets and the liabilities assumed are measured at fair value on the acquisition day. Significant estimates are required to measure the fair value of the assets and liabilities recognized as a result of the business combination including future cash flows, discount rate, volatility rate. - Determining the fair value of an unquoted financial asset or liability The fair value of unquoted financial assets or liability in Level 3 of the fair value hierarchy is determined using valuation techniques, generally using future cash flows discounted at current rates applicable for items with similar terms and risk characteristics. Changes in estimated future cash flows and estimated discount rates, after consideration of risks such as liquidity risk, credit risk and volatility, are liable to affect the fair value of these assets of liability. Contingent consideration is measured at fair value. The fair value is determined using valuation techniques and method, using future cash flows discounted. This requires management to make an estimate of the projected future cash flows. For information regarding contingent consideration, please refer to Note 5 and Note 16.

New Accounting Standards or Ame

New Accounting Standards or Amendments for 2023 and Forthcoming Requirements	12 Months Ended
	Dec. 31, 2023
New Accounting Standards or Amendments for 2023 and Forthcoming Requirements [Abstract]
NEW ACCOUNTING STANDARDS OR AMENDMENTS FOR 2023 AND FORTHCOMING REQUIREMENTS	Note 4:  New Accounting Standards or Amendments for 2023 and Forthcoming Requirements a. New Currently Effective Requirements - Amendment to IAS 1, Presentation of Financial Statements: “Disclosure of Accounting Policies.” According to the amendment to IAS 1, companies must provide disclosure of their material accounting policies rather than their significant accounting policies. Pursuant to the amendment, accounting policy information is material if, when considered with other information disclosed in the financial statements, it can be reasonably be expected to influence decisions that the users of the financial statements make on the basis of those financial statements. The amendment to IAS 1 also clarifies that accounting policy information is expected to be material if, without it, the users of the financial statements would be unable to understand other material information in the financial statements. The amendment also clarifies that immaterial accounting policy information need not be disclosed. The Company adopted Disclosure of Accounting Policies See Note 2: Material accounting policies. - Amendment to IAS 12, Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction The amendment narrows the scope of the exemption from recognizing deferred taxes as a result of temporary differences created at the initial recognition of assets and/or liabilities, so that it does not apply to transactions that give rise to equal and offsetting temporary differences. As a result, companies will need to recognize a deferred tax asset or a deferred tax liability for these temporary differences at the initial recognition of transactions that give rise to equal and offsetting temporary differences, such as lease transactions and provisions for decommissioning and restoration. The amendment is effective for annual periods beginning on January 1, 2023. The amendment did not have a material impact on the Company’s financial statements refer to note 22 for additional information. b. Forthcoming requirements - Amendment to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current Non-Current Liabilities with Covenants The amendment, together with the subsequent amendment to IAS 1 (see hereunder) replaces certain requirements for classifying liabilities as current or non-current. According to the amendment, a liability will be classified as non-current when the entity has the right to defer settlement for at least 12 months after the reporting period, and it “has substance” and is in existence at the end of the reporting period. According to the subsequent amendment, as published in October 2022, covenants with which the entity must comply after the reporting date do not affect classification of the liability as current or non-current. Additionally, the subsequent amendment adds disclosure requirements for liabilities subject to covenants within 12 months after the reporting date, such as disclosure regarding the nature of the covenants, the date they need to be complied with and facts and circumstances that indicate the entity may have difficulty complying with the covenants. Furthermore, the amendment clarifies that the conversion option of a liability will affect its classification as current or non-current, other than when the conversion option is recognized as equity. The amendment and subsequent amendment are effective for reporting periods beginning on or after January 1, 2024, with earlier application being permitted. The amendment and subsequent amendment are applicable retrospectively, including an amendment to comparative data. The Company does not expect the Amendment to have a material adverse impact on its financial statement.

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
BUSINESS COMBINATIONS	Note 5: - Business Combinations a. Acquisition of an FDA-Licensed Plasma Collection Center On March 1, 2021, the Company entered into an Asset Purchase Agreement with the privately held B&PR of Beaumont, TX, USA, for the acquisition of the FDA registered plasma collection facility as well as certain related rights and assets. The plasma collection facility currently specializes in the collection of hyper-immune plasma used in the manufacturing of KAMRHO (D), KAMRAB and KEDRAB. The acquisition, for a total consideration of $1,614 thousand, was consummated through the Company’s wholly owned subsidiary Kamada Plasma LLC, which operates the Company’s plasma collection activity in the U.S. The Company accounted for the acquisition as a business combination. The following table details the acquisition consideration: USD Cash paid $ 1,404 Payables for acquisition(a) 210 Total acquisition cost 1,614 (a) The acquisition consideration totaled $1,654 thousand, of which an amount of $1,404 thousand was paid at closing, and the balance of $250 thousand was paid in March 2022. The fair value of such deferred consideration was estimated at $210 as of the date of acquisition. In connection with the acquisition, the Company incurred costs of $140 thousand which included legal and other consulting fees. These costs were recorded in general and administrative expenses in the statement of profit and loss during 2020 and the first quarter of 2021. The fair value of the identifiable assets and liabilities on the acquisition date: USD Inventories 184 Property, plant and equipment 82 Intangible assets (a) 962 1,228 Other current liability (30 ) Net identifiable assets 1,198 Goodwill arising on acquisition (b) 416 Total acquisition cost 1,614 (a) The intangible assets represent the value of the FDA license for the plasma collection facility at fair value (Level 3) at the acquisition date, based on the Greenfield Method. Under such method, the subject intangible asset is valued using a hypothetical cashflow scenario of developing an operating business in an entity that at inception only holds the subject intangible asset. In measuring the FDA license for the plasma collection facility, the Company used an appropriate discount rate of 19%. (b) The goodwill arising as part of the acquisition is attributed to the expected benefits from the synergies of the combination of the Company’s activities and those of the acquired plasma collection facility. b. Acquisition of the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products On November 22, 2021 (the “Acquisition Date”), the Company entered into the Saol APA for the acquisition of the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products. The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The four acquired products include: ● CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) is a product indicated for the prophylaxis of cytomegalovirus disease associated with the transplantation of the kidney, lung, liver, pancreas, and heart. The product is the sole FDA approved IgG product for this indication. ● VARIZIG [Varicella Zoster Immune Globulin (Human)] is a product that contains antibodies specific for the Varicella zoster virus, and it is indicated for post-exposure prophylaxis of varicella (chickenpox) in high-risk patient groups, including immunocompromised children, newborns, and pregnant women. VARIZIG is intended to reduce the severity of chickenpox infections in these patients. The U.S. Centers for Disease Control (CDC) recommends Varicella zoster immune globulin (human) (such as VARIZIG) for postexposure prophylaxis of varicella for persons at high-risk for severe disease who lack evidence of immunity to varicella. The product is the sole FDA approved IgG product for this indication. ● WINRHO SDF is a Rho(D) Immune Globulin Intravenous (Human) product indicated for use in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomies, for Rho(D)-positive children with chronic or acute immune thrombocytopenia (ITP), adults with chronic ITP, and children and adults with ITP secondary to HIV infection. WinRho SDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women. The product is FDA approved. ● HEPAGAM B is a hepatitis B Immune Globulin (Human) (HBIg) product indicated to both prevent hepatitis B virus (HBV) recurrence following liver transplantation in hepatitis B surface antigen positive (HBsAg- positive) patients and provide post-exposure prophylaxis. The product is FDA approved. The Company accounted for the acquisition as a business combination. The following table details the total acquisition consideration as of the Acquisition Date: USD Cash paid at closing $ 95,000 Contingent consideration liability (a) 21,705 Deferred consideration (b) 13,788 Settlement of preexisting relationship (c) (3,786 ) Total acquisition cost 126,707 (a) Pursuant to the Saol APA, and in addition to the cash paid at closing, the Company agreed to pay up to $50,000 thousand of contingent consideration subject the achievement of sales thresholds for the period commencing on the Acquisition Date and ending on December 31, 2034. The Company may be entitled for up to $3,000 thousand credit deductible from the contingent consideration payments due for the years 2023 through 2027, subject to certain conditions as defined in the Saol APA. During 2023, the entitlement of the credit was not met. The contingent consideration totaled $21,705 thousand, which represents its fair value (Level 3) at the Acquisition Date, based on an Option Pricing Method (OPM), “Monte Carlo Simulation” model. In measuring the contingent consideration liability as of the Acquisition Date, the Company used an appropriate risk-adjusted discount rate of 10.6 % and volatility of 13.6%. The fair value of the contingent consideration was $21,855 thousand and $23,534 thousand as of December 31, 2023, and December 31, 2022, respectively. During the year ended December 31, 2023, the Company paid the first sales milestone in the amount of $3,000 thousand, which was accounted for as a reduction of the liability. The Company accounted for $1,321 thousand, $1,539 thousand and $290 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively as financing expenses in the statement of profit and loss to reflects the changes in the fair value of the liability. In measuring the contingent consideration liability, as of December 31, 2023, and 2022 the Company used an appropriate risk-adjusted discount rate of 11.4% and volatility of 15.17%, and an appropriate risk-adjusted discount rate of 11.8% and volatility of 14.21%, respectively. As of December 31, 2023, the second sales threshold was met, and the second milestone payment on account of the contingent consideration was paid during February 2024. For further information about the contingent consideration, refer to Note 14 and Note 16. (b) Pursuant to the Saol APA, the Company acquired inventory valued at $14,199 thousand which will be paid in ten quarterly installments of $1,500 thousand each or the remaining balance at the final installment. Such deferred inventory consideration totaled $13,788 thousand which represents the Fair value (Level 2) at the Acquisition Date. The interest rate used to calculate such fair value was based on the Company’s cost of debt, which was estimated based on the long-term bank loan obtained to partially fund the acquisition. Through December 31, 2023, the Company made eight quarterly installments on account of such inventory related debt. For further information about the deferred consideration, refer to Note 14b and Note 16. (c) In December 2019, the Company entered into a binding term-sheet for a 12-year contract manufacturing agreement with Saol to manufacture CYTOGAM. Through the Acquisition Date, the Company received a total of $3,786 thousand from Saol to partially fund the technology transfer activities required under such engagement. Such engagement was automatically terminated on the Acquisition Date, and such funds, previously accounted for as deferred revenues, were offset from the acquisition consideration as settlement of preexisting relationship. The following tables details the fair value of the identifiable assets and liabilities on the Acquisition Date: Fair value USD Inventory(a) 22,849 Intangible assets(b) 121,174 Assumed liability(c) (47,213 ) Net identifiable assets 98,810 Goodwill arising on acquisition(d) 29,897 Total acquisition cost 126,707 (a) Inventory was valued at cost which represent its fair value. (b) The following table details the intangible assets identified Fair value Customer Relations (1) 33,514 Intellectual property (2) 79,141 Assumed contract manufacturing agreement (3) 8,519 Total Intangible assets 121,174 (1) Customer Relations represents its fair value (Level 3) at the Acquisition Date, based on a Multi Period Excess Earnings Method (“MPEEM”). In measuring the Customer Relations, the Company used an appropriate risk-adjusted discount rate of 11% and churn rate of 5%. (2) Intellectual property represents its fair value (Level 3) at the Acquisition Date, based on a Relief from Royalties (“RFRM”) Method. In measuring the Intellectual property, the Company used an appropriate risk-adjusted discount rate of 11% and Royalties rate of 15.2%. (3) Assumed contact manufacturing agreement represents its fair value (Level 3) at the Acquisition Date, based on With and Without method. Under the With and Without method the value of an intangible asset is calculated by comparing the cash-flow in a situation where the valued asset is part of the business versus the cash-flow in situation where the asset is not part of the business. The Company used an appropriate risk-adjusted discount rate of 11%. (c) Pursuant to the Saol APA, the Company assumed certain of Saol’s liabilities for the future payment of royalties (some of which are perpetual) and milestone payments to third parties subject to the achievement of corresponding CYTOGAM related net sales thresholds and milestones. The fair value of such assumed liabilities at the Acquisition Date was estimated at $47,213 thousand, which was calculated based on the Option Pricing Method (OPM), Monte Carlo Simulation, and discounted cash flow using a discount rate in the range of 2.25 % and 11% and the volatility of 10.8-14.2%. Refer to Note 14 and Note 16 for more information. Such assumed liabilities include: ● Royalties:10% of the annual global net sales of CYTOGAM up to $ 25,000 thousand and 5% of net sales that are greater than $ 25,000 thousand, in perpetuity; 2% of the annual global net sales of CYTOGAM in perpetuity; and 8% of the annual global net sales of CYTOGAM for a period of six years following the completion of the technology transfer of the manufacturing of CYTOGAM to the Company, subject to a maximum aggregate of $5,000 thousand per year and the total amount of $30,000 thousand throughout the entire six years period. ● Sales milestones: $1,500 thousand in the event that the annual net sales of CYTOGAM in the United States market exceeds $18,766 thousand during the twelve months period ending June 30, 2022. Such milestone was achieved and paid during 2023; and $1,500 thousand in the event that the annual net sales of CYTOGAM in the United States market exceeds $18,390 thousand during the twelve months period ending June 30, 2023. Such milestone was not achieved and was written off the outstanding liability. ● Milestone: $8,500 thousand upon the receipt of FDA approval for the manufacturing of CYTOGAM at the Company’s manufacturing facility. During May 2023, the Company received such FDA approval and paid the milestone of $8,500 thousand. (d) The goodwill arising on acquisition is attributed to the expected benefits from the synergies of the combination of the activities of the Company and the acquired business. As of the Acquisition Date, the Company recognized the fair value of the assets acquired and liabilities assumed in the business combination according to a provisional measurement. As of December 31, 2022, the valuation of the identifiable assets and liabilities was completed. No adjustments were required to be recorded. The Company incurred acquisition related cost of $1,094 thousand related mainly to legal and other consulting fees. These costs were recorded in general and administrative expenses in the statement of profit and loss during 2021.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
CASH AND CASH EQUIVALENTS	Note 6: - Cash and Cash Equivalents December 31, 2023 2022 U.S. Dollars in thousands Cash and deposits for immediate withdrawal $ 40,630 $ 31,411 Cash equivalents in NIS deposits (1) 15,011 2,847 Total Cash and Cash Equivalents $ 55,641 $ 34,258 (1) The deposits bear interest of 5.1% per year, as of December 31, 2023, and 2.85%-3.8% per year as of December 31, 2022.

Trade Receivables, Net

Trade Receivables, Net	12 Months Ended
	Dec. 31, 2023
Trade Receivables, Net [Abstract]
TRADE RECEIVABLES, NET	Note 7: Trade Receivables, Net December 31, 2023 2022 U.S. Dollars in thousands Open accounts: In NIS $ 9,084 $ 9,469 In USD 10,642 17,659 $ 19,726 $ 27,128 Checks receivable 151 124 $ 19,877 $ 27,252 Less allowance for doubtful accounts(1) - - Total Trade receivables, net $ 19,877 $ 27,252 (1) As of December 31, 2023 and 2022 no allowance for doubtful accounts was recognized. An analysis of past due but not impaired trade receivables with reference to reporting date: Past due trade receivables with aging of Neither Up to 31-60 Days 61-90 Days 91-120 Days Over Total December 31, 2023 $ 18,294 $ 1,391 $ 11 $ 10 $ 26 $ 145 $ 19,877 December 31, 2022 $ 22,710 $ 3,260 $ 788 $ 84 $ 7 $ 402 $ 27,252

Other Accounts Receivables

Other Accounts Receivables	12 Months Ended
	Dec. 31, 2023
Other Accounts Receivables [Abstract]
OTHER ACCOUNTS RECEIVABLES	Note 8: - Other Accounts Receivables December 31, 2023 2022 U.S. Dollars in thousands Prepaid expenses $ 4,405 $ 3,875 Inventory designated for R&D activities - 3,732 Government authorities 981 645 Derivatives financial instruments mainly measured at fair value through other comprehensive income 149 - Accrued income 45 451 Other(1) 385 7 Total Other Accounts Receivables $ 5,965 $ 8,710 (1) The balance includes short-term lease in the amount of $134 thousand that was classified to other accounts receivables (refer to Note 15 for further details), and $247 thousand bank guarantee provided (refer to Note 19 for further details).

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
INVENTORIES	Note 9: - Inventories December 31, 2023 2022 U.S. Dollars in thousands Finished products $ 42,526 $ 30,429 Purchased products 11,021 4,754 Work in progress 6,653 12,276 Raw materials 28,279 21,326 Total Inventories $ 88,479 $ 68,785 (1) During the years 2023, 2022 and 2021, the Company recognized, as cost of revenues, an impairment for inventories carried at net realizable value totaled of $4,399 thousand, $3,996 thousand, and $2,982 thousand, respectively.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	Note 10: - Property, Plant And Equipment a. Composition and changes: 2023 Land and Machinery Vehicles Computers, Leasehold (2) Total U.S. Dollars in thousands Cost Balance at January 1, 2023 $ 35,090 $ 35,343 $ 31 $ 10,337 $ 1,566 $ 82,367 Additions 951 2,764 - 1,135 1,544 6,394 Sale and write-off - (110 ) - - (17 ) (127 ) Balance as of December 31, 2023 36,0418 37,997 31 11,472 3,093 88,631 Accumulated Depreciation Balance as of January 1, 2023 22,154 25,493 26 7,882 655 56,210 Depreciation 1,140 1,875 3 1,168 123 4,309 Sale and write-off - (109 ) - - - (109 ) Balance as of December 31, 2023 23,294 27,259 29 9,050 778 60,410 Depreciated cost as of December 31, 2023 $ 12,747 $ 10,738 $ 2 $ 2,422 $ 2,315 $ 28,224 (1) Including labor costs charged in 2023 to the cost of facilities, machinery, and equipment in the amount of $1,426 thousand. (2) Including Right – of use assets depreciation expense in the amount of $20 thousand that was capitalized to the Leasehold Improvements during 2023. Also refer to Note 15. 2022 Land and Machinery Vehicles Computers, Leasehold Total U.S. Dollars in thousands Cost Balance at January 1, 2022 $ 34,543 33,439 31 9,371 1,184 78,568 Additions 547 1,906 - 966 382 3,801 Sale and write-off - (2 ) - - - (2 ) Balance as of December 31, 2022 35,090 35,343 31 10,337 1,566 82,367 Accumulated Depreciation Balance as of January 1, 2022 21,091 23,804 23 6,808 535 52,261 Depreciation 1,063 1,691 3 1,074 120 3,951 - (2 ) - - - (2 ) Balance as of December 31, 2022 22,154 25,493 26 7,882 655 56,210 Depreciated cost as of December 31, 2022 $ 12,936 $ 9,850 $ 5 $ 2,455 $ 911 $ 26,157 (1) Including labor costs charged in 2022 to the cost of facilities, machinery, and equipment in the amount of $1,403 thousands. b. As for liens, refer to Note 19. c. Leasing rights of land from the Israel land administration. December 31, 2023 2022 U.S. Dollars in thousands Under finance lease $ 1,091 $ 1,119 Kamada Assets Ltd., a subsidiary of the Company, capitalized leasing rights from the Israel Lands Administration for an area of 16,880 m² in Beit Kama, Israel, on which the Company’s manufacturing plant and other buildings are located. As part of a new outline which were approved during 2021, the plant area was adjusted to 14,880 m². The amount attributed to capitalized rights is presented under property, plant and equipment and is depreciated over the leasing period, which includes the option period. During 2010, Kamada Assets signed an agreement with the Israel Lands Administration to consolidate its leasing rights and extend the lease period to 2058; the lease also includes an extension option allowing the parties to extend the lease for an additional 49 years following the conclusion of the initial term.

Intangible Assets, Goodwill and

Intangible Assets, Goodwill and Other Long Term Assets	12 Months Ended
	Dec. 31, 2023
Intangible Assets, Goodwill and Other Long Term Assets [Abstract]
Intangible Assets, Goodwill and Other Long Term Assets	Note 11: - Intangible Assets, Goodwill and Other Long Term Assets December 31, 2023 2022 U.S. Dollars in thousands Intangible Assets and Goodwill 139,955 147,009 Long term pre-paid expenses 510 63 Total Other Long-Term Assets $ 140,465 $ 147,072 1. Intangible Assets: (a) Composition and changes 2023 Intellectual Customer Goodwill Other Total U.S. Dollars in thousands Cost: Balance as of January 1, 2023 80,103 $ 33,514 $ 30,313 $ 11,101 $ 155,031 Purchases - - - 129 129 Balance as of December 31, 2023 $ 80,103 $ 33,514 $ 30,313 $ 11,230 $ 155,160 Accumulated amortization and impairment: Balance as of January 1, 2023 5,853 1,855 - 314 8,022 Amortization recognized in the year 5,376 1,676 - 131 7,183 Balance as of December 31, 2023 11,229 3,531 - 444 15,204 Amortized cost at December 31, 2023 $ 68,874 $ 29,983 $ 30,313 $ 10,785 $ 139,955 (1) Includes assumed contract manufacturing agreement and distribution right of certain therapeutic products to be distributed in Israel, subject to IL MOH and or EMA marketing authorization. The Company was required to make certain upfront and milestone payments on account of such distribution rights. These payments are accounted for as long-term assets through obtaining IL MOH marketing authorization and will subsequently be amortized during the expected distribution right’s useful life. 2022 Intellectual Customer Goodwill Other Total U.S. Dollars in thousands Cost: Balance as of January 1, 2022 80,103 33,514 30,313 10,501 154,431 Purchases - - - 600 600 Balance as of December 31, 2022 $ 80,103 $ 33,514 $ 30,313 $ 11,101 $ 155,031 Accumulated amortization and impairment: Balance as of January 1, 2022 477 179 - 183 839 Amortization recognized in the year 5,376 1,676 - 131 7,183 Balance as of December 31, 2022 5,853 1,855 - 314 8,022 Amortized cost at December 31, 2022 $ 74,250 $ 31,659 $ 30,313 $ 10,787 $ 147,009 (b) Amortization: Amortization expenses of intangible assets are classified in statement of profit or loss as follows: Year ended December 31, 2023 2022 2021 USD in thousands Cost of goods sold 5,376 5,376 574 Selling and marketing expenses 1,807 1,807 265 7,183 7,183 839 (d) Allocation of goodwill to cash-generating units December 31, 2023 2022 U.S. Dollars in thousands Proprietary $ 30,313 $ 30,313 The goodwill is attributed to the Proprietary Products segment, which represent the lowest level within the Company at which goodwill is monitored for internal management purposes. Impairment test of goodwill for the year ended on December 31, 2023: Impairment loss for goodwill is recognized if the recoverable amount of the goodwill is less than the carrying amount. The recoverable amount is the greater of fair value less costs of disposal, or value in use of the relevant reporting level (i.e., a CGU of a group of CGUs). The Company performed an assessment for goodwill impairment for its Proprietary Products segment, which is the level at which goodwill is monitored for internal management purposes, and concluded that the fair value of the Proprietary Products segment exceeds the carrying amount by approximately 16%. The carrying amount of goodwill assigned to this segment is in the amount of $30,313 thousand. When evaluating the fair value of the Proprietary Products segment, the Company used a discounted cash flow model which utilized Level 3 measures that represent unobservable inputs. Key assumptions used to determine the estimated fair value include: (a) internal cash flows forecasts for 5 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long-term future growth rate of -4.8% determined based on the long-term expected prospects of the reporting unit; and (c) a discount rate (post-tax) of 11.8 % which reflects the weighted-average cost of capital adjusted for the relevant risk associated with the Proprietary Products segment’s operations. Actual results may differ from those assumed in the Company’s valuation method. It is reasonably possible that the Company’s assumptions described above could change in future periods. If any of these were to vary materially from the Company’s plans, it may record impairment of goodwill allocated to this reporting unit in the future. A hypothetical decrease in the growth rate of 1% or an increase of 1% to the discount rate would have reduced the fair value of the Proprietary Products segment reporting unit by approximately $4,800 thousand and $21,000 thousand, respectively. The sensitivity analysis described above does not lead to increase of the recoverable amount over the carrying amount. Based on the Company’s assessment as of December 31, 2023, no goodwill was determined to be impaired.

Trade Payables

Trade Payables	12 Months Ended
	Dec. 31, 2023
Trade Payables [Abstract]
TRADE PAYABLES	Note 12: - Trade Payables December 31, 2023 2022 U.S. Dollars in thousands Open debts mainly in USD $ 11,167 $ 12,731 Open debts in EUR 7,266 10,629 Open debts in NIS 6,371 9,557 Total Trade Payables $ 24,804 $ 32,917

Other Accounts Payables

Other Accounts Payables	12 Months Ended
	Dec. 31, 2023
Other Accounts Payables [Abstract]
OTHER ACCOUNTS PAYABLES	Note 13: - Other Accounts Payables a. Composition: December 31, 2023 2022 U.S. Dollars in thousands Employees and payroll accruals $ 7,542 $ 6,683 Government grants (b) 177 201 Derivatives financial instruments - 92 Accrued Expenses and Others 542 609 Total Other Accounts Payables $ 8,261 $ 7,585 b. Government grants: Presented in the statement of financial position and Profit or Loss and Other Comprehensive Income: December 31, 2023 2022 U.S. Dollars in thousands Current Assets $ 104 $ 3 Current liability $ 177 $ 201 Royalties paid during the year $ - $ - Expense (income) carried to Research and Development cost $ 61 $ 29

Loans and Financial Liabilities

Loans and Financial Liabilities	12 Months Ended
	Dec. 31, 2023
Loans and Financial Liabilities [Abstract]
LOANS AND FINANCIAL LIABILITIES	Note 14: - Loans and Financial liabilities a. Bank Loans December 31, 2023 2022 U.S. Dollars in thousands Bank loans (1) - 17,407 Less current maturities of bank loans - 4,444 Total Long term bank loans $ - $ 12,963 1. Bank loan On November 15, 2021, the Company secured a $40,000 thousand credit facility from Bank Hapoalim, an Israeli bank. The credit facility comprised of the following: (1) A $20,000 thousand long-term loan. The loan bore an interest at a rate of SOFR (Secured Overnight Financing Rate) +2.18% and was payable over 54 equal monthly installments commencing June 16, 2022. On September 19, 2023, the Company repaid in full the outstanding balance of the loan. (2) A $20,000 thousand short-term revolving credit facility. The credit facility bore an interest at a rate of SOFR +1.75%, or a commitment fee of 0.2% calculated over the unutilized balance of the facility. As of December 31, 2022, the Company did not utilize such facility. The credit facility was in effect for an initial period of 12 months, and effective as of January 1, 2023, the credit facility was amended such that the $20 million short-term revolving credit facility was reduced to a NIS 35 million (approx. $10 million) credit facility and the credit facility was extended for an additional period of 12 months. Borrowings under the amended credit facility accrue interest at a rate of PRIME + 0.55 and are repayable no later than 12 months from the date advanced. The Company is required to pay an annual fee of 0.275% for the Bank’s credit allocation. As of December 31, 2023, the Company did not utilize such facility. On January 1, 2024, the credit facility was extended for an additional 12 months. Pursuant to the loan and credit facility agreement, the Company is required to meet the following financial covenants for the years ending December 31, 2022, and onwards: (1) The Shareholder’s Equity shall at no time be less than 30% of the Total Assets; examined on a quarterly basis; (2) The Shareholder’s Equity shall at no time be less than $120,000 thousand; examined on a quarterly basis; (3) The ratio between:(a) the short term financial debt less current maturities of long term debt (in as much as such are included therein); and (b) the Working Capital, as such term is defined in the loan agreement, shall at no time exceed 0.8; examined on a quarterly basis; and (4) The ratio between: (a) the EBITDA as such term is defined in the loan agreement; and (b) the current maturities of long term debt to financial institutions plus out of pocket financial expenses, net, reported in the course of four consecutive quarters immediately preceding the examination date, shall not be less than 1.1 during each of the years 2022 and 2024 and not less than 1.25 in the year 2025 and onwards, examined on an annual basis. As of December 31, 2023 and 2022, the Company was in compliance with the financial covenants. See Note 14 regarding pledge information related to the bank loans. b. Financial liabilities originated or assumed through business combinations December 31, 2023 2022 U.S. Dollars in thousands Contingent consideration (1) 21,855 23,534 Assumed liabilities (2) 46,375 61,016 Less current maturities (14,996 ) (29,708 ) Total Long term contingent consideration and assumed liabilities $ 53,234 54,842 (1) The fair value of the contingent consideration was $21,855 thousand and $23,534 thousand as of December 31, 2023, and December 31, 2022, respectively. During the year ended December 31, 2023, the Company paid the first sales milestone in the amount of $3,000 thousand, which was accounted for as a reduction of the liability. The Company accounted for $1,321 thousand, $1,539 thousand, and $290 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively as financing expenses in the statement of profit and loss to reflects the changes in the fair value of the liability. Through December 31, 2023, the second sales threshold was met, and the second milestone payment was paid during February 2024. Refer to Note 5b and Note 18 for details on the contingent consideration. (2) The assumed liabilities are measured at amortized cost. The decrease in the balance of the assumed liabilities reflects the changes in time value and changes in expected payments. The value of the assumed liabilities was $46,375 thousand and $61,016 thousand as of December 31, 2023, and 2022, respectively. During the years ended December 31, 2023, and 2022, the Company paid a total of $14,300 thousand and $5,626 thousand on account of such assumed liabilities. The Company accounted for $341 thousand of financing income and $4,727 thousand, and $704 thousand of financing expenses for the years ended December 31, 2023, 2022 and 2021, respectively to reflects the changes in the value of the assumed liabilities.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
LEASES	Note 15: - Leases Leases The Company has lease agreements with respect to the following items: 1. Office and storage spaces: On November 2016, the Company entered into a lease agreement for office space and a laboratory facility in Rehovot, Israel for an initial period of ten years (which includes a three-year extension through November 2026). In March 2023, the lease agreement was amended and the lease period was extended for an additional eight years through January 2032. On March 7, 2023, the Company's U.S. subsidiary Kamada Plasma LLC entered into a lease agreement for a 12,000 square feet premises in Uvalde, Houston, Texas to be used as a plasma collection center. The lease is in effect for an initial period of ten years commencing February 2024, and includes an option to extend the lease for two consecutive periods of five years each. 2. Vehicles: The Company leases vehicles for the use of certain of its employees. The lease term is mainly for three-year periods from several leasing entities. 3. Office equipment (i.e. printing and photocopying machines): The Company leases office equipment (i.e., printing and photocopying machines), each for a five-year period. Right-of-use assets composition and changes in lease liabilities Right-of-use-assets Rented (3) Vehicles Computers, Total Lease (1)(2) U.S Dollars in thousands As of January 1, 2023 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 Additions to right-of-use assets 5,131 1,415 - 6,546 6,682 Termination lease (109 ) - (109 ) (107 ) Depreciation expense (500 ) (738 ) (6 ) (1,244 ) - Exchange rate differences - - - - (96 ) Repayment of lease liabilities - - - - (850 ) As of December 31, 2023 $ 6,363 $ 1,397 $ 1 $ 7,761 $ 8,822 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 3.06%–7.11% evaluated based on credit risk, terms of the leases and other economic variables. (2) The balance does not include current maturities of lease of $134 thousand that were classified to other accounts receivables due to expected lease incentive. (3) Out of the Depreciation expense $20 thousand was capitalized to the Leasehold Improvements. During 2023, the Company recognized $367 thousand as interest expenses on lease liabilities. During 2023, the total cash outflow for leases was $850 thousand. Right-of-use-assets Rented Vehicles Computers, Total Lease (1) U.S Dollars in thousands As of January 1, 2022 $ 2,165 $ 913 $ 15 $ 3,093 $ 4,314 Additions to right -of -use assets - 551 - 551 551 Lease termination - (52 ) - (52 ) (59 ) Depreciation expense (433 ) (583 ) (8 ) (1,024 ) Exchange rate differences - - - - (448 ) Repayment of lease liabilities - - - - (1,164 ) As of December 31, 2022 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 1.94%-4.6% evaluated based on credit risk, terms of the leases and other economic variables. During 2022, the Company recognized $148 thousand as interest expenses on lease liabilities. During 2022, the total cash outflow for leases was $1,164 thousand. Maturity analysis of the Company’s lease liabilities (including interest): As of December 31, 2023: Less than 1 to 2 2 to 3 3 to 5 6 and Total Lease liabilities (including interest) $ 2,918 $ 3,045 $ 1,689 $ 2,009 $ 6,759 $ 16,420 As of December 31, 2022: Less than 1 to 2 2 to 3 3 to 5 6 and Total Lease liabilities (including interest) $ 1,119 $ 907 $ 732 $ 683 $ - $ 3,441 Lease extension The Company has leases that include extension options. These options provide flexibility in managing the leased assets and align with the Company’s business needs. The Company exercises judgement in deciding whether it is reasonably certain that the extension options will be exercised. The lease agreement entered into by Kamada Plasma LLC for the premises in Uvalde, Texas to be used as a plasma collection center is in effect for an initial period of ten years and Kamada Plasma LLC has the option to extend the lease for two consecutive periods of five years each, upon six months prior written notice. The Company has reasonable certainty that the extension option will be exercised in order to avoid a significant adverse impact to its operating activities.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
FINANCIAL INSTRUMENTS	Note 16: - Financial Instruments a. Classification of financial assets and liabilities The financial assets liabilities in the balance sheet are classified by groups of financial instruments pursuant to IFRS 9: December 31, 2023 2022 U.S. Dollars in thousands Financial assets Financial assets at fair value through profit or loss: Foreign exchange forward contracts 8 - Total Financial assets at fair value through profit or loss $ 8 $ - Financial assets at fair value through other comprehensive income: Cash flow hedges 141 - Total Financial assets at fair value through other comprehensive income: $ 141 $ - Financial assets at cost: Cash and cash equivalent 55,641 34,258 Total Financial assets at cost $ 55,641 $ 34,258 Total financial assets $ 55,790 $ 34,258 Financial liabilities Financial liabilities at fair value through profit or loss: Foreign exchange forward contracts - 4 Contingent consideration in business combination 21,855 23,534 Total financial liabilities at fair value through profit or loss $ 21,855 $ 23,538 Financial liabilities at fair value through other comprehensive income: Cash flow hedges - 88 Total financial liabilities at fair value through other comprehensive income $ - $ 88 Financial liabilities measured at amortized cost: Assumed liabilities through business combination 46,375 61,016 Bank loans - 17,407 Leases 8,822 3,193 Total financial liabilities measured at amortized cost $ 55,197 $ 81,616 Total financial and lease liabilities $ 77,052 $ 105,242 b. Financial risk factors The Company’s activities expose it to various financial risks, such as market risk (foreign currency risk, interest rate risk and price risk), credit risk and liquidity risk. The Company’s investment policy focuses on activities that will preserve the Company’s capital. The Company utilizes derivatives to hedge certain exposures to risk. Risk management is the responsibility of the Company’s management and specifically that of the Company’s Chief Executive Officer (CEO) and Chief Financial Officer (CFO), in accordance with the policy approved by the Board of Directors. The Board of Directors provides principles for the overall risk management. 1. Market risks Foreign exchange risk The Company operates in an international environment and is exposed to foreign exchange risk resulting from the exposure to different currencies, mainly the NIS and EUR. Foreign exchange risks arise from recognized assets and liabilities denominated in a foreign currency other than the functional currency, such as trade and other accounts receivables, trade and other accounts payables, loans and capital leases. As of December 31, 2023, and 2022, the Company held financial derivatives intended to hedge changes in the exchange rate of the USD vs. the NIS and the EUR (see also Note 16f. below). 2. Credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term bank deposits, trade receivables and foreign currency derivative contracts. a) Cash, cash equivalent and short term investments: The Company holds cash, cash equivalents, short term deposits and other financial instruments at major financial institutions in Israel and the United States. In accordance with Company policy, evaluations of the relative strength of credit of the various financial institutions are made on an ongoing basis. Short-term investments include short-term deposits with low risk for a period less than one year. b) Trade receivables: The Company regularly monitors the credit extended to its customers and their general financial condition, and, when necessary, requires collateral as security for the debt such as letters of creditor and down payments. In addition, the Company partially insures its overseas sales with foreign trade risk insurance. Refer to Note 7 for additional information. The Company keeps constant track of customer debt, and, to the extent required, accounts for an allowance for doubtful accounts that adequately reflects, in the Company’s assessment, the loss embodied in the debts the collection of which is in doubt. The Company’s maximum exposure to credit risk for the components of the statement of financial position as of December 31, 2023, and 2022 is the carrying amount of trade receivables. c) Foreign currency derivative contracts: The Company is exposed to foreign currency exchange fluctuations, primarily in USD vs. NIS and EUR. Consequently, it enters into various foreign currency exchange contracts with major financial institutions (see also Note 16f. below). d) Interest rate risk: Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s long-term liabilities with floating interest. 3. Liquidity risk The table below summarizes the maturity profile of the Company’s financial liabilities based on contractual undiscounted payments: December 31, 2023 Less than 1 to 2 2 to 3 3 to 5 6 and Total Trade payables $ 24,804 - - - - 24,804 Assumed liabilities (1) 11,996 4,152 4,261 7,836 18,130 46,375 Other accounts payables 8,261 - - - - 8,261 Lease liabilities (including interest) 2,918 3,045 1,689 2,009 6,759 16,420 $ 47,979 7,197 5,950 9,845 24,889 95,860 (1) Due the nature of the account which include infinite payments for royalties and milestones to third parties the assumed liabilities reflect the discounted amount. see Note 18e December 31, 2022 Less than 1 to 2 2 to 3 3 to 5 6 and Total Trade payables $ 32,917 - - - - $ 32,917 Assumed liabilities 23,708 5,030 4,087 7,928 20,263 61,016 Other accounts payables 7,585 - - - - 7,585 Bank loans (including interest) 4,841 4,677 4,580 4,111 - 18,208 Lease liabilities (including interest) 1,119 907 732 683 - 3,441 $ 70,170 $ 10,614 $ 9,399 $ 12,722 $ 20,263 $ 123,167 Changes in liabilities arising from financing activities January 1, Payments Foreign New Business Revaluation Write off December 31, U.S. Dollars in thousands Contingent consideration (1) 23,534 (3,000 ) - - - 1,321 21,855 Assumed liabilities 61,016 (14,300 ) - - (341 ) 46,375 Bank loans 17,407 (17,407 ) - - - - Leases 3,193 (850 ) (96 ) 6,682 - - (107 ) 8,822 Total $ 105,150 $ (35,557 ) $ (96 ) $ 6,682 $ - $ 980 $ (107 ) $ 77,052 (1) The contingent consideration fair value as of December 31, 2023, was based on an Option Pricing Method (OPM), “Monte Carlo Simulation” model. In measuring the contingent consideration liability, the Company used an appropriate risk-adjusted discount rate of 11.4% and volatility of 15.17%. totaled $21,855 thousand. c. Fair value The following table demonstrates the carrying amount and fair value of the financial assets and liabilities presented in the financial statements not at fair value: Carrying Amount Fair Value December 31, December 31, 2023 2022 2023 2022 U.S. Dollars in thousands Assumed liabilities 46,375 61,016 46,468 56,946 Bank loans - 17,407 - 17,071 Leases 8,822 3,193 8,973 3,183 Total Financial liabilities $ 55,197 $ 81,616 $ 55,441 $ 77,200 The fair value of the bank loans, leases and the assumed liabilities was based on standard pricing valuation model such as a discounted cash-flow model which considers the present value of future cash flows discounted by an interest rate that reflects market conditions (Level 3). The carrying amount of cash and cash equivalents, short-term bank deposits, trade and other receivables, trade and other payables approximates their fair value, due to the short-term maturities of the financial instruments. d. Classification of financial instruments by fair value hierarchy Financial assets (liabilities) measured at fair value: Financial assets (liabilities) measured at fair value: Level 1 Level 2 Level 3 (1) U.S. Dollars in thousands December 31, 2023 Derivatives instruments - 149 - Contingent consideration(1) - - (21,855 ) $ - $ 149 $ (21,855 ) Financial assets (liabilities) measured at fair value: Level 1 Level 2 Level 3 (1) U.S. Dollars in thousands December 31, 2022 Derivatives instruments - (92 ) - Contingent consideration(1) - - (23,534 ) $ - $ (92 ) $ (23,534 ) (1) For changes in Contingent Consideration see above During 2023 and 2022, there was no transfer due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument. Sensitivity tests and principal work assumptions The selected changes in the relevant risk variables were determined based on management’s estimate as to reasonable possible changes in these risk variables. The Company has performed sensitivity tests of principal market risk factors that are liable to affect its reported operating results or financial position. The sensitivity tests present the profit or loss in respect of each financial instrument for the relevant risk variable chosen for that instrument as of each reporting date. The test of risk factors was determined based on the materiality of the exposure of the operating results or financial condition of each risk with reference to the functional currency and assuming that all the other variables are constant. December 31, 2023 2022 U.S. Dollars in thousands Sensitivity test to changes in interest rate risk Gain (loss) from change: 1% increase in basis points of SOFR $ - $ (13 ) 1% decrease in basis points of SOFR $ - $ 13 Sensitivity test to changes in foreign currency: Gain (loss) from change: 5% increase in NIS $ (454 ) $ (57 ) 5% decrease in NIS $ 454 $ 57 5% increase in Euro $ (271 ) $ (389 ) 5% decrease in Euro $ 271 $ 389 e. Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9: December 31, 2023 2022 U.S. Dollars in thousands In NIS: Bank loans measured at amortized cost $ - $ - Leases measured at amortized cost 6,275 3,193 $ 6,275 $ 3,193 In USD: Contingent consideration at fair value through profit or loss 21,855 23,534 Assumed liabilities measured at amortized cost 46,375 61,016 Bank loans measured at amortized cost - 17,407 Leases measured at amortized cost (1) 2,547 - $ 70,777 $ 101,957 1 The balance does not include current maturities of lease of $134 thousand that was classified to other accounts receivables due to expected lease incentive. f. Derivatives and hedging: Derivatives instruments not designated as hedging The Company has foreign currency forward contracts designed to protect it from exposure to fluctuations in exchange rates, mainly of NIS and EUR, in respect of its trade receivables, trade payables. Foreign currency forward contracts are not designated as cash flow hedges, fair value or net investment in a foreign operation. These derivatives are not considered as hedge accounting. As of December 31, 2023, the fair value of the derivative instruments not designated as hedging was a financial asset of $8 thousand. The open transactions for those derivatives were in an amount of $9,149 thousands. Cash flow hedges As of December 31, 2022, the Company held NIS/USD hedging contracts (cylinder contracts) designated as hedges of expected future salaries expenses and for expected future purchases from Israeli suppliers. The main terms of these positions were set to match the terms of the hedged items. As of December 31, 2023, the fair value of the derivative instruments designated as hedge accounting was an asset of $141 thousand. The open transactions for those derivatives were in an amount of $389 thousand. Cash flow hedges of the expected salaries and suppliers’ expenses as of December 31, 2023, were estimated as effective and accordingly a net unrecognized income was recorded in other comprehensive income in the amount of $228 thousand, net. The ineffective portion was allocated to finance expenses.

Employee Benefit Liabilities, N

Employee Benefit Liabilities, Net	12 Months Ended
	Dec. 31, 2023
Employee Benefit Liabilities, Net [Abstract]
EMPLOYEE BENEFIT LIABILITIES, NET	Note 17: - Employee Benefit Liabilities, NET Employee benefits consist of short-term benefits and post-employment benefits. Post-employment benefits: According to the labor laws and Israeli Severance Pay Law, the Company is required to pay compensation to an employee upon dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Israeli Severance Pay Law, as specified below. The Company’s liability is accounted for as a post-employment benefit only for employees not under Section 14. The computation of the Company’s employee benefit liability is made in accordance with a valid employment contract, or a collective bargaining agreement based on the employee’s salary and employment terms which establish the entitlement to receive the compensation. The post-employment employee benefits are normally financed by contributions classified as defined benefit plans, as detailed below: 1. Defined contribution deposit Israeli employees defined contribution plan: The Company’s agreements with part of its employees are in accordance with Section 14 of the Israeli Severance Pay Law. Contributions made by the Company in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. The expenses for the defined benefit deposit in 2023, 2022 and 2021 were $925 thousand, $873 thousand, and $1,023 thousand, respectively. U.S. employees defined contribution plan: Since August 2022, the Company’s U.S. subsidiary has a 401(k) defined contribution plan covering certain employees in the U.S. During the years ended December 31, 2023, and December 31, 2022 the U.S. subsidiary recorded expenses for matching contributions in the amount of $62 thousand and $11 thousand, respectively. 2. Defined benefit plans The Company accounts for the payment of compensation as a defined benefit plan for which an employee benefit liability is recognized and for which the Company deposits amounts in a long-term employee benefit fund and in qualifying insurance policies. 3. Expenses recognized in comprehensive income (loss): Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Current service cost $ 194 $ 223 $ 281 Past service cost - - 415 Interest expenses, net 28 15 23 Total employee benefit expenses 222 238 716 Actual return on plan assets $ 50 $ (25 ) $ 349 The expenses are presented in the Statement of Comprehensive income (loss) as follows Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Cost of revenues $ 155 $ 166 $ 499 Research and development 22 24 90 Selling and marketing 33 27 62 General and administrative 23 21 65 $ 233 $ 238 $ 716 4. The plan liabilities, net: December 31, 2023 2022 U.S. Dollars in thousands Defined benefit obligation $ 4,399 $ 4,379 Fair value of plan assets 3,778 3,707 Total liabilities, net $ 621 $ 672 5. Changes in the present value of defined benefit obligation 2023 2022 U.S. Dollars in thousands Balance at January 1, $ 4,380 $ 5,434 Interest costs 200 78 Current service cost 194 223 Past service cost - - Benefits paid (376 ) (202 ) Demographic assumptions 13 (9 ) Financial assumptions (91 ) (715 ) Past Experience 209 206 Currency Exchange (130 ) (636 ) Balance at December 31, $ 4,399 $ 4,379 6. Plan assets a) Plan assets Plan assets comprise assets held by long-term employee benefit funds and qualifying insurance policies. b) Changes in the fair value of plan assets 2023 2022 U.S. Dollars in thousands Balance at January 1, $ 3,707 $ 4,154 Expected return 172 62 Contributions by employer 173 181 Benefits paid (206 ) (181 ) Demographic assumptions - - Financial assumptions - (4 ) Past Experience 50 (20 ) Currency exchange (118 ) (485 ) Balance at December 31, $ 3,778 $ 3,707 7. The principal assumptions underlying the defined benefit plan 2023 2022 2021 % Discount rate of the plan liability 5.3 5.1 3.1 Future salary increases 3.0 3.0 3.0 The sensitivity analyses below have been determined based on reasonably possible changes of the principal assumptions underlying the defined benefit plan as mentioned above, occurring at the end of the reporting period. In the event that the discount rate would be one percent higher or lower, and all other assumptions were held constant, the defined benefit obligation would decrease by $92 thousand or increase by $124 thousand, respectively. In the event that the expected salary growth would increase or decrease by one percent, and all other assumptions were held constant, the defined benefit obligation would increase by $118 thousand or decrease by $87 thousand, respectively.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	12 Months Ended
	Dec. 31, 2023
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	Note 18: - Contingent Liabilities and Commitments a. On August 23, 2010, the Company entered into a 30 year collaboration agreement with Baxter Healthcare Corporation (“Baxter”) with respect for granting of the distribution rights for GLASSIA. During 2015, Baxter assigned all its rights under the collaboration agreement to Baxalta US Inc. (“Baxalta”) which was acquired during 2016 by Shire plc. (“Shire”), which is now part of Takeda (“Takeda” and in these consolidated financial statements Baxter, Baxalta and Shire will be referred to as “Takeda”). The collaboration agreement consists of three main agreements (1) an Exclusive Manufacturing, Supply and Distribution agreement for GLASSIA in the United States, Canada, Australia and New Zealand (the “Territory” and the “Distribution Agreement”, respectively); (2) Technology License Agreement for the use of the Company’s knowhow and patents for the production, continued development and sale of GLASSIA by Takeda (the “License Agreement”) in the Territory; and (3) A Paste Supply Agreement for the supply by Takeda of plasma derived fraction IV-1 to be used by the Company for the production of GLASSIA (the “Raw Materials Supply Agreement”). Pursuant to the agreements, the Company was entitled to certain upfront and milestone payments at a total amount of $45 million, and for a minimum commitment of Takeda to acquire GLASSIA produced by the Company over the first five years of the term of the Distribution Agreement. In addition, upon initiation of sales of GLASSIA manufactured by Takeda, the Company would be entitled to royalty payments at a rate of 12% on net sales of Glassia through August 2025, and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually (the “Royalty Payments”). Through December 31, 2021, the Company accounted for as income all of the $45 million associated with the upfront and milestone payments from Takeda pursuant to the Distribution and License Agreements as amended. On March 31, 2021, the Company entered into an amendment to the Technology License Agreement with Takeda with respect to GLASSIA. Pursuant to the amendment the Company undertook to transfer to Takeda the U.S. Biologics License Application (BLA) of the product upon completion of the transition of GLASSIA manufacturing to Takeda, in consideration for a $2 million payment from Takeda. Such amount was paid by Takeda and accounted for as income during the first quarter of 2022. During 2021 the Company terminated the production and supply of GLASSIA to Takeda and Takeda initiated its own production of GLASSIA for distribution in the Territory. Accordingly, commencing 2022, Takeda initiated royalty payments to the Company as defined above. For the years ended December 31, 2023, and 2022 the Company accounted for a total of $16.11 million and $12.2 million from sales-based royalty income from Takeda, respectively. Pursuant to the Distribution Agreement, Takeda is responsible to conduct any required additional clinical studies required to obtain or maintain GLASSIA’s marketing authorization in the Territory. Under certain conditions, the Company will be required to participate in the funding of these clinical studies in a total amount not to exceed $10 million. Pursuant to the Raw Material Supply Agreement Takeda undertook to provide the Company, free of charge, all quantities of plasma derived fraction IV-1 required by the Company for manufacturing GLASSIA to be sold to Takeda for distribution in the Territory. The Company accounts for the fair value of the plasma derived fraction IV-1 used and sold as revenues and charges the same fair value to cost of revenue. In addition, the Company has the right to acquire from Takeda plasma derived fraction IV-1 for its continued development and for the production, sale and distribution of GLASSIA by the Company outside the Territory. b. In November 2006, the Company entered into an agreement with PARI GmbH (“PARI”) in connection with a supply by PARI of a certain medical device required for the development of the Company’s Inhaled AAT product. Pursuant to the agreement, the Company was licensed to use developments made by PARI. Furthermore, PARI will provide the Company certain quantities of devices for carrying out clinical trials, free of charge. In the event that the development is successful, and the underlining product obtains required marketing authorization, the Company will pay PARI royalties based on sales of the devices through the later of the device patents expiration period or 15 years from the first commercial sale of the Company’s the Inhaled AAT product. On expiration of the royalty period, the license will become non-exclusive, and the Company shall be entitled to use the rights granted to it pursuant to the agreement without paying royalties or any other compensation. In addition, and according to a mechanism set in the agreement, PARI would be required to pay royalties to the Company of the total net sales of the device exceeding a certain amount, through the later of the device patents expiration period or 15 years from the first commercial sale of the Company’s Inhaled AAT product. In February 2008, the parties executed an amendment to the agreement according to which the exclusive global license granted to the Company was expanded to two additional indications. The royalties’ obligations mentioned above, are applicable to all indications. In addition, the parties entered into a commercialization and supply agreement, which ensures long-term regular supply of the device, including spare parts. In May 2019, the Company signed a Clinical Study Supply Agreement (“CSSA”) with PARI for the supply of the required quantities of controller kits and the web portal associated with PARI’s device required for the Company’s continued clinical trials with respect to the Inhaled AAT product. The CSSA is a supplement agreement to the commercialization and supply agreement and will expire upon the expiration or termination of such agreement. c. In July 2011, the Company entered into a strategic collaboration agreement with Kedrion Biopharma Inc. (“Kedrion”) for clinical development, marketing, distribution, and sales in the United States of the Company’s rabies immune globulin (Human) under the trade name KEDRAB. The product is manufactured and marketed by the Company in other countries under a different trade name KAMRAB. The Company obtained U.S marketing authorization from the FDA for KEDRAB in August 2017, and the commercial launch of the product in the United States was initiated at the beginning of 2018. In October 2016, the parties entered into an amendment to the agreement pursuant to which the parties agreed to conduct a required post-marketing-commitment clinical study which was initiated in March 2017 and finalized during 2020. The cost of the study was equally shared between the parties. In April 2020, the Company entered into a binding term sheet with Kedrion for the co-development, manufacturing and distribution of a human plasma-derived Anti-SARS-CoV-2 polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients. The plasma-derived Anti-SARS-CoV-2 IgG product was developed and manufactured utilizing the Company’s proprietary IgG platform technology. Pursuant to the agreed terms, Kedrion provided plasma, collected at its U.S. plasma collection centers, from donors who have recovered from the virus. The Company was responsible for product development, manufacturing, clinical development, with Kedrion’s support, and regulatory submissions. The binding term sheet remained in effect until June 30, 2021. No definitive agreement was entered to between the parties, and the Company terminated this product development program. In December 2023, the Company entered into a binding memorandum of understanding with Kedrion for the amendment and extension of the distribution agreement between the parties. Under the term of the binding memorandum of understanding, during fiscal years 2024 through 2027, Kedrion will purchase annual minimum quantities of KEDRAB, with aggregate revenues to Kamada of approximately $180 million for such four-year period. d. In July 2019, the Company entered into a 7-year Master Clinical Services Agreement with a third party for the provision of certain clinical research services and other tasks to be performed by such third party, in connection with the Company’s Phase III clinical study for its inhaled AAT product. e. In December 2019, the Company entered into a binding term sheet for a 12-year contract manufacturing agreement with Saol to manufacture CYOTGAM. As a result of the execution and consummation of the Saol APA as detailed below, which included the acquisition of all rights relating to CYTOGAM, the previous engagement with Saol with respect to this product expired. Following the successful execution of the technology transfer from the previous manufacturer and pending all necessary FDA approvals, the Company obtained during May 2023 FDA approval to manufacture CYTOGAM at its facility in Beit Kama, Israel. As of December 31, 2023, and 2022, the Company recognized an asset related to the costs to fulfill a contract in the net amounts of $8,495 thousand and $7,577 thousand, respectively Refer to Note 2m for further information. On November 22, 2021, the Company entered into the Saol APA for the acquisition of the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products. Under the terms of the Saol APA, the Company paid Saol a $95 million upfront payment, and agreed to pay up to an additional $50 million of contingent consideration subject the achievement of sales thresholds for the period commencing on the Acquisition Date and ending on December 31, 2034. The Company may be entitled for up to $3 million credit deductible from the contingent consideration payments due for the years 2023 through 2027, subject to certain conditions as defined in the agreement between the parties. As of December 31, 2023, the Company had paid the first milestone payment on account of the contingent consideration and the second sales threshold was met. The second milestone payment on account of the contingent consideration was paid during February 2024. In addition, the Company acquired inventory valued at $14.2 million and agreed to pay the consideration to Saol in ten quarterly installments of $1.5 million each or the remaining balance at the final installment. As of December 31, 2023, the Company paid eight of the quarterly instalments and the remaining two installments will be paid during the first half of 2024. As part of the acquisition, the Company assumed certain of Saol’s liabilities for the future payment of royalties (some of which are perpetual) and milestone payments to third party subject to the achievement of corresponding CYTOGAM related net sales thresholds and milestones. Such assumed liabilities include: ● Royalties: 10 % of the annual global net sales of CYTOGAM up to $25 million and 5 % of net sales that are greater than $25 million, in perpetuity; 2% of the annual global net sales of CYTOGAM in perpetuity; and, 8% of the annual global net sales of CYTOGAM for period of six years following the completion of the technology transfer of the manufacturing of CYTOGAM to the Company, subject to a maximum aggregate of $5 million per year and for total amount of $30 million throughout the entire six years period. ● Sales milestones: $1.5 million in the event that the annual net sales of CYTOGAM in the U.S. market exceeds $18.8 million during the twelve months period ended June 30, 2022, which milestone was met and the milestone payment was paid during 2023; and $1.5 million in the event that the annual net sales of CYTOGAM in the United States market exceeds $18.4 million during the twelve months period ended June 30, 2023, which milestone was not met. ● Milestone: $8.5 million upon the receipt of FDA approval for the manufacturing of CYTOGAM at Company’s manufacturing facility in Israel. During May 2023, the Company received such FDA approval and paid the milestone of $8.5 million. To partially fund the acquisition costs, the Company secured a $40 million financing facility from an Israeli bank which comprised of a $20 million five-year loan and a $20 million short-term revolving credit facility. During September 2023, the Company repaid in full the outstanding balance of the $20 million five-year loan. Refer to Note 14. f. In December 2019, the Company entered into an agreement with Alvotech ehf. ("Alvotech"), a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the IL MOH. Pursuant to the agreement the Company is obligated to pay Alvotech certain milestone payments, in advance of the launch of the six biosimilar in Israel. In February 2022, the agreement was extended to include two additional biosimilar products. g. On January 14, 2021, the Company entered into an agreement with undisclosed international pharmaceutical companies to commercialize one of the distribution products, in Israel. Pursuant to the agreement the Company is obligate to pay royalties in the amount of 24% out of the net revenue from the sale of the product in the Israeli market. h. In May 2022, the Company terminated a distribution agreement with a third-party engaged to distribute the Company’s propriety products in Russia and Ukraine (the “Distributor”) and a power of attorney granted in connection with such distribution agreement to an affiliate of the Distributor (the “Affiliate”). In July 2022, the Affiliate filed a request for a conciliation hearing with the court in Geneva relying on the terminated power of attorney and seeking damages for the alleged inability to sell the remaining product inventory previously acquired from the Company and compensation for the lost customer base. The conciliation hearing was held on March 17, 2023, and the Affiliate was granted authorization to proceed to file a Statement of Claim before the competent tribunal within three months. On June 13, 2023, the Affiliate filed its Statement of Claim with the tribunal of first instance in Geneva, seeking alleged damages in the total amount of $6.7 million. The Company was officially notified of such filing on November 17, 2023. The Company has filed a motion with the tribunal of first instance challenging its jurisdiction over the Affiliate’s claims, submitting that such claims should have been brought before an arbitral tribunal, as contractually agreed between the parties. Until the tribunal of first instance in Geneva rules on the motion, the Affiliate’s claims will not be heard. To date, based on the Company's external legal counsel, it is not possible to assess the prospects of the claim against the Company and any potential liabilities and impact on the Company’s business.

Guarantees and Charges

Guarantees and Charges	12 Months Ended
	Dec. 31, 2023
Guarantees and Charges [Abstract]
GUARANTEES AND CHARGES	Note 19: - Guarantees and Charges a. The Company provided a bank guarantee in the amount of $354 thousand mainly in favor of the lessor of its leased office facility in Rehovot, Israel, as guarantee for meeting its obligations under the lease agreement. b. In connection with the Saol APA, the Company secured a debt facility from an Israeli bank (see Note 14) pursuant to which, the Company undertook not to create any first ranking floating charge over all or materially all of its property and assets in favor of any third party unless certain terms, as defined in the loan agreement, have been satisfied. c. The Company provided a bank guarantee in the amount of $247 thousand as part of the terms and conditions of a tender. In order to obtain the bank guarantee the Company deposited the full amount of the bank guarantee in a collateral account. Refer to Note 8 for further information. d. The Company provided a security deposit totaling $417 thousand in accordance with the terms and conditions outlined in the lease agreement for the plasma collection center. This deposit serves as a guarantee to ensure the Company’s compliance with its obligations under the lease. Accordance with the terms and conditions, within the initial lease period of 10 years, an expected sum of $40 thousand is anticipated to be reimbursed to the Company annually.

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
EQUITY	Note 20: - Equity a. Share capital December 31, 2023 December 31, 2022 Authorized Outstanding Authorized Outstanding Ordinary shares of NIS 1 par value 70,000,000 57,479,528 70,000,000 44,832,843 b. Changes in share capital: Issued and outstanding share capital: Number of shares Balance as of January 1, 2022 44,799,794 Issue of shares - Exercise of options into share units 1,421 Vesting of restricted shares units 31,628 Balance as of December 31, 2022 44,832,843 Issue of shares 12,631,579 Exercise of options into shares units 2,662 Vesting of restricted shares units 12,444 Balance as of December 31, 2023 57,479,528 c. Rights attached to Shares Voting rights at the shareholders general meeting, rights to dividend, rights in case of liquidation of the Company and rights to nominate directors. d. Share options and restricted shares units During 2023 and 2022, 42,175 and 8,325 share options, respectively, were exercised, on a net exercise basis, into 2,662 and 1,408 ordinary shares of NIS 1 par value each and 12,444 and 31,608 restricted shares units were vested, respectively. The total consideration from such exercise totaled $4 and $9 thousand for 2023 and 2022, respectively. For additional information regarding options and restricted shares units granted to employees and management in 2023, refer to Note 21 below. e. Capital management in the Company The Company’s goals in its capital management are to preserve capital ratios that will ensure stability and liquidity to support business activity and create maximum value for shareholders. f. Issuance of ordinary shares by the Company On November 21, 2019, FIMI, the leading private equity firm in Israel acquired from third parties 5,240,956 ordinary shares at a price of $6.00, representing ownership of approximately 13% of the Company’s then outstanding shares. On February 10, 2020, the Company consummated a private placement with FIMI, pursuant to which the Company issued 4,166,667 ordinary shares at a price of $6.00 per share, for total gross proceeds of $25 million. Upon closing of the private placement, FIMI’s aggregate ownership represented approximately 21% of the Company’s then outstanding shares. On September 7, 2023, the Company consummated a private placement with FIMI, pursuant to which the Company issued 12,631,579 ordinary shares at a price of $4.75 per share (which represented the average closing price of the Company’s shares on NASDAQ during the 20 trading days prior to the date of execution of the private placement), for total gross proceeds of $60 million. Following the closing of the private placement, FIMI beneficially owned approximately 38% of the Company’s outstanding ordinary shares and became a controlling shareholder of the Company, within the meaning of the Israeli Companies Law, 1999. Concurrently with the execution of the share purchase agreement, the Company entered into an amended and restated registration rights agreement with FIMI pursuant to which, among other things, the Company undertook to file with the U.S. Securities and Exchange Commission a registration statement registering the resale of all of the ordinary shares held by FIMI, per its request, at any time commencing after the lapse of six months following the closing of the private placement. Mr. Ishay Davidi, Ms. Lilach Asher-Topilsky and Mr. Uri Botzer, members of the Company’s board of directors, are executives of FIMI.

Share-Based Payment

Share-Based Payment	12 Months Ended
	Dec. 31, 2023
Share-Based Payment [Abstract]
SHARE-BASED PAYMENT	Note 21: - Share-Based Payment On July 24, 2011, the Company’s Board of Directors adopted the 2011 Israeli Share Option Plan. In September 2016, the Company’s Board of Directors approved an amendment to the plan, to include the issuance of restricted shares units (“RSU”) under the plan and renamed it the Israeli Share Award Plan (“2011 Plan”). In August 2021, the Company’s Board of Directors approved a 10-year extension of the 2011 Plan, until August 9, 2031, and adopted a few additional amendments to the 2011 Plan, and the 2011 Plan was further amended in October 2022. Options and RSU’s granted under the 2011 Plan, prior to January 2020, generally vest over a four-year period following the date of the grant in 13 installments: 25% on the first anniversary of the grant date and 6.25% at the end of each quarter thereafter. As of 2020, options and RSUs granted under the 2011 Plan generally vest in four equal annual installments of 25% each. In February 2022, the Company’s Board of Directors adopted the U.S. Taxpayer Appendix to the 2011 Plan (the “U.S. Appendix”), which provides for the grant of options and RSU to persons who are subject to U.S. federal income tax. The U.S. Appendix provides for the grant to U.S. employees of options that qualify as incentive stock options (“ISOs”) under the U.S. Internal Revenue Code of 1986, as amended. The U.S. Appendix was approved by our shareholders at the annual general meeting held in December 2022. a. Expense recognized in the financial statements The share-based compensation expense that was recognized for services received from employees and members of the Company’s Board of Directors is presented in the following table: For the Year Ended December 31 2023 2022 2021 U.S. Dollar in thousands Cost of revenues $ 249 $ 308 $ 69 Research and development 167 204 79 Selling and marketing 238 254 34 General and administrative 660 372 347 Total share-based compensation $ 1,314 $ 1,138 $ 529 b. Share options granted: 1. On February 27, 2023, the Company’s Board of Directors approved the grant of options to purchase up to 147,000 ordinary shares of the Company under the 2011 Plan and the US Appendix. The Company granted, out of the above mentioned, to employees and executive officers the following: Under the Israeli Share Option Plan: - On February 27, 2023, options to purchase 60,331 ordinary shares of the Company, at an exercise price of NIS 16.53 (USD 4.50) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $108 thousand. - On March 1, 2023, options to purchase 3,333 ordinary shares of the Company, at an exercise price of NIS 16.63 (USD 4.57) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $6 thousand. - On March 2, 2023, options to purchase 40,000 ordinary shares of the Company, at an exercise price of NIS 16.76 (USD 4.60) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $71 thousand. - On April 23, 2023, options to purchase 40,000 ordinary shares of the Company, at an exercise price of NIS 17.67 (USD 4.83) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $65 thousand. Under the US Appendix: - On February 27, 2023, options to purchase 3,333 ordinary shares of the Company, at an exercise price of USD 4.57 per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $6 thousand. 2. On May 28, 2023, options to purchase 90,000 ordinary shares of the Company, under the Israeli Share Option Plan, at an exercise price of NIS 19.46 (USD 5.25) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $217 thousand. 3. On August 15, 2023, options to purchase 20,000 ordinary shares of the Company, at an exercise price of NIS 20.07 (USD 5.33) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $37 thousand. 4. On August 21, 2023, options to purchase up to 54,650 ordinary shares of the Company under the 2011 Plan and the US Appendix. The Company granted, out of the above mentioned, to employees and executive officers the following: Under the Israeli Share Option Plan: - On August 21, 2023, options to purchase 24,050 ordinary shares of the Company, at an exercise price of NIS 21.54 (USD 5.68) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $48 thousand. - On September 26, 2023, options to purchase 9,050 ordinary shares of the Company, at an exercise price of NIS 20.60 (USD 5.39) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $17 thousand. - On October 4, 2023, options to purchase 2,500 ordinary shares of the Company, at an exercise price of NIS 21.51 (USD 5.39) per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $5 thousand. Under the US Appendix: - On August 21, 2023, options to purchase 7,500 ordinary shares of the Company, at an exercise price of USD 5.86 per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $18 thousand. - On August 30, 2023, options to purchase 9,050 ordinary shares of the Company, at an exercise price of USD 5.91 per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $22 thousand. - On September 25, 2023, options to purchase the 2,500 ordinary shares of the Company, at an exercise price of USD 5.47 per share. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated on the date of grant at $6 thousand. 5. On September 7, 2023, options to purchase an aggregate 32,000 ordinary shares of the Company, at an exercise price of NIS 21.63 (USD 5.62) per share, were granted to the Company’s newly elected external directors (within the meaning of Israeli law), who were appointed following the closing of the private placement with FIMI. The fair value of the options calculated on the date of grant using the binomial option valuation model was estimated at $45 thousand. 6. On February 29, 2024, the Company’s Board of Directors approved the grant of options to purchase up to 27,467 ordinary shares of the Company under the 2011 Plan and the US Appendix. Under the Israeli Share Option plan: - 20,800 options to purchase ordinary shares of the Company, at exercise price of NIS 23.91 (USD 6.67) per share. The fair value of the options was estimated on the date of grant at $51 thousands. Under the Israeli Share Option plan: - 6,667 options to purchase the ordinary shares of the Company, at an exercise price of USD 6.62 per share. The fair value of the options was estimated on the date of grant was estimated at $17 thousands. e. Change of Awards during the Year The following table lists the number of share options, the weighted average exercise prices of share options and changes in share options grants during the year: 2023 2022 2021 Number of Weighted Number of Weighted Number of Weighted In NIS In NIS In NIS Outstanding at beginning of year 3,247,814 19.91 1,504,678 20.38 1,660,958 20.38 Granted 343,647 18.60 2,076,800 19.27 - - Exercised (42,175 ) 19.04 (8,325 ) 16.47 (28,672 ) 16.93 Forfeited (279,305 ) 19.57 (325,339 ) 19.14 (127,608 ) 20.29 Outstanding at end of year 3,269,981 18.82 3,247,814 19.91 1,504,678 20.65 Exercisable at end of year 1,469,084 19.83 1,049,329 20.38 1,067,363 19.78 The weighted average remaining contractual life for the share options 4.01 4.67 3.33 The range of exercise prices for share options outstanding as of December 31, 2023, and 2022 were NIS 16.53- NIS 29.68. Exercise is by net exercise method. f. The following table lists the number of RSUs and changes in RSUs grants during the year: Number of RSs 2023 2022 2021 Outstanding at beginning of year 14,705 49,561 104,519 Granted - - - End of restriction period (12,444 ) (31,608 ) (52,538 ) Forfeited (386 ) (3,248 ) (2,420 ) Outstanding at end of year 1,875 14,705 49,561 The weighted average remaining contractual life for the restricted share units 0.25 0.96 3.40 g. Measurement of the fair value of share options: The Company uses the binomial model when estimating the grant date fair value of equity-settled share options. The measurement was made at the grant date of equity-settled share options since the options were granted to employees and Board of Directors members. The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan. 2023 2022 2021 (1) Dividend yield (%) - - - Expected volatility of the share prices (%) 26-38 23-40 - Risk-free interest rate (%) 3.76-4.70 0.4-3.55 - Contractual term of up to (years) 6.5 6.5 - Exercise multiple 2 2 - Weighted average share prices (NIS) 16.10-19.46 13.6-18.41 - Expected average forfeiture rate (%) 0-8.5 0-8.5 - (1) During the year ended December 31, 2021, no grants of options or RSU were made Under the US Appendix: 2023 2022 2021 (1) Dividend yield (%) - - - Expected volatility of the share prices (%) 34-47 27-47 - Risk-free interest rate (%) 3.76-5.03 0.91-3.54 - Contractual term of up to (years) 6.5 6.5 - Exercise multiple - - - Weighted average share prices (NIS) 4.22-5.55 4.8-5.37 - Expected average forfeiture rate (%) 5.5-8.5 1.9-8.5 -

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2023
Taxes on Income [Abstract]
TAXES ON INCOME	Note 22: - Taxes on Income a. Tax laws applicable to the Company Law for the Encouragement of Industry (Taxes), 1969 The Law for the Encouragement of Industry (Taxes), 1969 (the “Encouragement of Industry Law”), provides several tax benefits for “Industrial Companies.” Pursuant to the Encouragement of Industry Law, a company qualifies as an Industrial Company if it is a resident of Israel and at least 90% of its income in any tax year (exclusive of income from certain defense loans) is generated from an “Industrial Enterprise” that it owns. An Industrial Enterprise is defined as an enterprise whose principal activity, in a given tax year, is industrial activity. An Industrial Company is entitled to certain tax benefits, including: (i) a deduction of the cost of purchases of patents, know -how and certain other intangible property rights (other than goodwill) used for development or promotion of the Industrial Enterprise in equal amounts over a period of eight years, beginning from the year in which such rights were first used, (ii) the right to elect to file consolidated tax returns, under certain conditions, with additional Israeli Industrial Companies under its control, and (iii) the right to deduct expenses related to public offerings in equal amounts over a period of three years beginning from the year of the offering. Eligibility for benefits under the Encouragement of Industry Law is not contingent upon the approval of any governmental authority. The Company believes that it currently qualifies as an industrial company within the definition of the Industry Encouragement Law. The Company cannot confirm that the Israeli tax authorities will agree that the Company qualifies, or, if qualified, that it will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future. Law for the Encouragement of Capital Investments, 1959 Tax benefits prior to Amendment 60 The Company’s facilities in Israel have been granted Approved Enterprise status under the Law for the Encouragement of Capital Investments, 1959, commonly referred to as the “Investment Law”. The Investment Law provides that capital investments in a production facility (or other eligible assets) may be designated as an Approved Enterprise. Under the Approved Enterprise programs, a company is eligible for certain benefits such as governmental grants and tax incentives. The benefits period is limited to the earlier of 12 years from completion of the investment or commencement of production (“Year of Operation”), or 14 years from the year in which the certificate of approval was obtained. The Company’s benefit period under the Approved Enterprise programs ended by the end of 2017. Tax benefits under Amendment 60 On April 1, 2005, an amendment to the Investment Law was affected (“Amendment 60”). The amendment revised the criteria for investments qualified to receive tax benefits. An eligible investment program under the amendment will qualify for benefits as a Privileged Enterprise (rather than the previous terminology of Approved Enterprise). The Company received a Tax Ruling from the Israeli Tax Authority that its activity is an industrial activity, and the Company will be eligible for the status of a Privileged Enterprise, provided that it meets the requirements under the ruling. Pursuant to the Tax Ruling, the Year of Election was 2009. The Company also subsequently elected 2012 as a Year of Election. Through December 31, 2023, the Company did not utilize the tax benefits under its Privileged Enterprise and those expired at the end of 2023. Amendment 68 to the Encouragement Law: As of January 1, 2011, new legislation amending the Investment Law was affected. Pursuant to Amendment 68 a new status of “Preferred Company” and “Preferred Enterprise”, replacing the then existing status of “Privileged Company” and “Privileged Enterprise”. A Preferred Company is an industrial company owning a Preferred Enterprise which meets certain conditions (including a minimum threshold of 25% export). However, under this new legislation the requirement for a minimum investment in productive assets was cancelled. Under Amendment 68, a uniform corporate tax rate will apply to all qualifying income of the Preferred Company, as opposed to the former law, which was limited to income from the Approved Enterprises during the benefits period. The Company evaluated the effect of the adoption of Amendment 68 on its tax position, and as of the date of the approval of the financial statements, the Company believes that it will not apply for the benefits under Amendment 68. Amendment 73 to the Encouragement Law: Amendment 73 to the Encouragement Law also prescribes special tax tracks for technological enterprises, which became effective in 2017, as follows: Preferred technological enterprise, which is defined in the Encouragement Law as a company that owns the enterprise and is a member of a group whose total consolidated revenues are less than NIS 10 billion in the tax year, will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%). Special preferred technological enterprise which is a member of a group whose total consolidated revenues exceed NIS 10 billion in the tax year will be subject to tax at a rate of 6% on preferred income from the enterprise, regardless of the enterprise’s geographical location. Any dividends distributed to “foreign companies”, as defined in the Encouragement Law, deriving from income from the technological enterprises will be subject to tax at a rate of 4%, subject to the conditions prescribed in Section 51Z to the Encouragement Law. The Company evaluated the effect of the adoption of Amendment 73 on its tax position, and as of the date of the approval of the financial statements, the Company did not apply for the benefits under Amendment 73. The Company may elect to apply for these benefits in the future. b. Tax rates applicable to the Company (other than the applicable preferred tax) The Israeli corporate income tax rate was 23% since 2018. c. Tax assessments The Company has finalized tax assessments through the end of tax year 2018. d. Taxation of the subsidiaries: Kamada Inc and Kamada Plasma LLC are incorporated in the United States and are subject to U.S. Federal and State tax laws and Franchise Tax. The two subsidiaries file a joint tax return. On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was signed into law. Among other things, the Act reduces the corporate tax rate to 21% from 35%. On February 16, 2022, the Company incorporated KI Biopharma LLC, as a wholly-owned subsidiary of Kamada Ltd. KI Biopharma LLC is a disregarded (tax transparent) entity for U.S. tax purposes. e. Carry forward losses for tax purposes and other temporary differences As of December 31, 2023, the Company has carried forward losses and other temporary differences in the amount of $26,929 thousand. Final tax assessments for the years 2019 onwards could have an impact on the balance of carry forward tax losses for which deferred tax asset was not recognized. As of December 31, 2023, the Company did not record deferred tax asset for the remaining carry forward losses due to estimation that their utilization in the foreseeable future is not probable. f. Uncertain tax positions The Company analyzed uncertainty involving income taxes on its financial statements and whether it has any potential impact on the financial statements. As of December 31, 2023, and 2022, the application of IFRIC 23 did not have a material effect on the financial statements. g. Deferred taxes: The Company records deferred tax assets for carry forward losses and other temporary differences, as their utilization in the foreseeable future is estimated to be probable. As of December 31, 2023, 2022 and 2021 the Company did not record deferred tax assets for the remaining carry forward losses due to estimation that their utilization in the foreseeable future is not probable. Deferred tax liabilities have not been recognized for the immaterial temporary differences associated with investments in subsidiaries because the disposal of these subsidiaries in the foreseeable future is not probable and because distributions of dividends by these companies are not subject to tax. h. Taxes on income Year ended December 31, 2023 2022 2021 U.S. Dollars in thousands Current taxes $ 145 $ 62 $ 345 Deferred tax expenses (income) - - - Taxes in respect of prior years - - - Taxes on income $ 145 $ 62 $ 345 i. Theoretical tax 2023-2021 The reconciliation between the statutory tax rate and the effective tax rate as recorded in profit or loss for the years ended December 31, 2023, 2022 and 2021 does not provide significant information, mainly because the Company did not recognize deferred taxes, and therefore is not presented.

Supplementary Information to th

Supplementary Information to the Statements of Profit and Loss	12 Months Ended
	Dec. 31, 2023
Supplementary Information to the Statements of Profit and Loss [Abstract]
SUPPLEMENTARY INFORMATION TO THE STATEMENTS OF PROFIT AND LOSS	Note 23: - Supplementary Information to the Statements of Profit and Loss a. Additional information about revenues Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Revenues from major customers each of whom amount to 10% or more, of total revenues Customer A (1) 32,800 16,195 11,947 Customer B (2) $ 16,129 $ 14,205 $ 31,936 Customer C (3) 9,230 12,255 12,357 $ 58,159 $ 42,655 $ 56,240 (1) Revenue is attributed to the Proprietary segment. Refer to Note 18 (c) for more information. (2) Revenue is attributed to the Proprietary segment. Refer to Note 18 (a) for more information. (3) Revenue is attributed mainly to the Distribution segment and in 2023; the total is less than 10% of total Revenues b. Revenues based on the location of the customers, are as follows: Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands U.S.A $ 73,741 $ 65,296 $ 49,763 Israel 31,296 32,031 35,774 Canada 11,162 10,555 - Europe 7,088 5,277 5,677 Latin America 12,928 11,293 9,127 Asia 6,147 4,581 3,167 Others 157 306 134 Total Revenue $ 142,519 $ 129,339 $ 103,642 c. Cost of goods sold Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Cost of materials (1) $ 70,308 $ 53,666 $ 63,945 Salary and related expenses 16,330 14,967 17,486 Subcontractors 6,354 4,673 4,892 Depreciation and amortization (2) 9,000 8,553 3,627 Energy 1,383 1,365 1,464 Other manufacturing expenses 1,235 1,785 1,298 Total Cost of goods sold before Inventory change 100,610 85,009 92,712 Decrease (increase) in inventories (17,581 ) (2,373 ) (19,398 ) Total Cost of goods sold $ 87,029 $ 82,636 $ 73,314 (1) Costs of materials for the year ended December 31, 2021, includes $24,282 of inventory obtained in connection with the business combination. Refer to Note 5b for further detail on the business combination. (2) Including amortization of intangible assets in the amount of $5,376 for each of the years ended December 31, 2023 and 2022, and $574 for the year ended December 31, 2021 d. Research and development Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 5,110 $ 5,608 $ 5,076 Subcontractors 4,677 4,216 3,656 Materials and allocation of facility costs 2,971 2,538 1,896 Depreciation and amortization 586 574 616 Others 589 236 113 Total Research and development $ 13,933 $ 13,172 $ 11,357 For additional information regarding government grant refer to Note 13(b) e. Selling and marketing Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 4,907 4,047 1,930 Packing, shipping and delivery 1,366 1,484 912 Marketing and advertising 2,634 3,676 1,340 Registration and marketing fees 4,362 3,463 1,262 Depreciation and amortization (1) 2,090 2,056 488 Others 834 558 346 Total Selling and marketing $ 16,193 $ 15,284 $ 6,278 (1) Including amortization of intangible assets in the amount of $1,807 for each of the years ended December 2023 and 2022, and $265 for the year ended December 31, 2021. f. General and administrative Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 5,283 $ 4,455 3,853 Employees welfare 1,337 1,299 1,259 Professional fees and public company expense 4,305 4,213 5,055 Depreciation, amortization and impairment 1,035 973 875 Communication and software services 1,201 905 977 Others 1,220 958 617 Total General and administrative $ 14,381 $ 12,803 $ 12,636 g. Financial (expense) income Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Financial income Interest income from cash deposit $ 588 $ 91 $ 295 Financial expense Revaluation of long term liabilities (980 ) (6,266 ) (994 ) Fees and interest expense to financial institutions (1,298 ) (914 ) (283 ) Financial income and (expense) Derivatives instruments measured at fair value 149 548 (565 ) Translation differences of financial assets and liabilities (94 ) (250 ) 358 Total Financial (expense) income $ (1,635 ) $ (6,791 ) $ (1,189 )

Income (Loss) Per Share

Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2023
Income (Loss) Per Share [Abstract]
INCOME (LOSS) PER SHARE	Note 24: - Income (loss) Per Share a. Details of the number of shares and income (loss) used in the computation of income (loss) per share Year Ended December 31, 2023 2022 2021 Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Income Attributed to equity holders of the Company U.S. Dollars U.S. Dollars U.S. Dollars For the computation of basic income (loss) 48,830,479 8,284 44,815,248 $ (2,321 ) 44,771,766 $ (2,230 ) Effect of potential dilutive ordinary shares 4,845,035 41,328 - 130,177 - For the computation of diluted income (loss) 53,675,514 8,284 44,856,576 $ (2,321 ) 44,901,943 $ (2,230 ) b. The computation of the diluted income per share for the years ending December 31, 2023, 2022 and 2021 considered the options and RSs due to their dilutive effect.

Operating Segments

Operating Segments	12 Months Ended
	Dec. 31, 2023
Operating Segments [Abstract]
OPERATING SEGMENTS	Note 25: - Operating Segments a. General The operating segments are identified on the basis of information that is reviewed by the chief operating decision makers (“CODM”) to make decisions about resources to be allocated and assess its performance. Accordingly, for management purposes, the Company is organized into operating segments based on the products and services of the business units and has two operating segments as follows: Proprietary Products Development, manufacturing, sales and distribution of plasma-derived protein therapeutics. Distribution Distribute imported drug products in Israel, which are manufactured by third parties. Segment performance is evaluated based on revenues and gross profit in the financial statements. The segment results reported to the CODM include items that are allocated directly to the segments and items that can be allocated on a reasonable basis. Items that were not allocated, mainly the Company’s corporate office, research and development costs, sales and marketing costs, general and administrative costs and financial costs (consisting of finance expenses and finance income and including fair value adjustments of financial instruments), are managed on a Company basis. The segment liabilities do not include loans and financial liabilities as these liabilities are managed on a Company basis. The Company's CODM does not regularly review asset information by segments and, therefore, the Company does not report asset information by segment. b. Reporting on operating segments Proprietary Distribution Total U.S. Dollars in thousands Year Ended December 31, 2023 Revenues $ 115,458 $ 27,061 $ 142,519 Gross profit $ 52,116 $ 3,374 $ 55,490 Unallocated corporate expenses (45,426 ) Finance income, net (1,635 ) Income before taxes on income $ 8,429 Proprietary Distribution Total U.S Dollars in thousands Year Ended December 31, 2022 Revenues $ 102,598 $ 26,741 $ 129,339 Gross profit $ 44,369 $ 2,334 $ 46,703 Unallocated corporate expenses (42,171 ) Finance income, net (6,791 ) Income before taxes on income $ (2,259 ) Proprietary Distribution Total U.S. Dollars in thousand Year Ended December 31, 2021 Revenues $ 75,521 $ 28,121 $ 103,642 Gross profit $ 27,327 $ 3,001 $ 30,328 Unallocated corporate expenses (31,024 ) Finance expense, net (1,189 ) Loss before taxes on income $ (1,885 )

Balances and Transactions with

Balances and Transactions with Related Parties	12 Months Ended
	Dec. 31, 2023
Balances and Transactions with Related Parties [Abstract]
BALANCES AND TRANSACTIONS WITH RELATED PARTIES	Note 26: - Balances and Transactions with Related Parties a. Balances with related parties December 31, December 31, U.S. Dollars in thousands Trade receivable $ - $ 544 Trade payables $ 96 $ 101 Other accounts payables $ 45 $ 85 b. Transactions with employed/directors that accounts as related parties Year Ended December 31, 2023 2021 2020 U.S. Dollars in thousands Remuneration of directors not employed by the Company or on its behalf $ 548 $ 331 $ 487 Number of People to whom the Salary and remuneration Refer: Directors not employed by the Company 11 9 9 Total Directors employed and not employed by the Company 11 9 9 c. Transactions with key executive personnel (including non-related parties) Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and Related Expenses $ 3,771 $ 3,590 $ 2,791 Share-based payment 728 547 255 Total $ 4,499 $ 4,137 $ 3,046 d. Transactions with related parties Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Revenues $ 2,676 $ 5,298 $ 5,356 Cost of Goods Sold $ 7 $ 19 $ 51 Selling and marketing expenses $ - $ - $ - General and administrative expenses $ 223 $ 214 $ 227 e. Terms of Transactions with Related Parties Sales to related parties are conducted at market prices. Outstanding trade receivables due from related parties the end of the year bears no interest and their settlement will be in cash. For the years ended December 31, 2023, 2022 and 2021, the Company recorded no allowance for doubtful accounts for trade receivable due from related parties. 1. Tuteur SACIFIA (“Tuteur”), a company registered in Argentina, was formerly controlled by Mr. Ralf Hahn, the former Chairman of the Company's board of directors, and its currently under the control of the Hahn family. Mr. Ralf Hahn’s son, Mr. Jonathan Hahn, currently the President and a director of Tuteur, served as a director of the Company from March 2010 until November 2023. In August 2011, the Company entered into a distribution agreement with Tuteur that amended and restated a distribution agreement the parties entered into in November 2001, as amended on August 19, 2014, January 25, 2017, and January 21, 2019, under which Tuteur acted as the exclusive distributor of GLASSIA and KAMRHO(D) in Argentina, Paraguay and Bolivia. The distribution agreement, as amended, expired on December 31, 2019, and pending the execution of a new distribution agreement, the parties continued to act in accordance with the expired distribution agreement. In May 2020, the Company entered into a new distribution agreement with Tuteur, which supersedes the former agreement in its entirety, pursuant to which Tuteur serves as the exclusive distributor of GLASSIA and KAMRHO(D) in Argentina, Paraguay, Bolivia and Uruguay. Under the new distribution agreement, Tuteur is responsible, at its own expense, for obtaining marketing authorization and/or registration for each of the products in the foregoing territories that is not already approved and registered. If Tuteur fails to register any product in any territory within 12 months after receipt of our approval of all relevant documents, the Company shall be entitled to terminate the agreement with respect to such product or terminate the exclusivity granted to Tuteur with respect to such product. The agreement includes minimum annual purchase commitments by Tuteur, with respect to sales of any products in territories where registration has been completed, commencing as of the effective date of the agreement, and with respect to sale of any products in the other territories, commencing the first year following the registration of any such product in the applicable territory; and the parties agreed to negotiate in good faith the minimum quantities to be purchased by Tuteur in each following marketing year. If Tuteur fails to purchase and pay for the minimum quantity for any product in any marketing year, the Company is entitled to (i) terminate the agreement on a product-by-product basis and/or (ii) terminate the exclusivity and/or narrow the scope of the territories, if applicable, on a product-by-product basis. The price per product per territory payable by Tuteur pursuant to the agreement will be the higher of 50% of such product’s net price sold by Tuteur in the territory or a minimum supply price as defined in the agreement. In addition, Tuteur has undertaken to issue a guarantee (from a U.S., Israeli or a western Europe bank) for every new order of product, in the value of each order, which must be provided prior to the shipment of the product and extended through the complete payment of the amount due on any such order or shipment; such guarantee may not be required to the extent we are able to obtain adequate credit insurance covering the value of each order through its complete payment. The Company retain ownership of all relevant intellectual property in the products. The agreement is in effect for a period of five years, and thereafter shall automatically renew for additional periods of one year each, unless either party notifies the other party of its desire to terminate the agreement by prior written notice of at least 12 months before the expiration of any of the additional periods. The Company is entitled to terminate the agreement with respect to all or certain territories in the event of a change of control of Tuteur, its failure to register the products and obtain all marketing approvals within the period set forth above, its failure to purchase and pay for the minimum quantities for two consecutive years (provided that Tuteur will be obligated, during the second marketing year, to purchase the minimum quantity for the preceding marketing year on a product-by-product basis) or if Tuteur discontinues selling the products, after completing registration and obtaining required approvals, for longer than 45 days or 90 days or more in the event such discontinuation is caused due to a force majeure event. The agreement includes a mutual indemnification undertaking, standard confidentiality obligations and obligations of Tuteur to comply with anti-corruption and privacy laws. The agreement includes a non-compete undertaking of Tuteur during the term of the agreement and for a period of 12 months thereunder (other than in the event the agreement is terminated for cause by Tuteur due to the Company's breach of the agreement). On July 4, 2022, the Company and Tuteur entered into a supplemental letter agreement to the distribution agreement, pursuant to which Tuteur undertook to be responsible for an investigator-initiated targeted screening program for AATD in Uruguay in patients diagnosed with obtrusive pulmonary disease, with the purpose of identifying patients suitable for treatment with GLASSIA, to be conducted at Sociedad Uruguaya de Neumologia, Montevideo, Uruguay. The Company undertook to support the funding of the study up to $30,000, inclusive of all applicable taxes. Tuteur undertook to provide the Company all collected data, information, results and reports generated or derived as a result of the study, and to obtain in advance all necessary approvals for the study. According to the terms of the agreement, the Company shall not be responsible for or bear any liability arising from or in connection with the study. In September 2022, following a decrease in the market price of KAMRHO(D) in Argentina mainly due to the impact of the COVID-19 pandemic and recent changes to treatment protocols that reduced overall consumption of the product, the Company's Board of Directors approved the reduction of the minimum supply price (as defined in the distribution agreement) of the product in Argentina and Paraguay for the 2022 supplies. In February 2023, the Company and Tuteur entered into an amendment to the distribution agreement, pursuant to which KAMRHO(D)’s price for the territories of Argentina and Paraguay payable by Tuteur pursuant to the agreement will be the higher of 60% of KAMRHO(D)’s net price sold by Tuteur in these territories or a minimum supply price (as defined in the amendment to the distribution agreement). In March 2023, the Company's Board of Directors approved a one-time amendment to the payment terms under the distribution agreement with respect to two shipments of GLASSIA and KAMRHO(D) to be supplied to Tuteur by the end of the first quarter of 2023. In June 2023, due to continued political and economic changes and related mandates imposed by the Argentinian government, the Company's Board of Directors approved further amendments to the distribution agreement, pursuant to which Tuteur may issue a bank guarantee from an Argentinian bank against improved payment terms and supply price. In January 2024, following additional mandates imposed by the Argentinian government, the Company and Tuteur entered into an amendment to the distribution agreement, pursuant to which, so long as Tuteur does not undergo a “Change of Control” or “Management Change” (as such terms are defined in the amendment), Tuteur will not be required to provide a bank guarantee for orders shipped from December 1, 2023 and onwards, if the total outstanding amount due from Tuteur to the Company does not exceed $1.5 million at any time; provided that such a bank guarantee will be required for any shipment of product that, if shipped, would result in the total outstanding amount due by Tuteur to us to exceed such amount. 2. On July 29, 2015, the Company entered into a distribution agreement with Khairi S.A. (“Khairi”), a company held, inter alia, by Mr. Leon Recanati, which was at the time the Chairman of the Company’s Board of Directors, and Mr. Jonathan Hahn, who served as a director of the Company until November 2023, and his siblings, for the distribution of GLASSIA and KAMRHO(D) in Uruguay. The distribution agreement with Khairi was an arm’s length transaction. For the years ended on December 31, 2019, 2020 and 2021 there were no sales of product by the Company to Khairi. The agreement expired on December 31, 2020. 3. FIMI, the leading private equity firm in Israel, beneficially owns approximately 38% of the Company’s outstanding ordinary shares and is a controlling shareholder of the Company, within the meaning of the Israeli Companies Law, 1999. Refer to Note 20 for further detail. The following Israeli entities: G-1 Secure Solutions Ltd., E&M Computing Ltd., and Graffiti Office Supplies & Paper Marketing Ltd., which are controlled by or affiliated with the FIMI Funds, are currently engaged by the Company for the provision of certain services relating to its continuous operations in non-material amounts and at market prices. f. CEO employment terms Year Effective date Company’s Board Monthly December 31, NIS USD 2020 July 1, 2019 March 2020 ₪ 88,000 $ 25,462 2021 July 1, 2021 October 2021 ₪ 92,400 $ 28,607 2022 July 1, 2022 November 2022 ₪ 96,000 $ 28,575 2023 July 1, 2023 December 2023 ₪ 100,000 $ 27,570 During 2023, the Company accounted for a bonus accrual to the CEO in the amount of $176 thousand.

Events Subsequent to the Report

Events Subsequent to the Reporting Period	12 Months Ended
	Dec. 31, 2023
Events Subsequent to the Reporting Period [Abstract]
EVENTS SUBSEQUENT TO THE REPORTING PERIOD	Note 27: - Events Subsequent to the Reporting Period With respect to grant of options to employees see Note 21b.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of presentation of financial statements	a. Basis of presentation of financial statements 1. These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standard Board. 2. Measurement basis: The Company’s consolidated financial statements are prepared on a cost basis, except for financial assets and liabilities (including derivatives and contingent consideration) which are measured at fair value through profit or loss (See Note 16). The Company has elected to present profit or loss items using the “function of expense” method. b. The Company’s operating cycle is one year.
Functional currency, presentation currency and foreign currency	c. Functional currency, presentation currency and foreign currency 1. Functional currency and presentation currency The consolidated financial statements are presented in U.S. dollars, which is the Company’s functional and presentation currency. 2. Transactions, assets and liabilities in foreign currency Transactions denominated in foreign currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in a foreign currency are translated at the exchange rate at the date of the transaction.
Business combinations and goodwill	d. Business combinations and goodwill: In November 2021, the Company acquired the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products from Saol, see Note 1(a). The acquisition was accounted for as a business combination, for which a key element of the consideration was contingent. The contingent consideration was recognized at fair value on the acquisition date and classified as a financial liability in accordance with IFRS 9. Contingent consideration is measured at fair value. The fair value is determined using valuation techniques and method, using future cash flows discounted. Subsequent changes in the fair value of the contingent consideration are recognized in profit or loss as finance income or finance expense. As part of the acquisition, the Company also assumed certain of Saol’s liabilities for the future payment of royalties (some of which are perpetual) and milestone payments to third party subject to the achievement of corresponding CYTOGAM related net sales. Such assumed liabilities were accounted for as a financial liability on the acquisition date. Subsequently, the financial liability is measured at amortized cost, per IFRS 9. Remeasurement of the financial liability is recognized as finance income or expense in the statement of operations. Refer to Note 5 and Note 16 for further information. Goodwill is initially measured at cost which represents the excess of the acquisition consideration over the net identifiable assets acquired and liabilities assumed. At each reporting date, the Company reviews the carrying amount of the goodwill to determine whether there is any indication of impairment.
Inventories	e. Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories comprises of the costs of purchase of raw and other materials and costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business. Cost of inventories is determined as follows: Raw materials At cost using the first-in, first-out method. Work in process Costs of raw materials, direct and indirect costs including labor, other materials and other indirect manufacturing costs allocated to the in process manufactured batches through the end of the reporting period. The allocation of indirect costs is accounted for on a quarterly basis by dividing the total quarterly indirect manufacturing cost to the batches manufactured during that quarter based on predetermined allocation factors. The Company determines a standard manufacturing capacity for each quarter. To the extent the actual manufacturing capacity in a given quarter is lower than the predetermined standard, than a portion of the indirect costs which is equal to the product of the overall quarterly indirect costs multiplied by the quarterly manufacturing shortfall rate is recognized as costs of revenues Finished products Costs of raw materials, direct and indirect costs including labor, other materials and other indirect manufacturing costs allocated to the manufactured finished products through completion of manufacturing process. Purchased products At cost using the first-in, first-out method. The Company periodically evaluates the condition and age of inventories and accounts for impairment of inventories with a lower market value or which are slow moving.
Financial instruments	f. Financial instruments 1 Financial assets The Company’s portfolio of financial assets consists mainly of trade receivables and bank deposits. The objective of the business model for managing the Company’s financial instruments is to collect the amounts due from them, and for bank deposits to earn contractual interest income on the amounts collected. All of the Company’s financial assets’ contractual cash flows represent solely payments of principal and interest (SPPI). Thus, the Company accounts for its financial assets under the amortized cost model. For those financial assets, the Company analyzes each material customer’s balance individually to evaluate and measure the expected credit losses (“ECLs”) of its trade receivables. Loss rates are based on actual credit loss experience, adjusted for current conditions and the Company’s view of the economic conditions over the expected lives of the trade receivables 2. Financial liabilities Financial liabilities within the scope of IFRS 9 are initially measured at fair value less transaction costs that are directly attributable to the issuance of the financial liability. After initial recognition, the accounting treatment of financial liabilities is based on their classification as follows: a) Financial liabilities measured at amortized cost Loans and assumed liabilities are measured based on their terms at amortized cost using the effective interest method taking into account directly attributable transaction costs. b) Financial liabilities measured at fair value Derivatives are classified as fair value through profit and loss unless they are designated as effective hedging instruments (see below). Transaction costs are recognized in profit or loss. After initial recognition, changes in fair value are recognized either in income (expenses) in respect of currency exchange differences and derivatives instruments line item for non-hedge accounting derivatives or in other comprehensive income for hedge accounting derivatives. For accounting for contingent consideration, see Note 2(d).
Derivative financial instruments designated as hedges	g. Derivative financial instruments designated as hedges The Company enters into contracts for derivative financial instruments such as forward currency contracts and cylinder strategy in respect of foreign currency to hedge risks associated with foreign exchange rates fluctuations and cash flows risk. Such derivative financial instruments are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. At the inception of a hedge relationship, the Company formally designates and documents the hedge relationship to which the Company wishes to apply hedge accounting and the risk management objective and strategy for undertaking the hedge. The hedge effectiveness is assessed at the end of each reporting period. Any gains or losses arising from changes in the fair value of derivatives that do not qualify for hedge accounting are recorded in profit or loss. Cash flow hedges The effective portion of the gain or loss on the hedging instrument is recognized as other comprehensive income (loss), while any ineffective portion is recognized immediately in profit or loss. Amounts recognized as other comprehensive income (loss) are reclassified to profit or loss when the hedged transaction affects profit or loss, such as when the hedged income or expense is recognized or when a forecast payment occurs.
Property, plant and equipment	h. Property, plant and equipment Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation and any related investment grants and excluding day-to-day servicing expenses. Cost includes spare parts and auxiliary equipment that can be used only in connection with the plant and equipment. The cost of assets includes the cost of materials, direct labor costs, as well as any costs directly attributable to bringing the asset to the location and condition necessary for it to operate in the manner intended by management. The Company’s assets include computer systems comprising hardware and software. Software forming an integral part of the hardware to the extent that the hardware cannot function without the software installed on it is classified as property, plant and equipment. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly % Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10 (*) Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.
Leases	i. Leases The Company enters into leases of office including facility dedicated for the plasma collection centers and storage spaces, vehicles, office equipment and lands as a lessee (see Note 15). For leases in which the Company is the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected to recognize the lease payments as an expense in profit or loss on a straight-line basis over the lease term. In measuring the lease liability, the Company has elected to apply the practical expedient and does not separate the lease components from the non-lease components (such as management and maintenance services, etc.). On the commencement date, the lease liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Company’s incremental borrowing rate. The Company determines the incremental borrowing rate based on its credit risk, the lease term and other economic variables deriving from the lease contract’s conditions and restrictions. In certain situations, the Company is assisted by an external valuation expert in determining the incremental borrowing rate. After the commencement date, the Company measures the lease liability using the effective interest rate method. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life or the lease term, as follows: % Mainly % Land and Buildings 5-10 10 Vehicles 20-33 33 office equipment (i.e. printing and photocopying machines) 20 20 Lease modification: Most of the Company’s lease modifications are for the extension of existing lease contracts. Thus, they do not reduce the scope of the lease or result in a separate lease. Under those modifications, the Company re-measures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset.
Intangible assets	j. Intangible assets Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Intangible assets with a finite useful life are amortized on a straight-line basis over their useful life, as follows: Estimated life Amortization method Intellectual property 15-20 Straight-line Customer Relations 20 Straight-line Production agreement 6 Straight-line Distribution right 10-15 Straight-line over the contract period Goodwill Indefinite Not amortized For additional information regarding intangible assets, see Note 11.
Impairment of non-financial assets	k. Impairment of non-financial assets At each reporting date, the Company reviews the carrying amount of non-financial assets (other than inventories, contract assets and deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the assets’ recoverable amount is estimated. Goodwill is tested annually for impairment on December 31 or more frequently if events or changes in circumstances indicate that there is an impairment. The Company’s goodwill is attributed to the Proprietary Products segment, which represents the lowest level within the Company at which goodwill is monitored for internal management purposes (see Note 11). Goodwill is tested for impairment by assessing the recoverable amount of the CGU (or group of CGUs) to which the goodwill has been allocated. An impairment loss is recognized if the recoverable amount of the CGU (or group of CGU to which goodwill has been allocated is less than the carrying amount of the CGU (or group of CGUs). Any impairment loss is allocated first to goodwill. Impairment losses recognized for goodwill cannot be reversed in subsequent periods. In the years ended December 31, 2023, and 2022, the Company did not recognize impairment losses.
Employee benefit liabilities	l. Employee benefit liabilities The Company has several employee benefit plans: 1. Short-term employee benefits Short-term employee benefits include salaries, paid annual leave, paid sick leave, recreation, and social security contributions are recognized as expenses as the services are rendered. A liability in respect of a cash bonus is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits The post-employment benefits plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. With respect to its employees in Israel, the Company has defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law, 1963 (the “Israeli Severance Pay Law”), under which the Company pays fixed contributions to certain employees under Section 14 and will have no legal or constructive obligation to pay further contributions. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee’s services. In addition, with respect to certain other employees who were hired by the Company prior to the establishment of the defined contribution plans pursuant to Section 14 to the Israeli Severance Pay Law, the Company operates a defined benefit plan in respect of severance pay pursuant to the Israeli Severance Pay Law. According to the Israeli Severance Pay Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The actuarial assumptions include expected salary increases and rates of employee’s turnover based on the estimated timing of payment. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to market yields at the reporting date on high quality corporate bonds that are linked to the Consumer Price Index with a term that is consistent with the estimated term of the severance pay obligation. In respect of its defined benefit plan obligation, the Company makes current deposits in pension funds and insurance companies (“plan assets”). Plan assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan assets are not available to the Company’s own creditors and cannot be returned directly to the Company. The liability for employee benefits shown in the statement of financial position reflects the present value of the defined benefit obligation less the fair value of the plan assets. U.S. employees defined contribution plan: Since August 2022, the Company’s U.S. subsidiary has a 401(k) defined contribution plan covering certain employees in the U.S. All eligible employees may elect to contribute up to 100% of their annual compensation to the plan through salary deferrals, subject to Internal Revenue Service limits. For the year ended December 31, 2023, the contribution limit was $22,500 per year (for certain employees over 50 years of age the maximum contribution was $30,000 per year). The U.S. subsidiary matches 3% of employee contributions to the plan with no limitation.
Revenue recognition	m. Revenue recognition The Company’s main source of revenue is from the sale of products to strategic partners and distributors. Starting from 2022, the Company also generates revenue in the form of royalties received under license agreement that grant the use of the Company’s knowledge and patents. Under the royalty exception, revenue is recognized when the underlying sales have occurred. On the contract’s inception date the Company assesses the goods or services promised in the contract with the customer and identifies the performance obligations in it. In order to identify distinct performance obligations in a contract with a customer, the Company examines whether it is providing a significant service of integrating the goods or services in the contract into one integrated outcome. The Company identifies the performance obligations when the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the Company promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. The Company recognizes revenue from contracts with customers when the control over the goods or services is transferred to the customer. Revenue recognition occurs at a point in time when control of the Company’s product is transferred to the customer, generally on delivery of the goods according to the shipment terms. The Company determines the transaction price separately for each contract with a customer taking into consideration variable prices, discounts, chargeback, rebates, adjustments to the net market price etc. The Company includes the estimated variable consideration in the transaction price only to the extent it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty is resolved. Following the acquisition of the Four FDA-Approved Plasma Derived Hyperimmune Commercial Products during November 2021, the Company, through its wholly-owned subsidiary Kamada Inc., sells these products in the U.S. market to wholesalers/distributors that redistribute/sell these products to other parties such as hospitals and pharmacies. Revenue recognition occurs at a point in time when control of the product is transferred to the wholesalers/distributors, generally on delivery of the goods. The Company’s gross sales are subject to various deductions, which are primarily composed of rebates and discounts to group purchasing organizations, government agencies, wholesalers, health insurance companies and managed healthcare organizations. These deductions represent estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions on gross sales for a reporting period. These adjustments are deducted from gross sales to arrive at net sales. The Company monitors the obligation for these deductions on at least a quarterly basis and records adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in the obligation is appropriate. The following summarizes the nature of the most significant adjustments to revenues generated from the sales of these products in the U.S. market: ● Wholesaler chargebacks: The Company has arrangements with certain indirect customers whereby the customer is able to buy products from wholesalers at reduced prices. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer’s contractual discounted price. Provisions for estimating chargebacks are calculated based on historical experience and product demand. The provision for chargebacks are recorded as a deduction from trade receivables on the consolidated statements of financial position. ● Fees for service: Consists of wholesaler/distributor fees. The wholesalers/distributors charge the Company fees for the redistribution of the products to hospitals and pharmacies. These fees are outlined in each wholesaler/distributor contract. The fees are invoiced to the Company monthly or quarterly by the wholesaler/distributor. The provisions for fees for service are recorded in the same period that the corresponding revenues are recognized. Costs to fulfill a contract: Costs to fulfill a contract, which primarily consist of costs arising from technology transfers in preparation of supply contracts or anticipated contracts, are recognized as an asset when the costs generate or enhance the Company’s resources that will be used in satisfying or continuing to satisfy the performance obligations in the future and are expected to be recovered. Costs to fulfill a contract consist of direct identifiable costs and indirect costs that can be attributed to a contract based on a reasonable allocation method. These costs include mainly salaries and other employee benefits costs. Costs to fulfill a contract are amortized on a systematic basis that is consistent with the provision of the goods and services under the contracts. As of December 31, 2023, and 2022, the Company recognized an asset related to the costs to fulfill a contract in the net amounts of $8,495 thousand and $7,577 thousand, respectively. The Company amortizes the contract asset over an 18-year period straight line basis, representing the expected duration of the relationship with the customer. In 2023, the Company recognized $51 thousand in amortization costs, which were included in the cost of goods sold. No impairment losses were recognized. Refer to Note 18e for further information.
Research and development costs	n. Research and development costs Research and development expenditures are recognized in profit or loss when incurred and include preclinical and clinical costs (as well as cost of materials associated with the development of new products or existing products for new therapeutic indications). In addition, these costs include additional product development activities with respect to approved and distributed products as well as post marketing commitment research and development activities. Since the Company’s development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and therefore, development expenditures are recognized in profit or loss when incurred.
Taxes on income	o. Taxes on income Current and Deferred taxes Taxes on income in profit or loss comprise of current taxes, deferred taxes and taxes in respect of prior years, which are mainly recognized in profit or loss. Deferred tax assets are reviewed at the end of each reporting period and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at the end of each reporting period and a respective deferred tax asset is recognized to the extent that their utilization is probable. The Company operates in multiple tax jurisdictions. Deferred taxes are offset in the statement of financial position if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. As of December 31, 2023, the Company did not record deferred tax asset for the remaining carry forward losses due to estimation that their utilization in the foreseeable future is not probable. Uncertain tax positions The Company evaluates potential uncertain tax positions, including additional tax and interest expenses, and recognizes a provision when it is more probable than not that the Company will have to use its economic resources to pay the such obligation. As of December 31, 2023 and 2022, the application of IFRIC 23 did not have a material effect on the financial statements.
Provisions	p. Provisions A provision in accordance with IAS 37 is recognized when the Company has a present (legal or constructive) obligation as a result of a past event, it is expected to require the use of economic resources to clear the obligation and a reliable estimate can be made of it.
Share-based payment transactions	q. Share-based payment transactions The Company’s employees and members of its Board of Directors are entitled to remuneration in the form of equity-settled share-based payment transactions, primarily in the form of options and restricted shares units. The cost of equity-settled transactions (options and restricted share units) with employees and members of the Board of Directors is measured at the fair value of the equity instruments granted at grant date. The fair value of options is determined using a standard option pricing model, the binomial option valuation model. The fair value of restricted share is determined using the share price at the grant date. The cost of equity-settled share-based payments transactions is recognized in profit or loss together with a corresponding increase in shareholder’s equity during the period which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees or directors become entitled to the award (“the vesting period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest.

Material Accounting Policies (T

Material Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Material Accounting Policies (Tables) [Line Items]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates	Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly % Buildings 2.5-4 4 Machinery and equipment 10-20 15 Vehicles 15 15 Computers, software, equipment and office furniture 6-33 33 Leasehold improvements (* ) 10 (*) Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.
Schedule of Depreciation of Right-of-Use Asset Useful Life	Right-of-use assets composition and changes in lease liabilities Right-of-use-assets Rented (3) Vehicles Computers, Total Lease (1)(2) U.S Dollars in thousands As of January 1, 2023 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 Additions to right-of-use assets 5,131 1,415 - 6,546 6,682 Termination lease (109 ) - (109 ) (107 ) Depreciation expense (500 ) (738 ) (6 ) (1,244 ) - Exchange rate differences - - - - (96 ) Repayment of lease liabilities - - - - (850 ) As of December 31, 2023 $ 6,363 $ 1,397 $ 1 $ 7,761 $ 8,822 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 3.06%–7.11% evaluated based on credit risk, terms of the leases and other economic variables. (2) The balance does not include current maturities of lease of $134 thousand that were classified to other accounts receivables due to expected lease incentive. (3) Out of the Depreciation expense $20 thousand was capitalized to the Leasehold Improvements. During 2023, the Company recognized $367 thousand as interest expenses on lease liabilities. During 2023, the total cash outflow for leases was $850 thousand. Right-of-use-assets Rented Vehicles Computers, Total Lease (1) U.S Dollars in thousands As of January 1, 2022 $ 2,165 $ 913 $ 15 $ 3,093 $ 4,314 Additions to right -of -use assets - 551 - 551 551 Lease termination - (52 ) - (52 ) (59 ) Depreciation expense (433 ) (583 ) (8 ) (1,024 ) Exchange rate differences - - - - (448 ) Repayment of lease liabilities - - - - (1,164 ) As of December 31, 2022 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 1.94%-4.6% evaluated based on credit risk, terms of the leases and other economic variables.
Schedule of Intangible Assets with finite Useful Life	Intangible assets with a finite useful life are amortized on a straight-line basis over their useful life, as follows: Estimated life Amortization method Intellectual property 15-20 Straight-line Customer Relations 20 Straight-line Production agreement 6 Straight-line Distribution right 10-15 Straight-line over the contract period Goodwill Indefinite Not amortized
Right-of-use assets [Member]
Material Accounting Policies (Tables) [Line Items]
Schedule of Depreciation of Right-of-Use Asset Useful Life	The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life or the lease term, as follows: % Mainly % Land and Buildings 5-10 10 Vehicles 20-33 33 office equipment (i.e. printing and photocopying machines) 20 20

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Schedule of Acquisition Consideration	The following table details the acquisition consideration: USD Cash paid $ 1,404 Payables for acquisition(a) 210 Total acquisition cost 1,614 (a) The acquisition consideration totaled $1,654 thousand, of which an amount of $1,404 thousand was paid at closing, and the balance of $250 thousand was paid in March 2022. The fair value of such deferred consideration was estimated at $210 as of the date of acquisition. The following table details the total acquisition consideration as of the Acquisition Date: USD Cash paid at closing $ 95,000 Contingent consideration liability (a) 21,705 Deferred consideration (b) 13,788 Settlement of preexisting relationship (c) (3,786 ) Total acquisition cost 126,707
Schedule of Fair Value of the Identifiable Assets and Liabilities on the Acquisition Date	The fair value of the identifiable assets and liabilities on the acquisition date: USD Inventories 184 Property, plant and equipment 82 Intangible assets (a) 962 1,228 Other current liability (30 ) Net identifiable assets 1,198 Goodwill arising on acquisition (b) 416 Total acquisition cost 1,614 (a) The intangible assets represent the value of the FDA license for the plasma collection facility at fair value (Level 3) at the acquisition date, based on the Greenfield Method. Under such method, the subject intangible asset is valued using a hypothetical cashflow scenario of developing an operating business in an entity that at inception only holds the subject intangible asset. In measuring the FDA license for the plasma collection facility, the Company used an appropriate discount rate of 19%. (b) The goodwill arising as part of the acquisition is attributed to the expected benefits from the synergies of the combination of the Company’s activities and those of the acquired plasma collection facility. The following tables details the fair value of the identifiable assets and liabilities on the Acquisition Date: Fair value USD Inventory(a) 22,849 Intangible assets(b) 121,174 Assumed liability(c) (47,213 ) Net identifiable assets 98,810 Goodwill arising on acquisition(d) 29,897 Total acquisition cost 126,707
Schedule of Intangible Assets	The following table details the intangible assets identified Fair value Customer Relations (1) 33,514 Intellectual property (2) 79,141 Assumed contract manufacturing agreement (3) 8,519 Total Intangible assets 121,174 (1) Customer Relations represents its fair value (Level 3) at the Acquisition Date, based on a Multi Period Excess Earnings Method (“MPEEM”). In measuring the Customer Relations, the Company used an appropriate risk-adjusted discount rate of 11% and churn rate of 5%. (2) Intellectual property represents its fair value (Level 3) at the Acquisition Date, based on a Relief from Royalties (“RFRM”) Method. In measuring the Intellectual property, the Company used an appropriate risk-adjusted discount rate of 11% and Royalties rate of 15.2%. (3) Assumed contact manufacturing agreement represents its fair value (Level 3) at the Acquisition Date, based on With and Without method. Under the With and Without method the value of an intangible asset is calculated by comparing the cash-flow in a situation where the valued asset is part of the business versus the cash-flow in situation where the asset is not part of the business. The Company used an appropriate risk-adjusted discount rate of 11%.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	December 31, 2023 2022 U.S. Dollars in thousands Cash and deposits for immediate withdrawal $ 40,630 $ 31,411 Cash equivalents in NIS deposits (1) 15,011 2,847 Total Cash and Cash Equivalents $ 55,641 $ 34,258 (1) The deposits bear interest of 5.1% per year, as of December 31, 2023, and 2.85%-3.8% per year as of December 31, 2022.

Trade Receivables, Net (Tables)

Trade Receivables, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Trade Receivables, Net [Abstract]
Schedule of Trade Receivables, Net	December 31, 2023 2022 U.S. Dollars in thousands Open accounts: In NIS $ 9,084 $ 9,469 In USD 10,642 17,659 $ 19,726 $ 27,128 Checks receivable 151 124 $ 19,877 $ 27,252 Less allowance for doubtful accounts(1) - - Total Trade receivables, net $ 19,877 $ 27,252 (1) As of December 31, 2023 and 2022 no allowance for doubtful accounts was recognized.
Schedule of Analysis of Past Due but Not Impaired Trade Receivables	An analysis of past due but not impaired trade receivables with reference to reporting date: Past due trade receivables with aging of Neither Up to 31-60 Days 61-90 Days 91-120 Days Over Total December 31, 2023 $ 18,294 $ 1,391 $ 11 $ 10 $ 26 $ 145 $ 19,877 December 31, 2022 $ 22,710 $ 3,260 $ 788 $ 84 $ 7 $ 402 $ 27,252

Other Accounts Receivables (Tab

Other Accounts Receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Other Accounts Receivables [Abstract]
Schedule of Other Accounts Receivables	December 31, 2023 2022 U.S. Dollars in thousands Prepaid expenses $ 4,405 $ 3,875 Inventory designated for R&D activities - 3,732 Government authorities 981 645 Derivatives financial instruments mainly measured at fair value through other comprehensive income 149 - Accrued income 45 451 Other(1) 385 7 Total Other Accounts Receivables $ 5,965 $ 8,710 (1) The balance includes short-term lease in the amount of $134 thousand that was classified to other accounts receivables (refer to Note 15 for further details), and $247 thousand bank guarantee provided (refer to Note 19 for further details).

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Schedule of Inventories	December 31, 2023 2022 U.S. Dollars in thousands Finished products $ 42,526 $ 30,429 Purchased products 11,021 4,754 Work in progress 6,653 12,276 Raw materials 28,279 21,326 Total Inventories $ 88,479 $ 68,785

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Composition and Movement of Property, Plant and Equipment	Composition and changes Land and Machinery Vehicles Computers, Leasehold (2) Total U.S. Dollars in thousands Cost Balance at January 1, 2023 $ 35,090 $ 35,343 $ 31 $ 10,337 $ 1,566 $ 82,367 Additions 951 2,764 - 1,135 1,544 6,394 Sale and write-off - (110 ) - - (17 ) (127 ) Balance as of December 31, 2023 36,0418 37,997 31 11,472 3,093 88,631 Accumulated Depreciation Balance as of January 1, 2023 22,154 25,493 26 7,882 655 56,210 Depreciation 1,140 1,875 3 1,168 123 4,309 Sale and write-off - (109 ) - - - (109 ) Balance as of December 31, 2023 23,294 27,259 29 9,050 778 60,410 Depreciated cost as of December 31, 2023 $ 12,747 $ 10,738 $ 2 $ 2,422 $ 2,315 $ 28,224 (1) Including labor costs charged in 2023 to the cost of facilities, machinery, and equipment in the amount of $1,426 thousand. (2) Including Right – of use assets depreciation expense in the amount of $20 thousand that was capitalized to the Leasehold Improvements during 2023. Also refer to Note 15. Land and Machinery Vehicles Computers, Leasehold Total U.S. Dollars in thousands Cost Balance at January 1, 2022 $ 34,543 33,439 31 9,371 1,184 78,568 Additions 547 1,906 - 966 382 3,801 Sale and write-off - (2 ) - - - (2 ) Balance as of December 31, 2022 35,090 35,343 31 10,337 1,566 82,367 Accumulated Depreciation Balance as of January 1, 2022 21,091 23,804 23 6,808 535 52,261 Depreciation 1,063 1,691 3 1,074 120 3,951 - (2 ) - - - (2 ) Balance as of December 31, 2022 22,154 25,493 26 7,882 655 56,210 Depreciated cost as of December 31, 2022 $ 12,936 $ 9,850 $ 5 $ 2,455 $ 911 $ 26,157 (1) Including labor costs charged in 2022 to the cost of facilities, machinery, and equipment in the amount of $1,403 thousands.
Schedule of Leasing Rights of Land from Israel Land Administration	Leasing rights of land from the Israel land administration. December 31, 2023 2022 U.S. Dollars in thousands Under finance lease $ 1,091 $ 1,119

Intangible Assets, Goodwill a_2

Intangible Assets, Goodwill and Other Long Term Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible Assets, Goodwill and Other Long Term Assets [Abstract]
Schedule of Other Long Term Assets	December 31, 2023 2022 U.S. Dollars in thousands Intangible Assets and Goodwill 139,955 147,009 Long term pre-paid expenses 510 63 Total Other Long-Term Assets $ 140,465 $ 147,072
Schedule of Composition and Movement	Composition and changes Intellectual Customer Goodwill Other Total U.S. Dollars in thousands Cost: Balance as of January 1, 2023 80,103 $ 33,514 $ 30,313 $ 11,101 $ 155,031 Purchases - - - 129 129 Balance as of December 31, 2023 $ 80,103 $ 33,514 $ 30,313 $ 11,230 $ 155,160 Accumulated amortization and impairment: Balance as of January 1, 2023 5,853 1,855 - 314 8,022 Amortization recognized in the year 5,376 1,676 - 131 7,183 Balance as of December 31, 2023 11,229 3,531 - 444 15,204 Amortized cost at December 31, 2023 $ 68,874 $ 29,983 $ 30,313 $ 10,785 $ 139,955 (1) Includes assumed contract manufacturing agreement and distribution right of certain therapeutic products to be distributed in Israel, subject to IL MOH and or EMA marketing authorization. The Company was required to make certain upfront and milestone payments on account of such distribution rights. These payments are accounted for as long-term assets through obtaining IL MOH marketing authorization and will subsequently be amortized during the expected distribution right’s useful life. 2022 Intellectual Customer Goodwill Other Total U.S. Dollars in thousands Cost: Balance as of January 1, 2022 80,103 33,514 30,313 10,501 154,431 Purchases - - - 600 600 Balance as of December 31, 2022 $ 80,103 $ 33,514 $ 30,313 $ 11,101 $ 155,031 Accumulated amortization and impairment: Balance as of January 1, 2022 477 179 - 183 839 Amortization recognized in the year 5,376 1,676 - 131 7,183 Balance as of December 31, 2022 5,853 1,855 - 314 8,022 Amortized cost at December 31, 2022 $ 74,250 $ 31,659 $ 30,313 $ 10,787 $ 147,009
Schedule of Amortization Expenses of Intangible Assets	Amortization expenses of intangible assets are classified in statement of profit or loss as follows: Year ended December 31, 2023 2022 2021 USD in thousands Cost of goods sold 5,376 5,376 574 Selling and marketing expenses 1,807 1,807 265 7,183 7,183 839
Schedule of Allocation of Goodwill to Cash-Generating Units	Allocation of goodwill to cash-generating units December 31, 2023 2022 U.S. Dollars in thousands Proprietary $ 30,313 $ 30,313

Trade Payables (Tables)

Trade Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Trade Payables [Abstract]
Schedule of Trade Payables	December 31, 2023 2022 U.S. Dollars in thousands Open debts mainly in USD $ 11,167 $ 12,731 Open debts in EUR 7,266 10,629 Open debts in NIS 6,371 9,557 Total Trade Payables $ 24,804 $ 32,917

Other Accounts Payables (Tables

Other Accounts Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Other Accounts Payables Abstract
Schedule of Other Accounts Payables	December 31, 2023 2022 U.S. Dollars in thousands Employees and payroll accruals $ 7,542 $ 6,683 Government grants (b) 177 201 Derivatives financial instruments - 92 Accrued Expenses and Others 542 609 Total Other Accounts Payables $ 8,261 $ 7,585
Schedule of Statement of Financial Position and Profit or Loss and Other Comprehensive Income	Presented in the statement of financial position and Profit or Loss and Other Comprehensive Income: December 31, 2023 2022 U.S. Dollars in thousands Current Assets $ 104 $ 3 Current liability $ 177 $ 201 Royalties paid during the year $ - $ - Expense (income) carried to Research and Development cost $ 61 $ 29

Loans and Financial Liabiliti_2

Loans and Financial Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Loans and Financial Liabilities [Abstract]
Schedule of Loans and Financial Liabilities	Bank Loans December 31, 2023 2022 U.S. Dollars in thousands Bank loans (1) - 17,407 Less current maturities of bank loans - 4,444 Total Long term bank loans $ - $ 12,963 On November 15, 2021, the Company secured a $40,000 thousand credit facility from Bank Hapoalim, an Israeli bank. The credit facility comprised of the following:
Schedule of Financial Liabilities	Financial liabilities originated or assumed through business combinations December 31, 2023 2022 U.S. Dollars in thousands Contingent consideration (1) 21,855 23,534 Assumed liabilities (2) 46,375 61,016 Less current maturities (14,996 ) (29,708 ) Total Long term contingent consideration and assumed liabilities $ 53,234 54,842 (1) The fair value of the contingent consideration was $21,855 thousand and $23,534 thousand as of December 31, 2023, and December 31, 2022, respectively. During the year ended December 31, 2023, the Company paid the first sales milestone in the amount of $3,000 thousand, which was accounted for as a reduction of the liability. The Company accounted for $1,321 thousand, $1,539 thousand, and $290 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively as financing expenses in the statement of profit and loss to reflects the changes in the fair value of the liability. Through December 31, 2023, the second sales threshold was met, and the second milestone payment was paid during February 2024. Refer to Note 5b and Note 18 for details on the contingent consideration. (2) The assumed liabilities are measured at amortized cost. The decrease in the balance of the assumed liabilities reflects the changes in time value and changes in expected payments. The value of the assumed liabilities was $46,375 thousand and $61,016 thousand as of December 31, 2023, and 2022, respectively. During the years ended December 31, 2023, and 2022, the Company paid a total of $14,300 thousand and $5,626 thousand on account of such assumed liabilities. The Company accounted for $341 thousand of financing income and $4,727 thousand, and $704 thousand of financing expenses for the years ended December 31, 2023, 2022 and 2021, respectively to reflects the changes in the value of the assumed liabilities.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Line Items]
Schedule of Right-of-Use Assets Composition and Changes in Lease Liabilities	Right-of-use assets composition and changes in lease liabilities Right-of-use-assets Rented (3) Vehicles Computers, Total Lease (1)(2) U.S Dollars in thousands As of January 1, 2023 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 Additions to right-of-use assets 5,131 1,415 - 6,546 6,682 Termination lease (109 ) - (109 ) (107 ) Depreciation expense (500 ) (738 ) (6 ) (1,244 ) - Exchange rate differences - - - - (96 ) Repayment of lease liabilities - - - - (850 ) As of December 31, 2023 $ 6,363 $ 1,397 $ 1 $ 7,761 $ 8,822 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 3.06%–7.11% evaluated based on credit risk, terms of the leases and other economic variables. (2) The balance does not include current maturities of lease of $134 thousand that were classified to other accounts receivables due to expected lease incentive. (3) Out of the Depreciation expense $20 thousand was capitalized to the Leasehold Improvements. During 2023, the Company recognized $367 thousand as interest expenses on lease liabilities. During 2023, the total cash outflow for leases was $850 thousand. Right-of-use-assets Rented Vehicles Computers, Total Lease (1) U.S Dollars in thousands As of January 1, 2022 $ 2,165 $ 913 $ 15 $ 3,093 $ 4,314 Additions to right -of -use assets - 551 - 551 551 Lease termination - (52 ) - (52 ) (59 ) Depreciation expense (433 ) (583 ) (8 ) (1,024 ) Exchange rate differences - - - - (448 ) Repayment of lease liabilities - - - - (1,164 ) As of December 31, 2022 $ 1,732 $ 829 $ 7 $ 2,568 $ 3,193 (1) The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 1.94%-4.6% evaluated based on credit risk, terms of the leases and other economic variables.
Lease Liabilities [Member]
Leases [Line Items]
Schedule of Maturity Analysis of Lease Liabilities	Maturity analysis of the Company’s lease liabilities (including interest): Less than 1 to 2 2 to 3 3 to 5 6 and Total Lease liabilities (including interest) $ 2,918 $ 3,045 $ 1,689 $ 2,009 $ 6,759 $ 16,420 Less than 1 to 2 2 to 3 3 to 5 6 and Total Lease liabilities (including interest) $ 1,119 $ 907 $ 732 $ 683 $ - $ 3,441

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Schedule of Groups of Financial Instruments	The financial assets liabilities in the balance sheet are classified by groups of financial instruments pursuant to IFRS 9: December 31, 2023 2022 U.S. Dollars in thousands Financial assets Financial assets at fair value through profit or loss: Foreign exchange forward contracts 8 - Total Financial assets at fair value through profit or loss $ 8 $ - Financial assets at fair value through other comprehensive income: Cash flow hedges 141 - Total Financial assets at fair value through other comprehensive income: $ 141 $ - Financial assets at cost: Cash and cash equivalent 55,641 34,258 Total Financial assets at cost $ 55,641 $ 34,258 Total financial assets $ 55,790 $ 34,258 Financial liabilities Financial liabilities at fair value through profit or loss: Foreign exchange forward contracts - 4 Contingent consideration in business combination 21,855 23,534 Total financial liabilities at fair value through profit or loss $ 21,855 $ 23,538 Financial liabilities at fair value through other comprehensive income: Cash flow hedges - 88 Total financial liabilities at fair value through other comprehensive income $ - $ 88 Financial liabilities measured at amortized cost: Assumed liabilities through business combination 46,375 61,016 Bank loans - 17,407 Leases 8,822 3,193 Total financial liabilities measured at amortized cost $ 55,197 $ 81,616 Total financial and lease liabilities $ 77,052 $ 105,242
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments	The table below summarizes the maturity profile of the Company’s financial liabilities based on contractual undiscounted payments: Less than 1 to 2 2 to 3 3 to 5 6 and Total Trade payables $ 24,804 - - - - 24,804 Assumed liabilities (1) 11,996 4,152 4,261 7,836 18,130 46,375 Other accounts payables 8,261 - - - - 8,261 Lease liabilities (including interest) 2,918 3,045 1,689 2,009 6,759 16,420 $ 47,979 7,197 5,950 9,845 24,889 95,860 (1) Due the nature of the account which include infinite payments for royalties and milestones to third parties the assumed liabilities reflect the discounted amount. see Note 18e Less than 1 to 2 2 to 3 3 to 5 6 and Total Trade payables $ 32,917 - - - - $ 32,917 Assumed liabilities 23,708 5,030 4,087 7,928 20,263 61,016 Other accounts payables 7,585 - - - - 7,585 Bank loans (including interest) 4,841 4,677 4,580 4,111 - 18,208 Lease liabilities (including interest) 1,119 907 732 683 - 3,441 $ 70,170 $ 10,614 $ 9,399 $ 12,722 $ 20,263 $ 123,167
Schedule of Changes in Liabilities Arising from Financing Activities	Changes in liabilities arising from financing activities January 1, Payments Foreign New Business Revaluation Write off December 31, U.S. Dollars in thousands Contingent consideration (1) 23,534 (3,000 ) - - - 1,321 21,855 Assumed liabilities 61,016 (14,300 ) - - (341 ) 46,375 Bank loans 17,407 (17,407 ) - - - - Leases 3,193 (850 ) (96 ) 6,682 - - (107 ) 8,822 Total $ 105,150 $ (35,557 ) $ (96 ) $ 6,682 $ - $ 980 $ (107 ) $ 77,052 (1) The contingent consideration fair value as of December 31, 2023, was based on an Option Pricing Method (OPM), “Monte Carlo Simulation” model. In measuring the contingent consideration liability, the Company used an appropriate risk-adjusted discount rate of 11.4% and volatility of 15.17%. totaled $21,855 thousand.
Schedule of Fair Value of the Financial Assets and Liabilities	The following table demonstrates the carrying amount and fair value of the financial assets and liabilities presented in the financial statements not at fair value: Carrying Amount Fair Value December 31, December 31, 2023 2022 2023 2022 U.S. Dollars in thousands Assumed liabilities 46,375 61,016 46,468 56,946 Bank loans - 17,407 - 17,071 Leases 8,822 3,193 8,973 3,183 Total Financial liabilities $ 55,197 $ 81,616 $ 55,441 $ 77,200
Schedule of Financial Assets (Liabilities) Measured at Fair Value	Financial assets (liabilities) measured at fair value: Financial assets (liabilities) measured at fair value: Level 1 Level 2 Level 3 (1) U.S. Dollars in thousands December 31, 2023 Derivatives instruments - 149 - Contingent consideration(1) - - (21,855 ) $ - $ 149 $ (21,855 ) Financial assets (liabilities) measured at fair value: Level 1 Level 2 Level 3 (1) U.S. Dollars in thousands December 31, 2022 Derivatives instruments - (92 ) - Contingent consideration(1) - - (23,534 ) $ - $ (92 ) $ (23,534 ) (1) For changes in Contingent Consideration see above
Schedule of Sensitivity Test to Changes in Interest Rate Risk	The test of risk factors was determined based on the materiality of the exposure of the operating results or financial condition of each risk with reference to the functional currency and assuming that all the other variables are constant. December 31, 2023 2022 U.S. Dollars in thousands Sensitivity test to changes in interest rate risk Gain (loss) from change: 1% increase in basis points of SOFR $ - $ (13 ) 1% decrease in basis points of SOFR $ - $ 13 Sensitivity test to changes in foreign currency: Gain (loss) from change: 5% increase in NIS $ (454 ) $ (57 ) 5% decrease in NIS $ 454 $ 57 5% increase in Euro $ (271 ) $ (389 ) 5% decrease in Euro $ 271 $ 389
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments	Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9: December 31, 2023 2022 U.S. Dollars in thousands In NIS: Bank loans measured at amortized cost $ - $ - Leases measured at amortized cost 6,275 3,193 $ 6,275 $ 3,193 In USD: Contingent consideration at fair value through profit or loss 21,855 23,534 Assumed liabilities measured at amortized cost 46,375 61,016 Bank loans measured at amortized cost - 17,407 Leases measured at amortized cost (1) 2,547 - $ 70,777 $ 101,957 1 The balance does not include current maturities of lease of $134 thousand that was classified to other accounts receivables due to expected lease incentive.

Employee Benefit Liabilities,_2

Employee Benefit Liabilities, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Employee Benefit Liabilities, Net [Abstract]
Schedule of Expenses Recognized in Comprehensive Income (Loss)	Expenses recognized in comprehensive income (loss): Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Current service cost $ 194 $ 223 $ 281 Past service cost - - 415 Interest expenses, net 28 15 23 Total employee benefit expenses 222 238 716 Actual return on plan assets $ 50 $ (25 ) $ 349
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss)	The expenses are presented in the Statement of Comprehensive income (loss) as follows Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Cost of revenues $ 155 $ 166 $ 499 Research and development 22 24 90 Selling and marketing 33 27 62 General and administrative 23 21 65 $ 233 $ 238 $ 716
Schedule of Plan Liabilities, Net	The plan liabilities, net: December 31, 2023 2022 U.S. Dollars in thousands Defined benefit obligation $ 4,399 $ 4,379 Fair value of plan assets 3,778 3,707 Total liabilities, net $ 621 $ 672
Schedule of Changes in Present Value of Defined Benefit Obligation	Changes in the present value of defined benefit obligation 2023 2022 U.S. Dollars in thousands Balance at January 1, $ 4,380 $ 5,434 Interest costs 200 78 Current service cost 194 223 Past service cost - - Benefits paid (376 ) (202 ) Demographic assumptions 13 (9 ) Financial assumptions (91 ) (715 ) Past Experience 209 206 Currency Exchange (130 ) (636 ) Balance at December 31, $ 4,399 $ 4,379
Schedule of Changes in Fair Value of Plan Assets	Changes in the fair value of plan assets 2023 2022 U.S. Dollars in thousands Balance at January 1, $ 3,707 $ 4,154 Expected return 172 62 Contributions by employer 173 181 Benefits paid (206 ) (181 ) Demographic assumptions - - Financial assumptions - (4 ) Past Experience 50 (20 ) Currency exchange (118 ) (485 ) Balance at December 31, $ 3,778 $ 3,707
Schedule of Principal Assumptions Underlying Defined Benefit Plan	The principal assumptions underlying the defined benefit plan 2023 2022 2021 % Discount rate of the plan liability 5.3 5.1 3.1 Future salary increases 3.0 3.0 3.0

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Share Capital	Share capital December 31, 2023 December 31, 2022 Authorized Outstanding Authorized Outstanding Ordinary shares of NIS 1 par value 70,000,000 57,479,528 70,000,000 44,832,843
Schedule of Issued and Outstanding Share Capital	Issued and outstanding share capital: Number of shares Balance as of January 1, 2022 44,799,794 Issue of shares - Exercise of options into share units 1,421 Vesting of restricted shares units 31,628 Balance as of December 31, 2022 44,832,843 Issue of shares 12,631,579 Exercise of options into shares units 2,662 Vesting of restricted shares units 12,444 Balance as of December 31, 2023 57,479,528

Share-Based Payment (Tables)

Share-Based Payment (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment [Abstract]
Schedule of Expense Recognized in Financial Statements	The share-based compensation expense that was recognized for services received from employees and members of the Company’s Board of Directors is presented in the following table: For the Year Ended December 31 2023 2022 2021 U.S. Dollar in thousands Cost of revenues $ 249 $ 308 $ 69 Research and development 167 204 79 Selling and marketing 238 254 34 General and administrative 660 372 347 Total share-based compensation $ 1,314 $ 1,138 $ 529
Schedule of Weighted Average Exercise Prices of Share	The following table lists the number of share options, the weighted average exercise prices of share options and changes in share options grants during the year: 2023 2022 2021 Number of Weighted Number of Weighted Number of Weighted In NIS In NIS In NIS Outstanding at beginning of year 3,247,814 19.91 1,504,678 20.38 1,660,958 20.38 Granted 343,647 18.60 2,076,800 19.27 - - Exercised (42,175 ) 19.04 (8,325 ) 16.47 (28,672 ) 16.93 Forfeited (279,305 ) 19.57 (325,339 ) 19.14 (127,608 ) 20.29 Outstanding at end of year 3,269,981 18.82 3,247,814 19.91 1,504,678 20.65 Exercisable at end of year 1,469,084 19.83 1,049,329 20.38 1,067,363 19.78 The weighted average remaining contractual life for the share options 4.01 4.67 3.33
Schedule of RSUs and Changes in RSUs	The following table lists the number of RSUs and changes in RSUs grants during the year: Number of RSs 2023 2022 2021 Outstanding at beginning of year 14,705 49,561 104,519 Granted - - - End of restriction period (12,444 ) (31,608 ) (52,538 ) Forfeited (386 ) (3,248 ) (2,420 ) Outstanding at end of year 1,875 14,705 49,561 The weighted average remaining contractual life for the restricted share units 0.25 0.96 3.40
Schedule of Inputs to Binomial Model Used for Fair Value Measurement	The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan. 2023 2022 2021 (1) Dividend yield (%) - - - Expected volatility of the share prices (%) 26-38 23-40 - Risk-free interest rate (%) 3.76-4.70 0.4-3.55 - Contractual term of up to (years) 6.5 6.5 - Exercise multiple 2 2 - Weighted average share prices (NIS) 16.10-19.46 13.6-18.41 - Expected average forfeiture rate (%) 0-8.5 0-8.5 - 2023 2022 2021 (1) Dividend yield (%) - - - Expected volatility of the share prices (%) 34-47 27-47 - Risk-free interest rate (%) 3.76-5.03 0.91-3.54 - Contractual term of up to (years) 6.5 6.5 - Exercise multiple - - - Weighted average share prices (NIS) 4.22-5.55 4.8-5.37 - Expected average forfeiture rate (%) 5.5-8.5 1.9-8.5 -

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2023
Taxes on Income [Abstract]
Schedule of Taxes on Income	Taxes on income Year ended December 31, 2023 2022 2021 U.S. Dollars in thousands Current taxes $ 145 $ 62 $ 345 Deferred tax expenses (income) - - - Taxes in respect of prior years - - - Taxes on income $ 145 $ 62 $ 345

Supplementary Information to _2

Supplementary Information to the Statements of Profit and Loss (Tables)	12 Months Ended
	Dec. 31, 2023
Supplementary Information to the Statements of Profit and Loss [Abstract]
Schedule of Additional Information about Revenues	Additional information about revenues Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Revenues from major customers each of whom amount to 10% or more, of total revenues Customer A (1) 32,800 16,195 11,947 Customer B (2) $ 16,129 $ 14,205 $ 31,936 Customer C (3) 9,230 12,255 12,357 $ 58,159 $ 42,655 $ 56,240 (1) Revenue is attributed to the Proprietary segment. Refer to Note 18 (c) for more information. (2) Revenue is attributed to the Proprietary segment. Refer to Note 18 (a) for more information. (3) Revenue is attributed mainly to the Distribution segment and in 2023; the total is less than 10% of total Revenues
Schedule of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows: Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands U.S.A $ 73,741 $ 65,296 $ 49,763 Israel 31,296 32,031 35,774 Canada 11,162 10,555 - Europe 7,088 5,277 5,677 Latin America 12,928 11,293 9,127 Asia 6,147 4,581 3,167 Others 157 306 134 Total Revenue $ 142,519 $ 129,339 $ 103,642
Schedule of Cost of Goods Sold	Cost of goods sold Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Cost of materials (1) $ 70,308 $ 53,666 $ 63,945 Salary and related expenses 16,330 14,967 17,486 Subcontractors 6,354 4,673 4,892 Depreciation and amortization (2) 9,000 8,553 3,627 Energy 1,383 1,365 1,464 Other manufacturing expenses 1,235 1,785 1,298 Total Cost of goods sold before Inventory change 100,610 85,009 92,712 Decrease (increase) in inventories (17,581 ) (2,373 ) (19,398 ) Total Cost of goods sold $ 87,029 $ 82,636 $ 73,314 (1) Costs of materials for the year ended December 31, 2021, includes $24,282 of inventory obtained in connection with the business combination. Refer to Note 5b for further detail on the business combination. (2) Including amortization of intangible assets in the amount of $5,376 for each of the years ended December 31, 2023 and 2022, and $574 for the year ended December 31, 2021 Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 5,110 $ 5,608 $ 5,076 Subcontractors 4,677 4,216 3,656 Materials and allocation of facility costs 2,971 2,538 1,896 Depreciation and amortization 586 574 616 Others 589 236 113 Total Research and development $ 13,933 $ 13,172 $ 11,357 Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 4,907 4,047 1,930 Packing, shipping and delivery 1,366 1,484 912 Marketing and advertising 2,634 3,676 1,340 Registration and marketing fees 4,362 3,463 1,262 Depreciation and amortization (1) 2,090 2,056 488 Others 834 558 346 Total Selling and marketing $ 16,193 $ 15,284 $ 6,278 (1) Including amortization of intangible assets in the amount of $1,807 for each of the years ended December 2023 and 2022, and $265 for the year ended December 31, 2021. Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and related expenses $ 5,283 $ 4,455 3,853 Employees welfare 1,337 1,299 1,259 Professional fees and public company expense 4,305 4,213 5,055 Depreciation, amortization and impairment 1,035 973 875 Communication and software services 1,201 905 977 Others 1,220 958 617 Total General and administrative $ 14,381 $ 12,803 $ 12,636 Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Financial income Interest income from cash deposit $ 588 $ 91 $ 295 Financial expense Revaluation of long term liabilities (980 ) (6,266 ) (994 ) Fees and interest expense to financial institutions (1,298 ) (914 ) (283 ) Financial income and (expense) Derivatives instruments measured at fair value 149 548 (565 ) Translation differences of financial assets and liabilities (94 ) (250 ) 358 Total Financial (expense) income $ (1,635 ) $ (6,791 ) $ (1,189 )

Income (Loss) Per Share (Tables

Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Income (Loss) Per Share [Abstract]
Schedule of Number of Shares and Income (Loss)	Details of the number of shares and income (loss) used in the computation of income (loss) per share Year Ended December 31, 2023 2022 2021 Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Income Attributed to equity holders of the Company Weighted Number of Shares Income Attributed to equity holders of the Company U.S. Dollars U.S. Dollars U.S. Dollars For the computation of basic income (loss) 48,830,479 8,284 44,815,248 $ (2,321 ) 44,771,766 $ (2,230 ) Effect of potential dilutive ordinary shares 4,845,035 41,328 - 130,177 - For the computation of diluted income (loss) 53,675,514 8,284 44,856,576 $ (2,321 ) 44,901,943 $ (2,230 )

Operating Segments (Tables)

Operating Segments (Tables)	12 Months Ended
	Dec. 31, 2023
Operating Segments [Abstract]
Schedule of Reporting on Operating Segments	Reporting on operating segments Proprietary Distribution Total U.S. Dollars in thousands Year Ended December 31, 2023 Revenues $ 115,458 $ 27,061 $ 142,519 Gross profit $ 52,116 $ 3,374 $ 55,490 Unallocated corporate expenses (45,426 ) Finance income, net (1,635 ) Income before taxes on income $ 8,429 Proprietary Distribution Total U.S Dollars in thousands Year Ended December 31, 2022 Revenues $ 102,598 $ 26,741 $ 129,339 Gross profit $ 44,369 $ 2,334 $ 46,703 Unallocated corporate expenses (42,171 ) Finance income, net (6,791 ) Income before taxes on income $ (2,259 ) Proprietary Distribution Total U.S. Dollars in thousand Year Ended December 31, 2021 Revenues $ 75,521 $ 28,121 $ 103,642 Gross profit $ 27,327 $ 3,001 $ 30,328 Unallocated corporate expenses (31,024 ) Finance expense, net (1,189 ) Loss before taxes on income $ (1,885 )

Balances and Transactions wit_2

Balances and Transactions with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2023
Balances and Transactions with Related Parties [Abstract]
Schedule of Balances with Related Parties	Balances with related parties December 31, December 31, U.S. Dollars in thousands Trade receivable $ - $ 544 Trade payables $ 96 $ 101 Other accounts payables $ 45 $ 85 Transactions with employed/directors that accounts as related parties Year Ended December 31, 2023 2021 2020 U.S. Dollars in thousands Remuneration of directors not employed by the Company or on its behalf $ 548 $ 331 $ 487 Number of People to whom the Salary and remuneration Refer: Directors not employed by the Company 11 9 9 Total Directors employed and not employed by the Company 11 9 9 Transactions with key executive personnel (including non-related parties) Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Salary and Related Expenses $ 3,771 $ 3,590 $ 2,791 Share-based payment 728 547 255 Total $ 4,499 $ 4,137 $ 3,046 Transactions with related parties Year Ended December 31, 2023 2022 2021 U.S. Dollars in thousands Revenues $ 2,676 $ 5,298 $ 5,356 Cost of Goods Sold $ 7 $ 19 $ 51 Selling and marketing expenses $ - $ - $ - General and administrative expenses $ 223 $ 214 $ 227
Schedule of CEO Employment Terms	CEO employment terms Year Effective date Company’s Board Monthly December 31, NIS USD 2020 July 1, 2019 March 2020 ₪ 88,000 $ 25,462 2021 July 1, 2021 October 2021 ₪ 92,400 $ 28,607 2022 July 1, 2022 November 2022 ₪ 96,000 $ 28,575 2023 July 1, 2023 December 2023 ₪ 100,000 $ 27,570

General (Details)

General (Details)	12 Months Ended
	Dec. 31, 2023
Disclosure of General Information About Financial Statements [Line Item]
Agreement on initiation of sales, description	Company ceased the production and sale of GLASSIA to Takeda during 2021, and during the first quarter of 2022, Takeda began to pay the Company royalties on sales of GLASSIA manufactured by Takeda, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each year from 2022 to 2040.
Number of operating segments	2
Subsidiary ownership interest, percentage	74%
FIMI Opportunity Funds [Member]
Disclosure of General Information About Financial Statements [Line Item]
Ownership percentage	38%

Material Accounting Policies (D

Material Accounting Policies (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Material Accounting Policies [Line Items]
Eligible employees, percentage	100%
Employee contribution		$ 62	$ 11
Employee contributions period		50 years
Employee contributions percentage		3%
Net amounts		$ 8,495	$ 7,577
Amortization costs		51
Bottom of range [member]
Material Accounting Policies [Line Items]
Employee contribution		22,500
Top of range [member]
Material Accounting Policies [Line Items]
Employee contribution		$ 30,000

Material Accounting Policies _2

Material Accounting Policies (Details) - Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates	12 Months Ended
	Dec. 31, 2023
Buildings [Member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Mainly %	4%
Buildings [Member] | Bottom of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	2.50%
Buildings [Member] | Top of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	4%
Machinery and equipment [Member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Mainly %	15%
Machinery and equipment [Member] | Bottom of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	10%
Machinery and equipment [Member] | Top of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	20%
Vehicles [Member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	15%
Mainly %	15%
Computers, software, equipment and office furniture [Member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Mainly %	33%
Computers, software, equipment and office furniture [Member] | Bottom of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	6%
Computers, software, equipment and office furniture [Member] | Top of range [member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life	33%
Leasehold improvements [Member]
Schedule of Depreciation on a Straight-line Basis Over the Useful Life of the Assets at Annual Rates [Line Items]
Percentage of useful life		[1]
Mainly %	10%
[1] Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

Material Accounting Policies _3

Material Accounting Policies (Details) - Schedule of Depreciation of Right-of-Use Asset Useful Life	12 Months Ended
	Dec. 31, 2023
Land and Buildings [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Mainly %	10%
Vehicles [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Mainly %	33%
Office equipment (i.e. printing and photocopying machines) [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Right-of-use asset of useful life or the lease term percentage	20%
Mainly %	20%
Bottom of range [member] | Land and Buildings [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Right-of-use asset of useful life or the lease term percentage	5%
Bottom of range [member] | Vehicles [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Right-of-use asset of useful life or the lease term percentage	20%
Top of range [member] | Land and Buildings [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Right-of-use asset of useful life or the lease term percentage	10%
Top of range [member] | Vehicles [Member]
Schedule of Depreciation of Right-of-Use Asset Useful Life [Line Items]
Right-of-use asset of useful life or the lease term percentage	33%

Material Accounting Policies _4

Material Accounting Policies (Details) - Schedule of Intangible Assets with Finite Useful Life	12 Months Ended
	Dec. 31, 2023
Intellectual property [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Amortization method	Straight-line
Customer Relations [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	20 years
Amortization method	Straight-line
Production agreement [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	6 years
Amortization method	Straight-line
Distribution right [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Amortization method	Straight-line over the contract period
Goodwill [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	Indefinite
Amortization method	Not amortized
Bottom of range [member] | Intellectual property [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	15 years
Bottom of range [member] | Distribution right [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	10 years
Top of range [member] | Intellectual property [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	20 years
Top of range [member] | Distribution right [Member]
Schedule of Intangible Assets with Finite Useful Life [Line Items]
Estimated life	15 years

Business Combinations (Details)

Business Combinations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022		Dec. 31, 2021	Dec. 31, 2019	Mar. 31, 2022
Business Combinations (Details) [Line Items]
Total consideration	$ 1,614
Cash transferred balance amount						$ 250
Deferred consideration	210
Legal and other consulting fees	$ 140
Discount rate	19%
Deferred inventory	$ 50,000
Credit deductible	$ 3,000
Risk- adjusted discount rate	10.60%
Volatility rate percentage	13.60%	14.21%
Contingent consideration total	$ 21,855	$ 23,534
Sales	3,000
Revenues	$ 142,519	129,339		$ 103,642
Risk-adjusted discount rate	11.80%
Acquired inventory	$ 14,199
Inventory installments	1,500
Deferred inventory	$ 13,788
Binding term					12 years
Fund transfer					$ 3,786
Fair value of such assumed liabilities description	The fair value of such assumed liabilities at the Acquisition Date was estimated at $47,213 thousand, which was calculated based on the Option Pricing Method (OPM), Monte Carlo Simulation, and discounted cash flow using a discount rate in the range of 2.25 % and 11% and the volatility of 10.8-14.2%. Refer to Note 14 and Note 16 for more information. Such assumed liabilities include:    ● Royalties:10% of the annual global net sales of CYTOGAM up to $ 25,000 thousand and 5% of net sales that are greater than $ 25,000 thousand, in perpetuity; 2% of the annual global net sales of CYTOGAM in perpetuity; and 8% of the annual global net sales of CYTOGAM for a period of six years following the completion of the technology transfer of the manufacturing of CYTOGAM to the Company, subject to a maximum aggregate of $5,000 thousand per year and the total amount of $30,000 thousand throughout the entire six years period.   ● Sales milestones: $1,500 thousand in the event that the annual net sales of CYTOGAM in the United States market exceeds $18,766 thousand during the twelve months period ending June 30, 2022. Such milestone was achieved and paid during 2023; and $1,500 thousand in the event that the annual net sales of CYTOGAM in the United States market exceeds $18,390 thousand during the twelve months period ending June 30, 2023. Such milestone was not achieved and was written off the outstanding liability.  ●Milestone: $8,500 thousand upon the receipt of FDA approval for the manufacturing of CYTOGAM at the Company’s manufacturing facility.
Manufacturing facility	$ 8,500
Legal and other consulting fees	$ 1,094
Multi-Period Excess Earnings Method [Member]
Business Combinations (Details) [Line Items]
Risk-adjusted discount rate	11%
Churn rate	5%
Relief from Royalties [Member]
Business Combinations (Details) [Line Items]
Risk-adjusted discount rate	11%
Royalties rate	15.20%
Fair value (Level 3) [Member]
Business Combinations (Details) [Line Items]
Total consideration	$ 21,705	$ 23,534	[1]
Risk-adjusted discount rate	11%
Business Combination [Member]
Business Combinations (Details) [Line Items]
Business combination gross profit, description	the Company entered into an Asset Purchase Agreement with the privately held B&PR of Beaumont, TX, USA, for the acquisition of the FDA registered plasma collection facility as well as certain related rights and assets.
Volatility rate percentage		15.17%
Revenues	$ 1,321	$ 1,539		$ 290
Risk-adjusted discount rate	11.40%
FDA-Licensed Plasma Collection Center [Member]
Business Combinations (Details) [Line Items]
Total consideration	$ 1,654
Cash paid	$ 1,404
[1] For changes in Contingent Consideration see above

Business Combinations (Detail_2

Business Combinations (Details) - Schedule of Acquisition Consideration $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
FDA-Licensed Plasma Collection Center [Member]
Schedule of Acquisition Consideration [Line Items]
Cash paid at closing	$ 1,404
Payables for acquisition	210	[1]
Total acquisition cost	1,614
FDA-Approved Plasma-Derived Hyperimmune Commercial Products [Member]
Schedule of Acquisition Consideration [Line Items]
Cash paid at closing	95,000
Contingent consideration liability	21,705
Deferred consideration	13,788
Settlement of preexisting relationship	(3,786)
Total acquisition cost	$ 126,707
[1] The acquisition consideration totaled $1,654 thousand, of which an amount of $1,404 thousand was paid at closing, and the balance of $250 thousand was paid in March 2022. The fair value of such deferred consideration was estimated at $210 as of the date of acquisition.

Business Combinations (Detail_3

Business Combinations (Details) - Schedule of Fair Value of the Identifiable Assets and Liabilities on the Acquisition Date $ in Thousands	Dec. 31, 2023 USD ($)
FDA-Licensed Plasma Collection Center [Member]
Schedule of Fair Value of the Identifiable Assets and Liabilities on the Acquisition Date [Line Items]
Inventories	$ 184
Property, plant and equipment	82
Intangible assets	962	[1]
Total intangible assets	1,228
Other current liability	(30)
Net identifiable assets	1,198
Goodwill arising on acquisition	416	[2]
Total acquisition cost	1,614
FDA-Approved Plasma-Derived Hyperimmune Commercial Products [Member]
Schedule of Fair Value of the Identifiable Assets and Liabilities on the Acquisition Date [Line Items]
Inventories	22,849
Intangible assets	121,174
Assumed liability	(47,213)
Net identifiable assets	98,810
Goodwill arising on acquisition	29,897
Total acquisition cost	$ 126,707
[1] The intangible assets represent the value of the FDA license for the plasma collection facility at fair value (Level 3) at the acquisition date, based on the Greenfield Method. Under such method, the subject intangible asset is valued using a hypothetical cashflow scenario of developing an operating business in an entity that at inception only holds the subject intangible asset. In measuring the FDA license for the plasma collection facility, the Company used an appropriate discount rate of 19%.

Business Combinations (Detail_4

Business Combinations (Details) - Schedule of Intangible Assets - Business Combination [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Schedule of Intangible Assets [Line Items]
Total Intangible assets	$ 121,174
Customer Relations [Member]
Schedule of Intangible Assets [Line Items]
Total Intangible assets	33,514	[1]
Intellectual property [Member]
Schedule of Intangible Assets [Line Items]
Total Intangible assets	79,141	[2]
Assumed contract manufacturing agreement [Member]
Schedule of Intangible Assets [Line Items]
Total Intangible assets	$ 8,519	[3]
[1] Customer Relations represents its fair value (Level 3) at the Acquisition Date, based on a Multi Period Excess Earnings Method (“MPEEM”). In measuring the Customer Relations, the Company used an appropriate risk-adjusted discount rate of 11% and churn rate of 5%. Intellectual property represents its fair value (Level 3) at the Acquisition Date, based on a Relief from Royalties (“RFRM”) Method. In measuring the Intellectual property, the Company used an appropriate risk-adjusted discount rate of 11% and Royalties rate of 15.2%. Assumed contact manufacturing agreement represents its fair value (Level 3) at the Acquisition Date, based on With and Without method. Under the With and Without method the value of an intangible asset is calculated by comparing the cash-flow in a situation where the valued asset is part of the business versus the cash-flow in situation where the asset is not part of the business. The Company used an appropriate risk-adjusted discount rate of 11%.

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details)	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents (Details) [Line Items]
Interest rate on deposits	5.10%
Bottom of range [member]
Cash and Cash Equivalents (Details) [Line Items]
Interest rate on deposits		2.85%
Top of range [member]
Cash and Cash Equivalents (Details) [Line Items]
Interest rate on deposits		3.80%

Cash and Cash Equivalents (De_2

Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Cash and Cash Equivalents [Abstract]
Cash and deposits for immediate withdrawal		$ 40,630	$ 31,411
Cash equivalents in NIS deposits	[1]	15,011	2,847
Total Cash and Cash Equivalents		$ 55,641	$ 34,258	$ 18,587	$ 70,197
[1] The deposits bear interest of 5.1% per year, as of December 31, 2023, and 2.85%-3.8% per year as of December 31, 2022.

Trade Receivables, Net (Details

Trade Receivables, Net (Details) - Schedule of Trade Receivables, Net - USD ($) $ in Thousands	Dec. 31, 2023		Dec. 31, 2022
Trade Receivables, Net (Details) - Schedule of Trade Receivables, Net [Line Items]
Total, Open accounts	$ 19,726		$ 27,128
Checks receivable	151		124
Total Trade receivables, gross	19,877		27,252
Less allowance for doubtful accounts		[1]
Total Trade receivables, net	19,877		27,252
NIS [Member]
Trade Receivables, Net (Details) - Schedule of Trade Receivables, Net [Line Items]
Open accounts trade receivables	9,084		9,469
USD [Member]
Trade Receivables, Net (Details) - Schedule of Trade Receivables, Net [Line Items]
Open accounts trade receivables	$ 10,642		$ 17,659
[1]As of December 31, 2023 and 2022 no allowance for doubtful accounts was recognized.

Trade Receivables, Net (Detai_2

Trade Receivables, Net (Details) - Schedule of Analysis of Past Due but Not Impaired Trade Receivables - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	$ 19,877	$ 27,252
Neither Past Due Nor Impaired [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	18,294	22,710
Past Due Trade Receivables Up to 30 Days [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	1,391	3,260
Past Due Trade Receivables 31-60 Days [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	11	788
Past Due Trade Receivables 61-90 Days [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	10	84
Past Due Trade Receivables 91-120 Days [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	26	7
Past Due Trade Receivables Over 121 Days [Member]
Schedule of Analysis of Past Due But Not Impaired Trade Receivables [Line Items]
Past due trade receivables	$ 145	$ 402

Other Accounts Receivables (Det

Other Accounts Receivables (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Other Accounts Receivables [Abstract]
Short-term lease	$ 134
Other accounts receivables	$ 247

Other Accounts Receivables (D_2

Other Accounts Receivables (Details) - Schedule of Other Accounts Receivables - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Schedule Of Other Accounts Receivables Abstract
Prepaid expenses		$ 4,405	$ 3,875
Inventory designated for R&D activities			3,732
Government authorities		981	645
Derivatives financial instruments mainly measured at fair value through other comprehensive income		149
Accrued income		45	451
Other(1)	[1]	385	7
Total Other Accounts Receivables		$ 5,965	$ 8,710
[1] The balance includes short-term lease in the amount of $134 thousand that was classified to other accounts receivables (refer to Note 15 for further details), and $247 thousand bank guarantee provided (refer to Note 19 for further details).

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventories [Abstract]
Net realizable value	$ 4,399	$ 3,996	$ 2,982

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventories [Abstract]
Finished products	$ 42,526	$ 30,429
Purchased products	11,021	4,754
Work in progress	6,653	12,276
Raw materials	28,279	21,326
Total Inventories	$ 88,479	$ 68,785

Property, Plant and Equipment_2

Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) m²	Dec. 31, 2022 USD ($)	Mar. 07, 2023 m²	Dec. 31, 2021 m²
Property, Plant and Equipment [Line Items]
Depreciation expense | $	$ 20,000
Area of capitalized leasing rights from israel land administration (in Square Meters) | m²	16,880
Plant area (in Square Meters) | m²			12,000	14,880
Extension option for lease with israel land administration	49 years
Machinery [member]
Property, Plant and Equipment [Line Items]
Cost of facilities, machinery and equipment | $	$ 142,600	$ 1,403,000

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of Composition and Movement of Property, Plant and Equipment - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		$ 26,157
Sale and write-off				$ (2)
Balance at ending		28,224		26,157
Land and Buildings [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Sale and write-off
Machinery and Equipment [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Sale and write-off	[1]			(2)
Vehicles [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Sale and write-off
Computers, Software, Equipment and Office Furniture [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Sale and write-off
Cost [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		82,367		78,568
Additions		6,394		3,801
Sale and write-off		(127)		(2)
Balance at ending		88,631		82,367
Cost [Member] | Land and Buildings [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning	[1]	35,090	[2]	34,543
Additions		951	[2]	547	[1]
Sale and write-off
Balance at ending	[2]	360,418		35,090	[1]
Cost [Member] | Machinery and Equipment [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning	[1]	35,343	[2]	33,439
Additions		2,764	[2]	1,906	[1]
Sale and write-off		(110)	[2]	(2)	[1]
Balance at ending	[2]	37,997		35,343	[1]
Cost [Member] | Vehicles [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		31		31
Additions
Sale and write-off
Balance at ending		31		31
Cost [Member] | Computers, Software, Equipment and Office Furniture [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		10,337		9,371
Additions		1,135		966
Sale and write-off
Balance at ending		11,472		10,337
Cost [Member] | Leasehold Improvements [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		1,566	[3]	1,184
Additions		1,544	[3]	382
Sale and write-off		(17)	[3]
Balance at ending	[3]	3,093		1,566
Accumulated Depreciation [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		56,210		52,261
Depreciation		4,309		3,951
Sale and write-off		(109)
Balance at ending		60,410		56,210
Depreciated cost		28,224		26,157
Accumulated Depreciation [Member] | Land and Buildings [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning	[1]	22,154	[2]	21,091
Depreciation		1,140	[2]	1,063	[1]
Sale and write-off	[2]
Balance at ending	[2]	23,294		22,154	[1]
Depreciated cost		12,747	[2]	12,936	[1]
Accumulated Depreciation [Member] | Machinery and Equipment [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning	[1]	25,493	[2]	23,804
Depreciation		1,875	[2]	1,691	[1]
Sale and write-off	[2]	(109)
Balance at ending	[2]	27,259		25,493	[1]
Depreciated cost		10,738	[2]	9,850	[1]
Accumulated Depreciation [Member] | Vehicles [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		26		23
Depreciation		3		3
Sale and write-off
Balance at ending		29		26
Depreciated cost		2		5
Accumulated Depreciation [Member] | Computers, Software, Equipment and Office Furniture [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		7,882		6,808
Depreciation		1,168		1,074
Sale and write-off
Balance at ending		9,050		7,882
Depreciated cost		2,422		2,455
Accumulated Depreciation [Member] | Leasehold Improvements [Member]
Schedule of Composition and Movement of Property, Plant and Equipment [Line Items]
Balance at beginning		655	[3]	535
Depreciation		123	[3]	120
Sale and write-off
Balance at ending	[3]	778		655
Depreciated cost		$ 2,315	[3]	$ 911
[1] Including labor costs charged in 2022 to the cost of facilities, machinery, and equipment in the amount of $1,403 thousands. Including labor costs charged in 2023 to the cost of facilities, machinery, and equipment in the amount of $1,426 thousand. Including Right – of use assets depreciation expense in the amount of $20 thousand that was capitalized to the Leasehold Improvements during 2023. Also refer to Note 15.

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of Leasing Rights of Land from Israel Land Administration - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Leasing Rights of Land from Israel Land Administration [Abstract]
Under finance lease	$ 1,091	$ 1,119

Intangible Assets, Goodwill a_3

Intangible Assets, Goodwill and Other Long Term Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Intangible Assets, Goodwill and Other Long Term Assets [Line Items]
Carrying amount percentage	16%
Carrying amount of goodwill (in Dollars)	$ 30,313	$ 30,313
Estimated future cash flows	5 years
Long term future growth rate	(4.80%)
Weighted-average cost of capital	11.80%
Growth rate	1%
Discount rate	1%
Bottom of range [member]
Intangible Assets, Goodwill and Other Long Term Assets [Line Items]
Proprietary products segments (in Dollars)	$ 4,800
Top of range [member]
Intangible Assets, Goodwill and Other Long Term Assets [Line Items]
Proprietary products segments (in Dollars)	$ 21,000

Intangible Assets, Goodwill a_4

Intangible Assets, Goodwill and Other Long Term Assets (Details) - Schedule of Other Long Term Assets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Long Term Assets [Line Items]
Intangible Assets and Goodwill	$ 139,955	$ 147,009
Long term pre-paid expenses	510	63
Total Other Long-Term Assets	$ 140,465	$ 147,072

Intangible Assets, Goodwill a_5

Intangible Assets, Goodwill and Other Long Term Assets (Details) - Schedule of Composition and Movement - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Jan. 01, 2022
Cost [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		$ 155,031	$ 154,431
Purchases		129	600
Balance as of ending		155,160	155,031
Cost [Member] | Intellectual property [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		80,103	80,103
Purchases
Balance as of ending		80,103	80,103
Cost [Member] | Customer Relationships [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		33,514	33,514
Purchases
Balance as of ending		33,514	33,514
Cost [Member] | Goodwill [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		30,313	30,313
Purchases
Balance as of ending		30,313	30,313
Cost [Member] | Other Intangibles [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning	[1]	11,101	10,501
Purchases	[1]	129	600
Balance as of ending	[1]	11,230	11,101
Accumulated Amortization and Impairment [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		8,022	839
Amortization recognized in the year		7,183	7,183
Balance as of ending		15,204	8,022
Amortized cost at December 31, 2022				$ 139,955
Accumulated Amortization and Impairment [Member] | Intellectual property [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		5,853	477
Amortization recognized in the year		5,376	5,376
Balance as of ending		11,229	5,853
Amortized cost at December 31, 2022				68,874
Accumulated Amortization and Impairment [Member] | Customer Relationships [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning		1,855	179
Amortization recognized in the year		1,676	1,676
Balance as of ending		3,531	1,855
Amortized cost at December 31, 2022				29,983
Accumulated Amortization and Impairment [Member] | Goodwill [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning
Amortization recognized in the year
Balance as of ending
Amortized cost at December 31, 2022				30,313
Accumulated Amortization and Impairment [Member] | Other Intangibles [Member]
Schedule of Composition and Movement [Line Items]
Balance as of beginning	[1]	314	183
Amortization recognized in the year	[1]	131	131
Balance as of ending	[1]	$ 444	314
Amortized cost at December 31, 2022	[1]			$ 10,785
Accumulated Amortization and Impairment [Member] | Previously stated [member]
Schedule of Composition and Movement [Line Items]
Amortized cost at December 31, 2022			147,009
Accumulated Amortization and Impairment [Member] | Previously stated [member] | Intellectual property [Member]
Schedule of Composition and Movement [Line Items]
Amortized cost at December 31, 2022			74,250
Accumulated Amortization and Impairment [Member] | Previously stated [member] | Customer Relationships [Member]
Schedule of Composition and Movement [Line Items]
Amortized cost at December 31, 2022			31,659
Accumulated Amortization and Impairment [Member] | Previously stated [member] | Goodwill [Member]
Schedule of Composition and Movement [Line Items]
Amortized cost at December 31, 2022			30,313
Accumulated Amortization and Impairment [Member] | Previously stated [member] | Other Intangibles [Member]
Schedule of Composition and Movement [Line Items]
Amortized cost at December 31, 2022	[1]		$ 10,787
[1] Includes assumed contract manufacturing agreement and distribution right of certain therapeutic products to be distributed in Israel, subject to IL MOH and or EMA marketing authorization. The Company was required to make certain upfront and milestone payments on account of such distribution rights. These payments are accounted for as long-term assets through obtaining IL MOH marketing authorization and will subsequently be amortized during the expected distribution right’s useful life.

Intangible Assets, Goodwill a_6

Intangible Assets, Goodwill and Other Long Term Assets (Details) - Schedule of Amortization Expenses of Intangible Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Amortization Expenses of Intangible Assets [Line Items]
Amortization expenses	$ 7,183	$ 7,183	$ 839
Cost of Goods Sold [Member]
Schedule of Amortization Expenses of Intangible Assets [Line Items]
Amortization expenses	5,376	5,376	574
Selling and Marketing Expenses [Member]
Schedule of Amortization Expenses of Intangible Assets [Line Items]
Amortization expenses	$ 1,807	$ 1,807	$ 265

Intangible Assets, Goodwill a_7

Intangible Assets, Goodwill and Other Long Term Assets (Details) - Schedule of Allocation of Goodwill to Cash-Generating Units - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Allocation of Goodwill to Cash-Generating Units [Line Items]
Proprietary	$ 30,313	$ 30,313

Trade Payables (Details) - Sche

Trade Payables (Details) - Schedule of Trade Payables - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Trade Payables [Abstract]
Open debts mainly in USD	$ 11,167	$ 12,731
Open debts in EUR	7,266	10,629
Open debts in NIS	6,371	9,557
Total Trade Payables	$ 24,804	$ 32,917

Other Accounts Payables (Detail

Other Accounts Payables (Details) - Schedule of Other Accounts Payables - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Other Accounts Payables Abstract
Employees and payroll accruals	$ 7,542	$ 6,683
Government grants	177	201
Derivatives financial instruments		92
Accrued Expenses and Others	542	609
Total Other Accounts Payables	$ 8,261	$ 7,585

Other Accounts Payables (Deta_2

Other Accounts Payables (Details) - Schedule of Statement of Financial Position and Profit or Loss and Other Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule Of Statement Of Financial Position And Profit Or Loss And Other Comprehensive Income Abstract
Current Assets	$ 104	$ 3
Current liability	177	201
Royalties paid during the year
Expense (income) carried to Research and Development cost	$ 61	$ 29

Loans and Financial Liabiliti_3

Loans and Financial Liabilities (Details) $ in Thousands, ₪ in Millions				1 Months Ended	12 Months Ended
		Jan. 01, 2023 USD ($)	Jan. 01, 2023 ILS (₪)	Nov. 15, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 16, 2022
Loans and Financial Liabilities [Line Items]
Credit facility				$ 40,000
Long-term loan					$ 20,000
Short-term credit facility					$ 20,000
Credit facility percentage					1.75%
Percentage of commitment fee					0.20%
Credit facility		$ 10,000	₪ 35
Loan and credit facility agreement description					(1)The Shareholder’s Equity shall at no time be less than 30% of the Total Assets; examined on a quarterly basis;   (2) The Shareholder’s Equity shall at no time be less than $120,000 thousand; examined on a quarterly basis;   (3) The ratio between:(a) the short term financial debt less current maturities of long term debt (in as much as such are included therein); and (b) the Working Capital, as such term is defined in the loan agreement, shall at no time exceed 0.8; examined on a quarterly basis; and   (4) The ratio between: (a) the EBITDA as such term is defined in the loan agreement; and (b) the current maturities of long term debt to financial institutions plus out of pocket financial expenses, net, reported in the course of four consecutive quarters immediately preceding the examination date, shall not be less than 1.1 during each of the years 2022 and 2024 and not less than 1.25 in the year 2025 and onwards, examined on an annual basis.
Contingent consideration					$ 21,855	$ 23,534
Sales					3,000
Amount of liability					1,321	1,539	$ 290
Assumed liabilities	[1]				46,375	61,016
Finance income					14,300	5,626
Financing expenses					$ 341	$ 4,727	$ 704
Forecast [Member]
Loans and Financial Liabilities [Line Items]
Interest rate					0.55%			2.18%
Financing facility		$ 20,000
Annual fee percentage					0.275%
[1]The assumed liabilities are measured at amortized cost. The decrease in the balance of the assumed liabilities reflects the changes in time value and changes in expected payments.The value of the assumed liabilities was $46,375 thousand and $61,016 thousand as of December 31, 2023, and 2022, respectively. During the years ended December 31, 2023, and 2022, the Company paid a total of $14,300 thousand and $5,626 thousand on account of such assumed liabilities. The Company accounted for $341 thousand of financing income and $4,727 thousand, and $704 thousand of financing expenses for the years ended December 31, 2023, 2022 and 2021, respectively to reflects the changes in the value of the assumed liabilities.

Loans and Financial Liabiliti_4

Loans and Financial Liabilities (Details) - Schedule of Loans and Financial Liabilities - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Schedule of Loans and Finanial Liabilities [Abstract]
Bank loans	[1]		$ 17,407
Less current maturities of bank loans			4,444
Total Long term bank loans			$ 12,963
[1] On November 15, 2021, the Company secured a $40,000 thousand credit facility from Bank Hapoalim, an Israeli bank. The credit facility comprised of the following:

Loans and Financial Liabiliti_5

Loans and Financial Liabilities (Details) - Schedule of Financial Liabilities - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Schedule of Financial Liabilities [Abstract]
Contingent consideration	[1]	$ 21,855	$ 23,534
Assumed liabilities	[2]	46,375	61,016
Less current maturities		(14,996)	(29,708)
Total Long term Contingent consideration and assumed liabilities		$ 53,234	$ 54,842
[1] The fair value of the contingent consideration was $21,855 thousand and $23,534 thousand as of December 31, 2023, and December 31, 2022, respectively. During the year ended December 31, 2023, the Company paid the first sales milestone in the amount of $3,000 thousand, which was accounted for as a reduction of the liability. The Company accounted for $1,321 thousand, $1,539 thousand, and $290 thousand, for the years ended December 31, 2023, 2022 and 2021, respectively as financing expenses in the statement of profit and loss to reflects the changes in the fair value of the liability. Through December 31, 2023, the second sales threshold was met, and the second milestone payment was paid during February 2024. Refer to Note 5b and Note 18 for details on the contingent consideration.

Leases (Details)

Leases (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2023	Nov. 15, 2016	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 07, 2023 m²	Dec. 31, 2021 m²
Leases [Line Items]
Lease agreement period	2 years	8 years	5 years
Square feet (in Square Meters) | m²					12,000	14,880
Lease term	10 years
Current maturities of lease			$ 134
Depreciation expense			20
Interest expenses on lease liabilities			16,420	$ 3,441
Total cash outflow for leases			$ 850	$ 1,164
Extension options term			2 years
Bottom Range [Member]
Leases [Line Items]
Weighted average rate			3.06%	1.94%
Top Range [Member]
Leases [Line Items]
Weighted average rate			7.11%	4.60%
Weighted Average [Member]
Leases [Line Items]
Interest expenses on lease liabilities			$ 367	$ 148

Leases (Details) - Schedule of

Leases (Details) - Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023		Dec. 31, 2022
Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities [Line Items]
Beginning balance		$ 2,568		$ 3,093
Additions to right -of -use assets		6,546		551
Termination lease		(109)		(52)
Depreciation expense		(1,244)		(1,024)
Exchange rate differences
Repayment of lease liabilities
Ending balance		7,761		2,568
Rented Offices [Member]
Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities [Line Items]
Beginning balance		1,732	[1]	2,165
Additions to right -of -use assets		5,131	[1]
Termination lease
Depreciation expense		(500)	[1]	(433)
Exchange rate differences
Repayment of lease liabilities
Ending balance	[1]	6,363		1,732
Vehicles [Member]
Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities [Line Items]
Beginning balance		829		913
Additions to right -of -use assets		1,415		551
Termination lease		(109)		(52)
Depreciation expense		(738)		(583)
Exchange rate differences
Repayment of lease liabilities
Ending balance		1,397		829
Computers, Software, Equipment and Office Furniture [Member]
Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities [Line Items]
Beginning balance		7		15
Additions to right -of -use assets
Termination lease
Depreciation expense		(6)		(8)
Exchange rate differences
Repayment of lease liabilities
Ending balance		1		7
Lease Liabilities [Member]
Schedule of Right-Of-Use Assets Composition and Changes in Lease Liabilities [Line Items]
Beginning balance	[2]	3,193	[3],[4]	4,314
Additions to right -of -use assets		6,682	[3],[4]	551	[2]
Termination lease		(107)	[3],[4]	(59)	[2]
Depreciation expense	[3],[4]
Exchange rate differences		(96)	[3],[4]	(448)	[2]
Repayment of lease liabilities		(850)	[3],[4]	(1,164)	[2]
Ending balance	[3],[4]	$ 8,822		$ 3,193	[2]
[1] Out of the Depreciation expense $20 thousand was capitalized to the Leasehold Improvements. The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 1.94%-4.6% evaluated based on credit risk, terms of the leases and other economic variables. The weighted average incremental borrowing rate used to discount future lease payments in the calculation of the lease liability was in the range of 3.06%–7.11% evaluated based on credit risk, terms of the leases and other economic variables.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Maturity Analysis of Lease Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	$ 16,420	$ 3,441
Less than one year [Member]
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	2,918	1,119
1 to 2 [Member]
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	3,045	907
2 to 3 [Member]
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	1,689	732
3 to 5 [Member]
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	2,009	$ 683
6 and thereafter [Member]
Schedule of Maturity Analysis of Lease Liabilities [Line Items]
Lease liabilities (including interest)	$ 6,759

Financial Instruments (Details)

Financial Instruments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Financial Instruments (Details) [Line Items]
Other accounts receivables	$ 134,000
Other comprehensive income	228,000
“Monte Carlo Simulation” [Member]
Financial Instruments (Details) [Line Items]
Adjusted discount rate		11.40%
Volatility rate		15.17%
Fair value total		$ 21,855,000
Derivatives instruments not designated as hedging [Member]
Financial Instruments (Details) [Line Items]
Fair value of the derivative instruments not designated as hedging	8,000
Open transactions for derivative instruments	9,149,000
Cash flow hedges [member]
Financial Instruments (Details) [Line Items]
Open transactions for derivative instruments	389
Fair value of derivative instrument designated as hedging instrument	$ 141,000

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of Groups of Financial Instruments - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial assets
Total Financial assets at fair value through profit or loss	$ 8
Total Financial assets at fair value through other comprehensive income:	141
Cash and cash equivalent	55,641	34,258	$ 18,587	$ 70,197
Total Financial assets at cost	55,641	34,258
Total financial assets	55,790	34,258
Financial liabilities
Total financial liabilities at fair value through profit or loss	21,855	23,538
Total financial liabilities at fair value through other comprehensive income		88
Total financial liabilities measured at amortized cost	70,777	101,957
Total financial and lease liabilities	77,052	105,242
Foreign Exchange Forward Contracts [Member]
Financial liabilities
Total financial liabilities at fair value through profit or loss		4
Contingent Consideration in Business Combination [Member]
Financial liabilities
Total financial liabilities at fair value through profit or loss	21,855	23,534
Cash Flow Hedges [Member]
Financial liabilities
Total financial liabilities at fair value through other comprehensive income		88
Assumed Liabilities Through Business Combination [Member]
Financial liabilities
Total financial liabilities measured at amortized cost	46,375	61,016
Financial Liabilities Measured at Amortized Cost: Bank Loans [Member]
Financial liabilities
Total financial liabilities measured at amortized cost		17,407
Financial Liabilities Measured at Amortized Cost: Leases [Member]
Financial liabilities
Total financial liabilities measured at amortized cost	8,822	3,193
Total Financial Liabilities Measured At Amortized Cost [Member]
Financial liabilities
Total financial liabilities measured at amortized cost	55,197	81,616
Foreign Exchange Forward Contracts [Member]
Financial assets
Total Financial assets at fair value through profit or loss	8
Cash Flow Hedges [Member]
Financial assets
Total Financial assets at fair value through other comprehensive income:	$ 141

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of Financial Liabilities Based on Contractual Undiscounted Payments - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023		Dec. 31, 2022	May 31, 2023
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables	$ 24,804		$ 32,917
Assumed liabilities	46,375	[1]	61,016
Other accounts payables	8,261		7,585
Bank loans (including interest)			18,208	$ 8,500
Lease liabilities (including interest)	16,420		3,441
Financial liabilities	95,860		123,167
Less than one year [Member]
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables	24,804		32,917
Assumed liabilities	11,996	[1]	23,708
Other accounts payables	8,261		7,585
Bank loans (including interest)			4,841
Lease liabilities (including interest)	2,918		1,119
Financial liabilities	47,979		70,170
1 to 2 [Member]
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables
Assumed liabilities	4,152	[1]	5,030
Other accounts payables
Bank loans (including interest)			4,677
Lease liabilities (including interest)	3,045		907
Financial liabilities	7,197		10,614
2 to 3 [Member]
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables
Assumed liabilities	4,261	[1]	4,087
Other accounts payables
Bank loans (including interest)			4,580
Lease liabilities (including interest)	1,689		732
Financial liabilities	5,950		9,399
3 to 5 [Member]
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables
Assumed liabilities	7,836	[1]	7,928
Other accounts payables
Bank loans (including interest)			4,111
Lease liabilities (including interest)	2,009		683
Financial liabilities	9,845		12,722
6 and thereafter [Member]
Schedule of Financial Liabilities Based on Contractual Undiscounted Payments [Line Items]
Trade payables
Assumed liabilities	18,130	[1]	20,263
Other accounts payables
Bank loans (including interest)
Lease liabilities (including interest)	6,759
Financial liabilities	$ 24,889		$ 20,263
[1] Due the nature of the account which include infinite payments for royalties and milestones to third parties the assumed liabilities reflect the discounted amount. see Note 18e

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of Changes in Liabilities Arising from Financing Activities $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]
Beginning	$ 105,150
Payments	(35,557)
Foreign exchange movement	(96)
New loans and leases	6,682
Business combination
Revaluation	980
Write off	(107)
Ending	77,052
Contingent consideration [Member]
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]
Beginning	23,534	[1]
Payments	(3,000)	[1]
Foreign exchange movement		[1]
New loans and leases		[1]
Business combination		[1]
Revaluation	1,321	[1]
Write off		[1]
Ending	21,855	[1]
Assumed liabilities [Member]
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]
Beginning	61,016
Payments	(14,300)
Foreign exchange movement
New loans and leases
Business combination
Revaluation	(341)
Write off
Ending	46,375
Bank loans [Member]
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]
Beginning	17,407
Payments	(17,407)
New loans and leases
Business combination
Revaluation
Write off
Ending
Leases [Member]
Schedule of Changes in Liabilities Arising from Financing Activities [Line Items]
Beginning	3,193
Payments	(850)
Foreign exchange movement	(96)
New loans and leases	6,682
Business combination
Revaluation
Write off	(107)
Ending	$ 8,822
[1] The contingent consideration fair value as of December 31, 2023, was based on an Option Pricing Method (OPM), “Monte Carlo Simulation” model. In measuring the contingent consideration liability, the Company used an appropriate risk-adjusted discount rate of 11.4% and volatility of 15.17%. totaled $21,855 thousand.

Financial Instruments (Detail_5

Financial Instruments (Details) - Schedule of Fair Value of the Financial Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fair Value of the Financial Assets and Liabilities [Line Items]
Financial liabilities Carrying Amount	$ 55,197	$ 81,616
Financial liabilities Fair Value	55,441	77,200
Assumed liabilities [Member]
Schedule of Fair Value of the Financial Assets and Liabilities [Line Items]
Financial liabilities Carrying Amount	46,375	61,016
Financial liabilities Fair Value	46,468	56,946
Bank loans [Member]
Schedule of Fair Value of the Financial Assets and Liabilities [Line Items]
Financial liabilities Carrying Amount		17,407
Financial liabilities Fair Value		17,071
Leases [Member]
Schedule of Fair Value of the Financial Assets and Liabilities [Line Items]
Financial liabilities Carrying Amount	8,822	3,193
Financial liabilities Fair Value	$ 8,973	$ 3,183

Financial Instruments (Detail_6

Financial Instruments (Details) - Schedule of Financial Assets (Liabilities) Measured at Fair Value - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Contingent consideration	[1]
Financial assets (liabilities) measured at fair value
Level 2 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments			(92)
Contingent consideration	[1]
Financial assets (liabilities) measured at fair value		149	(92)
Level 3 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Contingent consideration		(21,705)	(23,534)	[1]
Financial assets (liabilities) measured at fair value		(21,855)	$ (23,534)
Derivatives instruments [Member] | Level 1 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Derivatives instruments [Member] | Level 2 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments		149
Derivatives instruments [Member] | Level 3 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Derivatives instruments
Contingent consideration [member] | Level 1 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Contingent consideration	[1]
Contingent consideration [member] | Level 2 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Contingent consideration	[1]
Contingent consideration [member] | Level 3 [Member]
Schedule of Financial Assets (Liabilities) Measured at Fair Value [Line Items]
Contingent consideration	[1]	$ (21,855)
[1] For changes in Contingent Consideration see above

Financial Instruments (Detail_7

Financial Instruments (Details) - Schedule of Sensitivity Test to Changes in Interest Rate Risk - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
1% increase in market price [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk		$ (13)
1% decrease in market price [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk		13
5% increase in NIS [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk	(454)	(57)
5% decrease in NIS [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk	454	57
5% increase in Euro [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk	(271)	(389)
5% decrease in Euro [Member]
Schedule of Sensitivity Test to Changes in Interest Rate Risk [Line Items]
Gain (loss) from change: Sensitivity test to changes in interest rate risk	$ 271	$ 389

Financial Instruments (Detail_8

Financial Instruments (Details) - Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments - USD ($) $ in Thousands		Dec. 31, 2023	Dec. 31, 2022
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Total		$ 70,777	$ 101,957
NIS [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9		6,275	3,193
Bank loans measured at amortized cost [Member] | NIS [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9
Bank loans measured at amortized cost [Member] | USD [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9			17,407
Leases measured at amortized cost [Member] | NIS [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9		6,275	3,193
Leases measured at amortized cost [Member] | USD [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9	[1]	2,547
Contingent consideration at fair value through profit or loss [Member] | USD [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9		21,855	23,534
Assumed liabilities measured at amortized cost [Member] | USD [Member]
Schedule of Linkage Terms of Financial Liabilities by Groups of Financial Instruments [Line Items]
Linkage terms of financial liabilities by groups of financial instruments pursuant to IFRS 9		$ 46,375	$ 61,016
[1]The balance does not include current maturities of lease of $134 thousand that was classified to other accounts receivables due to expected lease incentive.

Employee Benefit Liabilities,_3

Employee Benefit Liabilities, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Benefit Liabilities, NET [Line Items]
Expenses for defined benefit deposit	$ 925	$ 873	$ 1,023
Employees contributions amount	62	$ 11
Bottom of Range [Member]
Employee Benefit Liabilities, NET [Line Items]
Employees contributions amount	22,500
Increase (decrease) in defined benefit obligation	92
Increase (decrease) by one percent defined benefit obligation	87
Top of Range [Member]
Employee Benefit Liabilities, NET [Line Items]
Employees contributions amount	30,000
Top of Range [Member] | Discount rates [Member]
Employee Benefit Liabilities, NET [Line Items]
Increase (decrease) in defined benefit obligation	124
Top of Range [Member] | Expected salary growth [Member]
Employee Benefit Liabilities, NET [Line Items]
Increase (decrease) by one percent defined benefit obligation	$ 118

Employee Benefit Liabilities,_4

Employee Benefit Liabilities, Net (Details) - Schedule of Expenses Recognized in Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Expenses Recognized in Comprehensive Income (Loss) [Abstract]
Current service cost	$ 194	$ 223	$ 281
Past service cost			415
Interest expenses, net	28	15	23
Total employee benefit expenses	222	238	716
Actual return on plan assets	$ 50	$ (25)	$ 349

Employee Benefit Liabilities,_5

Employee Benefit Liabilities, Net (Details) - Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) [Line Items]
Total employee benefit expenses	$ 233	$ 238	$ 716
Cost of revenues [Member]
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) [Line Items]
Total employee benefit expenses	155	166	499
Research and development [Member]
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) [Line Items]
Total employee benefit expenses	22	24	90
Selling and marketing [member]
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) [Line Items]
Total employee benefit expenses	33	27	62
General and administrative [Member]
Schedule of Expenses Presented in Statement of Comprehensive Income (Loss) [Line Items]
Total employee benefit expenses	$ 23	$ 21	$ 65

Employee Benefit Liabilities,_6

Employee Benefit Liabilities, Net (Details) - Schedule of Plan Liabilities, Net - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Plan Liabilities, Net [Abstract]
Defined benefit obligation	$ 4,399	$ 4,379
Fair value of plan assets	3,778	3,707
Total liabilities, net	$ 621	$ 672

Employee Benefit Liabilities,_7

Employee Benefit Liabilities, Net (Details) - Schedule of Changes in Present Value of Defined Benefit Obligation - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Changes in Present Value of Defined Benefit Obligation [Line Items]
Balance at January 1,	$ 4,379	$ 5,434
Interest costs		78
Current service cost		223
Past service cost
Benefits paid		(202)
Demographic assumptions		(9)
Financial assumptions		(715)
Past Experience		206
Currency Exchange		(636)
Balance at December 31,		4,379
Defined Benefit Obligation [Member]
Schedule of Changes in Present Value of Defined Benefit Obligation [Line Items]
Balance at January 1,	4,380
Interest costs	200
Current service cost	194
Past service cost
Benefits paid	(376)
Demographic assumptions	13
Financial assumptions	(91)
Past Experience	209
Currency Exchange	(130)
Balance at December 31,	$ 4,399	$ 4,380

Employee Benefit Liabilities,_8

Employee Benefit Liabilities, Net (Details) - Schedule of Changes in Fair Value of Plan Assets - Plan assets [member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Changes in Fair Value of Plan Assets [Line Items]
Balance at January 1,	$ 3,707	$ 4,154
Expected return	172	62
Contributions by employer	173	181
Benefits paid	(206)	(181)
Demographic assumptions
Financial assumptions		(4)
Past Experience	50	(20)
Currency exchange	(118)	(485)
Balance at December 31,	$ 3,778	$ 3,707

Employee Benefit Liabilities,_9

Employee Benefit Liabilities, Net (Details) - Schedule of Principal Assumptions Underlying Defined Benefit Plan	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Principal Assumptions Underlying Defined Benefit Plan [Abstract]
Discount rate of the plan liability	5.30%	5.10%	3.10%
Future salary increases	3%	3%	3%

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) - USD ($) $ in Thousands

1 Months Ended

12 Months Ended

Jan. 14, 2021

Aug. 23, 2010

Dec. 31, 2019

Jul. 31, 2019

Nov. 30, 2006

Dec. 31, 2023

Jun. 30, 2023

Dec. 31, 2022

Jun. 30, 2022

Jun. 13, 2023

May 31, 2023

Dec. 31, 2021

Mar. 31, 2021

Contingent Liabilities and Commitments [Line Items]

License agreement, description

In addition, upon initiation of sales of GLASSIA manufactured by Takeda, the Company would be entitled to royalty payments at a rate of 12% on net sales of Glassia through August 2025, and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually (the “Royalty Payments”).

Royalty payments percentage

12%

Royalty payments percentage thereafter

6%

Royalty payments

$ 5,000

Payments received

$ 2,000

Royalty income

$ 16,110

$ 12,200

Agreements expiration period

15 years

Revenues

$ 180,000

Contract asset

8,495

7,577

Upfront payment

95,000

Additional payments

50,000

Contingent consideration payments

3,000

Acquired inventory

14,200

Inventory quarterly installments amount

$ 1,500

Assumed royalties liabilities, description

●Royalties: 10 % of the annual global net sales of CYTOGAM up to $25 million and 5 % of net sales that are greater than $25 million, in perpetuity; 2% of the annual global net sales of CYTOGAM in perpetuity; and, 8% of the annual global net sales of CYTOGAM for period of six years following the completion of the technology transfer of the manufacturing of CYTOGAM to the Company, subject to a maximum aggregate of $5 million per year and for total amount of $30 million throughout the entire six years period.

Annual net sales

$ 1,500

$ 1,500

Market exceeds amount

$ 18,400

$ 18,800

Manufacturing facility

$ 8,500

Bank

$ 18,208

$ 8,500

Financing facility

40,000

Five-year loan amount

20,000

Short-term credit facility

20,000

Outstanding balance

20,000

Payment to royalties percentage

24%

Affiliate filed value

$ 6,700

Baxter Healthcare Corporation [Member]

Contingent Liabilities and Commitments [Line Items]

Agreement term

30 years

Agreement payment amount

45,000

Amount received from distribution agreement

$ 45,000

Clinical studies total amount

$ 10,000

Patents [Member]

Contingent Liabilities and Commitments [Line Items]

Agreements expiration period

15 years

Master Clinical Services Agreement [Member]

Contingent Liabilities and Commitments [Line Items]

Agreements expiration period

7 years

Manufacturing Agreement [Member]

Contingent Liabilities and Commitments [Line Items]

Agreements expiration period

12 years

Guarantees and Charges (Details

Guarantees and Charges (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Guarantees and Charges [Line Items]
Value of loans for which collateral has been pledged description	the Company secured a debt facility from an Israeli bank (see Note 14) pursuant to which, the Company undertook not to create any first ranking floating charge over all or materially all of its property and assets in favor of any third party unless certain terms, as defined in the loan agreement, have been satisfied.
Bank guarantee	$ 247
Security deposit	$ 417
Lease period	10 years
Reimbursed amount	$ 40
Contingent liability for guarantees [member]
Guarantees and Charges [Line Items]
Guarantees amount	$ 354

Equity (Details)

Equity (Details) $ / shares in Units, $ in Thousands			12 Months Ended
	Sep. 07, 2023 USD ($) $ / shares shares	Feb. 10, 2020 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2023 ₪ / shares	Dec. 31, 2022 ₪ / shares	Dec. 31, 2021	Nov. 21, 2019 $ / shares shares
Equity [Line Items]
Restricted shares share					57,479,528	44,832,843	44,799,794
Restricted exercise shares options			2,662	1,421
Restricted share vested			12,444	31,628
Ordinary shares par value (in Dollars per share) | ₪ / shares					₪ 1	₪ 1
Gross proceeds (in Dollars) | $		$ 25,000
Outstanding shares, percentage		21%
Total gross proceeds (in Dollars) | $	$ 60,000
FIMI Funds [Member]
Equity [Line Items]
Ordinary shares acquired (in Shares) | shares								5,240,956
Ordinary shares par value (in Dollars per share) | $ / shares								$ 6
Outstanding shares percentage								13%
Issued aggregate ordinary shares (in Shares) | shares	12,631,579
Ordinary share price (in Dollars per share) | $ / shares	$ 4.75
FIMI beneficially owns percentage	38%
Restricted share units [member]
Equity [Line Items]
Restricted shares share					42,175	8,325
Restricted exercise shares options			2,662	1,408
Restricted share vested			12,444	31,608
Share options [member]
Equity [Line Items]
Total consideration exercised (in Dollars) | $			$ 4	$ 9
Private Placements [Member]
Equity [Line Items]
Ordinary shares acquired (in Shares) | shares		4,166,667
Ordinary shares par value (in Dollars per share) | $ / shares		$ 6

Equity (Details) - Schedule of

Equity (Details) - Schedule of Share Capital - shares	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Ordinary shares of NIS 1 par value, Authorized	70,000,000	70,000,000
Ordinary shares of NIS 1 par value, Outstanding	57,479,528	44,832,843

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Share Capital (Parentheticals) - ₪ / shares	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Ordinary shares par value	₪ 1	₪ 1

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Issued and Outstanding Share Capital	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Movement in Share Capital [Line items]
Beginning balance	44,832,843	44,799,794
Issue of shares	12,631,579
Exercise of options into share units	2,662	1,421
Vesting of restricted shares units	12,444	31,628
Ending balance	57,479,528	44,832,843

Share-Based Payment (Details)

Share-Based Payment (Details)

1 Months Ended

12 Months Ended

Aug. 31, 2021

Dec. 31, 2023 USD ($) $ / shares ₪ / shares shares

Dec. 31, 2022 ₪ / shares

Feb. 29, 2024 shares

Dec. 31, 2023 ₪ / shares

Oct. 04, 2023 USD ($) $ / shares shares

Oct. 04, 2023 ₪ / shares

Sep. 26, 2023 USD ($) $ / shares shares

Sep. 26, 2023 ₪ / shares

Sep. 25, 2023 USD ($) $ / shares shares

Sep. 07, 2023 USD ($) $ / shares shares

Sep. 07, 2023 ₪ / shares

Aug. 30, 2023 USD ($) $ / shares shares

Aug. 21, 2023 USD ($) $ / shares shares

Aug. 21, 2023 ₪ / shares

Aug. 15, 2023 USD ($) $ / shares shares

Aug. 15, 2023 ₪ / shares

May 28, 2023 USD ($) $ / shares shares

May 28, 2023 ₪ / shares

Apr. 23, 2023 USD ($) $ / shares shares

Apr. 23, 2023 ₪ / shares

Mar. 02, 2023 $ / shares shares

Mar. 02, 2023 ₪ / shares shares

Mar. 01, 2023 USD ($) $ / shares shares

Mar. 01, 2023 ₪ / shares

Feb. 27, 2023 USD ($) $ / shares shares

Feb. 27, 2023 ₪ / shares

Mar. 02, 2022 USD ($)

Dec. 31, 2021 ₪ / shares

Dec. 31, 2020 ₪ / shares

Share-Based Payment [Line Items]

Extension of share option plan

10 years

Vesting description of options

granted under the 2011 Plan, prior to January 2020, generally vest over a four-year period following the date of the grant in 13 installments: 25% on the first anniversary of the grant date and 6.25% at the end of each quarter thereafter.

Granted options, percentage

25%

Option granted

147,000

Exercise price of options | (per share)

$ 6.67

₪ 19.91

$ 5.33

₪ 20.07

₪ 20.38

₪ 20.38

Fair value of the options (in Dollars) | $

$ 17

$ 45,000

Ordinary shares

20,000

Exercise price range (in New Shekels per share) | ₪ / shares

$ 2,022

₪ 29.68

Israeli Share Option Plan [Member]

Share-Based Payment [Line Items]

Exercise price of options | (per share)

$ 6.62

₪ 23.91

Fair value of the options (in Dollars) | $

$ 51,000

Israeli Share Option Plan [Member] | Top of range [member]

Share-Based Payment [Line Items]

Option granted

20,800

Israeli Share Option Plan [Member] | Bottom of range [member]

Share-Based Payment [Line Items]

Option granted

6,667

Israeli Share Option Plan [Member]

Share-Based Payment [Line Items]

Option granted

2,500

9,050

24,050

40,000

40,000

40,000

3,333

60,331

Exercise price of options | (per share)

$ 5.39

₪ 21.51

$ 5.39

₪ 20.6

$ 5.68

₪ 21.54

$ 4.83

₪ 17.67

$ 4.6

₪ 16.76

$ 4.57

₪ 16.63

$ 4.5

₪ 16.53

Fair value of the options (in Dollars) | $

$ 108,000

Fair value of options (in Dollars) | $

$ 17,000

$ 48,000

$ 37,000

$ 65,000

$ 6,000

$ 71,000

US Share Option Plan [Member]

Share-Based Payment [Line Items]

Option granted

2,500

32,000

9,050

54,650

90,000

3,333

Exercise price of options | (per share)

$ 5.47

$ 5,620

₪ 21.63

$ 5.91

$ 5.86

$ 5.25

₪ 19.46

$ 4.57

Fair value of the options (in Dollars) | $

$ 6,000

$ 22,000

$ 18,000

Fair value of options (in Dollars) | $

$ 5,000

$ 217,000

$ 6

Number of share purchased

7,500

Non-adjusting events after reporting period [Member] | 2011 Option Plan [Member]

Share-Based Payment [Line Items]

Option granted

27,467

Share-Based Payment (Details) -

Share-Based Payment (Details) - Schedule of Expense Recognized in Financial Statements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Expense Recognized in Financial Statements [Line Items]
Total share-based compensation	$ 1,314	$ 1,138	$ 529
Cost of revenues [Member]
Schedule of Expense Recognized in Financial Statements [Line Items]
Total share-based compensation	249	308	69
Research and development [Member]
Schedule of Expense Recognized in Financial Statements [Line Items]
Total share-based compensation	167	204	79
Selling and marketing [Member]
Schedule of Expense Recognized in Financial Statements [Line Items]
Total share-based compensation	238	254	34
General and administrative [Member]
Schedule of Expense Recognized in Financial Statements [Line Items]
Total share-based compensation	$ 660	$ 372	$ 347

Share-Based Payment (Details)_2

Share-Based Payment (Details) - Schedule of Weighted Average Exercise Prices of Share - ₪ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Weighted Average Exercise Prices of Share [Abstract]
Number of Options, Outstanding at beginning of year (in Shares)	3,247,814	1,504,678	1,660,958
Weighted Average Exercise Price, Outstanding at beginning of year	₪ 19.91	₪ 20.38	₪ 20.38
Number of Options, Granted (in Shares)	343,647	2,076,800
Weighted Average Exercise Price, Granted	₪ 18.6	₪ 19.27
Number of Options, Exercised (in Shares)	(42,175)	(8,325)	(28,672)
Weighted Average Exercise Price, Exercised	₪ 19.04	₪ 16.47	₪ 16.93
Number of Options, Forfeited (in Shares)	(279,305)	(325,339)	(127,608)
Weighted Average Exercise Price, Forfeited	₪ 19.57	₪ 19.14	₪ 20.29
Number of Options, Outstanding at end of year (in Shares)	3,269,981	3,247,814	1,504,678
Weighted Average Exercise Price, Outstanding at end of year	₪ 18.82	₪ 19.91	₪ 20.65
Number of Options, Exercisable at end of year (in Shares)	1,469,084	1,049,329	1,067,363
Weighted Average Exercise Price, Exercisable at end of year	₪ 19.83	₪ 20.38	₪ 19.78
The weighted average remaining contractual life for the share options	₪ 4.01	₪ 4.67	₪ 3.33

Share-Based Payment (Details)_3

Share-Based Payment (Details) - Schedule of RSUs and Changes in RSUs - Number of RSUs [Member] - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment (Details) - Schedule of RSUs and Changes in RSUs [Line Items]
Outstanding at beginning of year	14,705	49,561	104,519
Granted
End of restriction period	(12,444)	(31,608)	(52,538)
Forfeited	(386)	(3,248)	(2,420)
Outstanding at end of year	1,875	14,705	49,561
The weighted average remaining contractual life for the restricted share units	3 months	11 months 15 days	3 years 4 months 24 days

Share-Based Payment (Details)_4

Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Israeli Share Option Plan [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Dividend yield (%)
Expected volatility of the share prices (%)
Risk-free interest rate (%)
Contractual term of up to (years)	6 years 6 months	6 years 6 months
Exercise multiple (in Dollars per share)	$ 2	$ 2
Weighted average share prices (NIS) (in Dollars per share)
Expected average forfeiture rate (%)
Israeli Share Option Plan [Member] | Bottom of Range [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Expected volatility of the share prices (%)	26%	23%
Risk-free interest rate (%)	3.76%	0.40%
Weighted average share prices (NIS) (in Dollars per share)	$ 16.1	$ 13.6
Expected average forfeiture rate (%)	0%	0%
Israeli Share Option Plan [Member] | Top of Range [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Expected volatility of the share prices (%)	38%	40%
Risk-free interest rate (%)	4.70%	3.55%
Weighted average share prices (NIS) (in Dollars per share)	$ 19.46	$ 18.41
Expected average forfeiture rate (%)	8.50%	8.50%
Restricted Stock Unit [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Dividend yield (%)
Expected volatility of the share prices (%)
Risk-free interest rate (%)
Contractual term of up to (years)	6 years 6 months	6 years 6 months
Exercise multiple (in Dollars per share)
Weighted average share prices (NIS) (in Dollars per share)
Expected average forfeiture rate (%)
Restricted Stock Unit [Member] | Bottom of Range [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Expected volatility of the share prices (%)	34%	27%
Risk-free interest rate (%)	3.76%	0.91%
Weighted average share prices (NIS) (in Dollars per share)	$ 4.22	$ 4.8
Expected average forfeiture rate (%)	5.50%	1.90%
Restricted Stock Unit [Member] | Top of Range [Member]
Share-Based Payment (Details) - Schedule of Inputs to Binomial Model Used for Fair Value Measurement [Line Items]
Expected volatility of the share prices (%)	47%	47%
Risk-free interest rate (%)	5.03%	3.54%
Weighted average share prices (NIS) (in Dollars per share)	$ 5.55	$ 5.37
Expected average forfeiture rate (%)	8.50%	8.50%

Taxes on Income (Details)

Taxes on Income (Details) $ in Thousands, ₪ in Billions		1 Months Ended	12 Months Ended
	Jan. 01, 2011	Dec. 22, 2017	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Taxes on Income [Line items]
Consolidated revenues (in New Shekels) | ₪				₪ 10
Percentage of subject to tax at a rate			12%	12%
Consolidated revenue exceeds (in New Shekels)			$ 142,519	₪ 10	$ 129,339	$ 103,642
Carried forward losses and other temporary difference amount (in Dollars) | $			$ 26,929
Bottom of range [Member]
Taxes on Income [Line items]
Reduce tax rate		21%
Top of range [Member]
Taxes on Income [Line items]
Reduce tax rate		35%
Law for the Encouragement of Industry (Taxes), 1969 [Member]
Taxes on Income [Line items]
Tax rate effect of foreign tax rates			90%	90%
Period of right to deduct expenses related to public offerings			three	three
Law for the Encouragement of Industry (Taxes), 1969 [Member] | Patents, know-how and certain other intangible [Member]
Taxes on Income [Line items]
Useful life of intangible assets			eight	eight
Law for the Encouragement of Capital Investments, 1959 [Member]
Taxes on Income [Line items]
Tax benefit description			The benefits period is limited to the earlier of 12 years from completion of the investment or commencement of production (“Year of Operation”), or 14 years from the year in which the certificate of approval was obtained.	The benefits period is limited to the earlier of 12 years from completion of the investment or commencement of production (“Year of Operation”), or 14 years from the year in which the certificate of approval was obtained.
Preferred Enterprise [Member]
Taxes on Income [Line items]
Tax rate	25%
Tax benefits under Amendment 60 [Member]
Taxes on Income [Line items]
Percentage of subject to tax at a rate			7.50%	7.50%
Legislative Amendments [Member]
Taxes on Income [Line items]
Corporate income tax rate			23%	23%
Development Zone A [Member]
Taxes on Income [Line items]
Percentage of subject to tax at a rate			6%	6%
Development Zone A [Member] | Tax benefits under Amendment 60 [Member]
Taxes on Income [Line items]
Percentage of subject to tax at a rate			4%	4%

Taxes on Income (Details) - Sch

Taxes on Income (Details) - Schedule of Taxes on Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Taxes on Income [Abstract]
Current taxes	$ 145	$ 62	$ 345
Deferred tax expenses (income)
Taxes in respect of prior years
Taxes on income	$ 145	$ 62	$ 345

Supplementary Information to _3

Supplementary Information to the Statements of Profit and Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Supplementary Information to the Statements of Profit and Loss [Line Items]
Percentage of total revenues	10%
Business combination.			$ 24,282
Amortization of intangible assets		$ 5,376
Cost of sales [Member]
Supplementary Information to the Statements of Profit and Loss [Line Items]
Amortization of intangible assets	$ 5,376		574
Selling, general and administrative expense [Member]
Supplementary Information to the Statements of Profit and Loss [Line Items]
Amortization of intangible assets	$ 1,807	$ 1,807	$ 265

Supplementary Information to _4

Supplementary Information to the Statements of Profit and Loss (Details) - Schedule of Additional Information about Revenues - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Additional Information about Revenues [Line Items]
Revenues from major customers		$ 58,159	$ 42,655	$ 56,240
Customer A [Member]
Schedule of Additional Information about Revenues [Line Items]
Revenues from major customers	[1]	32,800	16,195	11,947
Customer B [Member]
Schedule of Additional Information about Revenues [Line Items]
Revenues from major customers	[2]	16,129	14,205	31,936
Customer C [Member]
Schedule of Additional Information about Revenues [Line Items]
Revenues from major customers	[3]	$ 9,230	$ 12,255	$ 12,357
[1] Revenue is attributed to the Proprietary segment. Refer to Note 18 (c) for more information. Revenue is attributed to the Proprietary segment. Refer to Note 18 (a) for more information.

Supplementary Information to _5

Supplementary Information to the Statements of Profit and Loss (Details) - Schedule of Revenues Based on Location of Customers - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	$ 142,519	$ 129,339	$ 103,642
U.S.A [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	73,741	65,296	49,763
Israel [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	31,296	32,031	35,774
Canada [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	11,162	10,555
Europe [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	7,088	5,277	5,677
Latin America [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	12,928	11,293	9,127
Asia [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	6,147	4,581	3,167
Others [Member]
Schedule of Revenues Based on Location of Customers [Line Items]
Total Revenue	$ 157	$ 306	$ 134

Supplementary Information to _6

Supplementary Information to the Statements of Profit and Loss (Details) - Schedule of Cost of Goods Sold - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cost of goods sold [Member]
Schedule of Income and Expenses [Line Items]
Cost of materials	[1]	$ 70,308	$ 53,666	$ 63,945
Salary and related expenses		16,330	14,967	17,486
Subcontractors		6,354	4,673	4,892
Depreciation and amortization	[2]	9,000	8,553	3,627
Energy		1,383	1,365	1,464
Other manufacturing expenses		1,235	1,785	1,298
Total Cost of goods sold before Inventory change		100,610	85,009	92,712
Decrease (increase) in inventories		(17,581)	(2,373)	(19,398)
Total Cost of goods sold		87,029	82,636	73,314
Research and development [Member]
Schedule of Income and Expenses [Line Items]
Salary and related expenses		5,110	5,608	5,076
Subcontractors		4,677	4,216	3,656
Materials and allocation of facility costs		2,971	2,538	1,896
Depreciation and amortization		586	574	616
Others		589	236	113
Total Research and development		13,933	13,172	11,357
Selling and marketing [Member]
Schedule of Income and Expenses [Line Items]
Salary and related expenses		4,907	4,047	1,930
Packing, shipping and delivery		1,366	1,484	912
Marketing and advertising		2,634	3,676	1,340
Registration and marketing fees		4,362	3,463	1,262
Depreciation and amortization	[3]	2,090	2,056	488
Others		834	558	346
Total Selling and marketing		16,193	15,284	6,278
General and administrative [Member]
Schedule of Income and Expenses [Line Items]
Salary and related expenses		5,283	4,455	3,853
Employees welfare		1,337	1,299	1,259
Professional fees and public company expense		4,305	4,213	5,055
Depreciation, amortization and impairment		1,035	973	875
Communication and software services		1,201	905	977
Others		1,220	958	617
Total General and administrative		14,381	12,803	12,636
Financial (expense)income [Member]
Schedule of Income and Expenses [Line Items]
Interest income from cash deposit		588	91	295
Revaluation of long term liabilities		(980)	(6,266)	(994)
Fees and interest expense to financial institutions		(1,298)	(914)	(283)
Derivatives instruments measured at fair value		149	548	(565)
Translation differences of financial assets and liabilities		(94)	(250)	358
Total Financial (expense) income		$ (1,635)	$ (6,791)	$ (1,189)
[1] Costs of materials for the year ended December 31, 2021, includes $24,282 of inventory obtained in connection with the business combination. Refer to Note 5b for further detail on the business combination. Including amortization of intangible assets in the amount of $5,376 for each of the years ended December 31, 2023 and 2022, and $574 for the year ended December 31, 2021 Including amortization of intangible assets in the amount of $1,807 for each of the years ended December 2023 and 2022, and $265 for the year ended December 31, 2021.

Income (Loss) Per Share (Detail

Income (Loss) Per Share (Details) - Schedule of Number of Shares and Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Number of Shares and Income (Loss) [Abstract]
Weighted Number of Shares For the computation of basic income (loss)	48,830,479	44,815,248	44,771,766
Income Attributed to equity holders of the Company For the computation of basic income (loss)	$ 8,284	$ (2,321)	$ (2,230)
Weighted Number of Shares Effect of potential dilutive ordinary shares	4,845,035	41,328	130,177
Income Attributed to equity holders of the Company Effect of potential dilutive ordinary shares
Weighted Number of Shares For the computation of diluted income (loss)	53,675,514	44,856,576	44,901,943
Loss Attributed to equity holders of the Company For the computation of diluted income (loss)	$ 8,284	$ (2,321)	$ (2,230)

Operating Segments (Details)

Operating Segments (Details)	12 Months Ended
	Dec. 31, 2023
Operating Segments [Abstract]
Number of operating segments	2

Operating Segments (Details) -

Operating Segments (Details) - Schedule of Reporting on Operating Segments $ in Thousands, ₪ in Billions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Schedule of Reporting on Operating Segments [Line Items]
Revenues	$ 142,519	₪ 10	$ 129,339	$ 103,642
Gross profit	55,490		46,703	30,328
Unallocated corporate expenses	(45,426)		(42,171)	(31,024)
Finance income, net	(1,635)		(6,791)	(1,189)
Income (Loss) before taxes on income	8,429		(2,259)	(1,885)
Proprietary Products [Member]
Schedule of Reporting on Operating Segments [Line Items]
Revenues	115,458		102,598	75,521
Gross profit	52,116		44,369	27,327
Distribution [Member]
Schedule of Reporting on Operating Segments [Line Items]
Revenues	27,061		26,741	28,121
Gross profit	$ 3,374		$ 2,334	$ 3,001

Balances and Transactions wit_3

Balances and Transactions with Related Parties (Details) - USD ($)						1 Months Ended	12 Months Ended
	Dec. 01, 2023	Sep. 07, 2023	Jul. 04, 2022	Feb. 10, 2020	Nov. 21, 2019	Feb. 28, 2023	Dec. 31, 2023
Balances and Transactions with Related Parties [Line Items]
Price per product payable percentage							50%
Agreement period							5 years
Additional agreement periods							1 year
Consecutive years							2 years
Applicable taxes (in Dollars)			$ 30,000
Agreement payment percentage						60%
Outstanding due amount (in Dollars)	$ 1,500,000
Percentage of outstanding ordinary shares		38%		38%	38%
Bottom of range [member]
Balances and Transactions with Related Parties [Line Items]
Discontinues selling the products							45 days
Top of range [member]
Balances and Transactions with Related Parties [Line Items]
Discontinues selling the products							90 days
Chief Executive Officer [Member]
Balances and Transactions with Related Parties [Line Items]
Annual bonus (in Dollars)							$ 176,000

Balances and Transactions wit_4

Balances and Transactions with Related Parties (Details) - Schedule of Balances with Related Parties - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balances with related parties [Member]
Schedule of Transactions with Related Parties [Line Items]
Trade receivable		$ 544
Trade payables	$ 96	101
Other accounts payables	45	85
Transactions with employed/directors that accounts as related parties [Member]
Schedule of Transactions with Related Parties [Line Items]
Remuneration of directors not employed by the Company or on its behalf	548		$ 331	$ 487
Directors not employed by the Company	11		9	9
Total Directors employed and not employed by the Company	11		9	$ 9
Transactions with key executive personnel [Member]
Schedule of Transactions with Related Parties [Line Items]
Salary and Related Expenses	3,771	3,590	2,791
Share-based payment	728	547	255
Total	4,499	4,137	3,046
Transactions with related parties [Member]
Schedule of Transactions with Related Parties [Line Items]
Revenues	2,676	5,298	5,356
Cost of Goods Sold	7	19	51
Selling and marketing expenses
General and administrative expenses	$ 223	$ 214	$ 227

Balances and Transactions wit_5

Balances and Transactions with Related Parties (Details) - Schedule of CEO Employment Terms ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)
2020 [Member]
Balances and Transactions with Related Parties (Details) - Schedule of CEO Employment Terms [Line Items]
Effective date	July 1, 2019	July 1, 2019
Company’s Board approval Month/Year	March 2020	March 2020
Monthly Gross salary (NIS)	$ 25,462	₪ 88,000
Monthly Gross salary (USD)	$ 25,462	₪ 88,000
2021 [Member]
Balances and Transactions with Related Parties (Details) - Schedule of CEO Employment Terms [Line Items]
Effective date	July 1, 2021	July 1, 2021
Company’s Board approval Month/Year	October 2021	October 2021
Monthly Gross salary (NIS)	$ 28,607	₪ 92,400
Monthly Gross salary (USD)	$ 28,607	₪ 92,400
2022 [Member]
Balances and Transactions with Related Parties (Details) - Schedule of CEO Employment Terms [Line Items]
Effective date	July 1, 2022	July 1, 2022
Company’s Board approval Month/Year	November 2022	November 2022
Monthly Gross salary (NIS)	$ 28,575	₪ 96,000
Monthly Gross salary (USD)	$ 28,575	₪ 96,000
2023 [Member]
Balances and Transactions with Related Parties (Details) - Schedule of CEO Employment Terms [Line Items]
Effective date	July 1, 2023	July 1, 2023
Company’s Board approval Month/Year	December 2023	December 2023
Monthly Gross salary (NIS)	$ 27,570	₪ 100,000
Monthly Gross salary (USD)	$ 27,570	₪ 100,000